cancer_type,TMB (FMOne mutation burden per MB),Neoantigen burden per MB,Immune phenotype,response_label,user_question,full_query
BLCA,18.0,4.68627451,excluded,NR,"We have a white male patient with bladder urothelial carcinoma, and a bladder biopsy assessing the tumor immune microenvironment revealed a tumor mutational burden (TMB) of 18.0. Based on these findings, can we anticipate a favorable response to Atezolizumab therapy?","We have a white male patient with bladder urothelial carcinoma, and a bladder biopsy assessing the tumor immune microenvironment revealed a tumor mutational burden (TMB) of 18.0. Based on these findings, can we anticipate a favorable response to Atezolizumab therapy? Review the transcriptomic data and run the Compass tool to predict the patient's response to immune checkpoint inhibitor (ICI) therapy. Assess the Compass output focusing on immune efficiency markers, including macrophage activity, the IFNG pathway, genome integrity, cell proliferation, and cytotoxic T cell levels. Next, combine these results with the Compass predictions and patient metadata to compile a thorough summary of the immune landscape. Finally, develop detailed reasoning that uses the predicted responder status and the immune concept data to determine whether the patient is likely to respond to ICI therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-0257bb-ar-0257bbb.pkl. "
BLCA,1.0,0.31372549,desert,NR,"A white male patient with bladder urothelial carcinoma underwent transcriptomic profiling of his tumor immune microenvironment from a bladder biopsy, which revealed a tumor mutational burden of 1.0. Based on this data, what is the likelihood that he will respond favorably to Atezolizumab therapy?","A white male patient with bladder urothelial carcinoma underwent transcriptomic profiling of his tumor immune microenvironment from a bladder biopsy, which revealed a tumor mutational burden of 1.0. Based on this data, what is the likelihood that he will respond favorably to Atezolizumab therapy? Examine the transcriptomic data and utilize the Compass tool to forecast the patient's potential response to immune checkpoint inhibitor therapy. Focus your analysis on key immune markers—namely, macrophage activity, the interferon-gamma (IFNG) pathway, genomic stability, cell proliferation rates, and cytotoxic T cell levels. Integrate these findings with the Compass predictions and relevant patient metadata to create a comprehensive profile of the patient’s immune landscape. Finally, develop a detailed rationale based on the predicted responder status and the immune profile data to assess the likelihood of a favorable response to ICI therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-025b45-ar-025b45c.pkl. "
BLCA,44.0,6.196078431,inflamed,NR,"For a white female patient diagnosed with bladder urothelial carcinoma, whose bladder biopsy transcriptomic analysis indicates a tumor mutational burden (TMB) of 44.0, how likely is she to benefit from atezolizumab therapy?","For a white female patient diagnosed with bladder urothelial carcinoma, whose bladder biopsy transcriptomic analysis indicates a tumor mutational burden (TMB) of 44.0, how likely is she to benefit from atezolizumab therapy? Review the patient's transcriptomic data and use the Compass tool to predict their likely response to immune checkpoint inhibitor (ICI) therapy. In your evaluation, focus on critical immune parameters such as macrophage activity, the interferon-gamma (IFNG) pathway, genomic stability, cell proliferation rates, and cytotoxic T cell abundance. Combine these findings with Compass predictions and the patient's clinical metadata to construct a detailed immune profile. Finally, provide a comprehensive rationale based on the patient’s immune landscape and their predicted responder status to assess their potential benefit from ICI therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-032c64-ar-032c642.pkl. "
BLCA,2.0,1.470588235,excluded,NR,"For a white female patient with bladder urothelial carcinoma, transcriptomic analysis of the tumor immune microenvironment from a lymph node biopsy revealed a tumor mutational burden (TMB) of 2.0 mutations per megabase. Based on this data, how likely is a positive therapeutic response to atezolizumab?","For a white female patient with bladder urothelial carcinoma, transcriptomic analysis of the tumor immune microenvironment from a lymph node biopsy revealed a tumor mutational burden (TMB) of 2.0 mutations per megabase. Based on this data, how likely is a positive therapeutic response to atezolizumab? Review the patient's transcriptomic profile and utilize the Compass tool to estimate their response to immune checkpoint inhibitor therapy. In your assessment, carefully evaluate key immune factors including macrophage activity, interferon-gamma pathway activation, genomic stability, cell proliferation, and cytotoxic T cell presence. Integrate these molecular findings with the Compass predictions and the patient's clinical information to develop a detailed immune profile. Finally, provide a comprehensive rationale that explains the patient's immune landscape and predicts their likely benefit from ICI therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-0571f1-ar-0571f17.pkl. "
BLCA,8.0,,inflamed,R,"In a Caucasian male with bladder urothelial carcinoma, a transcriptomic analysis from a bladder biopsy showed a tumor mutation burden (TMB) of 8.0 mutations per megabase. Based on these findings, what is the likelihood that he will respond favorably to atezolizumab therapy?","In a Caucasian male with bladder urothelial carcinoma, a transcriptomic analysis from a bladder biopsy showed a tumor mutation burden (TMB) of 8.0 mutations per megabase. Based on these findings, what is the likelihood that he will respond favorably to atezolizumab therapy? Please review the patient's transcriptomic data and use the Compass tool to assess their potential response to immune checkpoint inhibitors. Focus your evaluation on key immune parameters such as macrophage function, activation of the interferon-gamma pathway, genomic stability, cell proliferation, and the presence of cytotoxic T cells. Combine these molecular insights with the Compass tool's predictions and the patient’s clinical details to create a comprehensive immune profile. Provide a detailed explanation of the findings and discuss the anticipated benefit of ICI therapy based on this integrated analysis.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-065890-ar-0658907.pkl. "
BLCA,6.0,0.921568627,,R,"I have a white female patient with bladder urothelial carcinoma. Transcriptomic profiling of her tumor immune microenvironment from a bladder biopsy shows a tumor mutational burden of 6.0. Based on current evidence, is this TMB level likely to predict a favorable response to Atezolizumab therapy?","I have a white female patient with bladder urothelial carcinoma. Transcriptomic profiling of her tumor immune microenvironment from a bladder biopsy shows a tumor mutational burden of 6.0. Based on current evidence, is this TMB level likely to predict a favorable response to Atezolizumab therapy? Please analyze the patient's transcriptomic data using the Compass tool to evaluate their likely response to immune checkpoint inhibitors (ICI). In your review, emphasize key immune markers including macrophage activity, interferon-gamma pathway activation, genomic stability, cell proliferation rates, and the presence of cytotoxic T cells. Integrate these molecular findings with the Compass tool’s predictions and the patient's clinical history to develop a comprehensive immune profile. Provide a detailed report of your findings, including an interpretation of how these data might predict the benefit of ICI therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-0684af-ar-0684af7.pkl. "
BLCA,11.0,0.745098039,excluded,R,"In a white male patient with bladder urothelial carcinoma, a kidney biopsy of the tumor immune microenvironment revealed a tumor mutational burden (TMB) of 11.0. Based on current evidence, how likely is it that this patient would respond to Atezolizumab therapy?","In a white male patient with bladder urothelial carcinoma, a kidney biopsy of the tumor immune microenvironment revealed a tumor mutational burden (TMB) of 11.0. Based on current evidence, how likely is it that this patient would respond to Atezolizumab therapy? Review the patient's transcriptomic data using the Compass tool to assess their potential response to immune checkpoint inhibitor therapy. Focus on quantifying key immune indicators, including macrophage activity, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T cell presence. Combine these molecular insights with the Compass tool’s predictions and the patient’s clinical history to construct a detailed immune profile. Finally, compile a comprehensive report that interprets how these data may inform the expected benefit of ICI treatment.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-075e03-ar-075e037.pkl. "
BLCA,18.0,2.117647059,excluded,R,"I have a white male patient with bladder urothelial carcinoma whose tumor immune microenvironment has been profiled via transcriptomic analysis from a bladder biopsy, revealing a tumor mutational burden (TMB) of 18.0. Based on these findings, could you provide insights on the likelihood of a favorable response to Atezolizumab therapy?","I have a white male patient with bladder urothelial carcinoma whose tumor immune microenvironment has been profiled via transcriptomic analysis from a bladder biopsy, revealing a tumor mutational burden (TMB) of 18.0. Based on these findings, could you provide insights on the likelihood of a favorable response to Atezolizumab therapy? Evaluate the patient’s transcriptomic data using the Compass tool to determine their likely response to immune checkpoint inhibitor therapy. In your analysis, quantify essential immune markers, specifically assessing macrophage activity, interferon-gamma signaling, genomic stability, cell proliferation, and the presence of cytotoxic T cells. Integrate these molecular findings with the Compass predictions and the patient’s clinical history to develop a detailed immune profile. Finally, prepare a comprehensive report that explains how these combined data might influence the anticipated benefit of ICI treatment.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-07a93a-ar-07a93a2.pkl. "
BLCA,,,excluded,NR,"We have a Caucasian female patient diagnosed with bladder urothelial carcinoma (BLCA). Transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy revealed an indeterminate tumor mutational burden (TMB). Based on these findings, how likely is it that the patient will respond to Atezolizumab therapy?","We have a Caucasian female patient diagnosed with bladder urothelial carcinoma (BLCA). Transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy revealed an indeterminate tumor mutational burden (TMB). Based on these findings, how likely is it that the patient will respond to Atezolizumab therapy? Please analyze the patient’s transcriptomic data with the Compass tool to assess their potential response to immune checkpoint inhibitor therapy. In your evaluation, quantify key immune markers including macrophage activity, interferon-gamma signaling, genomic stability, cell proliferation rates, and the abundance of cytotoxic T cells. Combine these molecular findings with the Compass output and the patient’s clinical history to construct a comprehensive immune profile. Finally, compile a detailed report discussing how this integrated information may influence the expected benefits of ICI treatment.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-08cce2-ar-08cce2f.pkl. "
BLCA,,,inflamed,NR,"For a Caucasian male patient diagnosed with bladder urothelial carcinoma, with a transcriptomic analysis of the tumor immune microenvironment from a nanobiopsy showing a tumor mutation burden of nan, how likely is he to respond to atezolizumab therapy?","For a Caucasian male patient diagnosed with bladder urothelial carcinoma, with a transcriptomic analysis of the tumor immune microenvironment from a nanobiopsy showing a tumor mutation burden of nan, how likely is he to respond to atezolizumab therapy? Please use the Compass tool to analyze the patient's transcriptomic data and evaluate their likely response to immune checkpoint inhibitor (ICI) therapy. In your analysis, quantify key immune parameters such as macrophage activity, interferon-gamma signaling, genomic stability, cell proliferation rates, and the levels of cytotoxic T cells. Integrate these molecular findings with the Compass data and the patient’s clinical history to develop a detailed immune profile. Finally, prepare a comprehensive report discussing how this combined information may affect the anticipated benefits of ICI treatment.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-09c84e-ar-09c84ec.pkl. "
BLCA,2.0,0.215686275,,NR,"A White male patient with bladder urothelial carcinoma has a transcriptomic profile of the tumor immune microenvironment, obtained via a kidney biopsy, showing a tumor mutational burden (TMB) of 2.0 mutations per megabase. Based on these findings, what is the likelihood that he will respond to Atezolizumab therapy?","A White male patient with bladder urothelial carcinoma has a transcriptomic profile of the tumor immune microenvironment, obtained via a kidney biopsy, showing a tumor mutational burden (TMB) of 2.0 mutations per megabase. Based on these findings, what is the likelihood that he will respond to Atezolizumab therapy? Please use the Compass tool to evaluate the patient's transcriptomic data and predict their response to immune checkpoint inhibitor therapy. Specifically, quantify key immune parameters such as macrophage activity, interferon-gamma signaling, genomic stability, cell proliferation rates, and cytotoxic T cell levels. Combine these molecular findings with the Compass analysis and the patient’s clinical history to generate a detailed immune profile. Finally, compile a comprehensive report explaining how these integrated data may influence the prospective benefits of ICI treatment.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-0a0f2b-ar-0a0f2ba.pkl. "
BLCA,8.0,1.274509804,excluded,NR,"In a white male patient with bladder urothelial carcinoma, a bladder biopsy revealed a transcriptomic profile of the tumor immune microenvironment with a tumor mutational burden of 8.0. Based on these findings, is it likely that the patient will benefit from Atezolizumab therapy?","In a white male patient with bladder urothelial carcinoma, a bladder biopsy revealed a transcriptomic profile of the tumor immune microenvironment with a tumor mutational burden of 8.0. Based on these findings, is it likely that the patient will benefit from Atezolizumab therapy? Please apply the Compass tool to analyze the patient’s transcriptomic data to assess their likely response to immune checkpoint inhibitor therapy. In this analysis, quantify essential immune markers including macrophage activity, interferon-gamma signaling, genomic stability, cell proliferation rates, and cytotoxic T cell levels. Then, integrate these molecular findings with the Compass results and the patient’s clinical history to construct a detailed immune profile. Finally, prepare a comprehensive report outlining how these combined data may influence the anticipated benefits of ICI treatment.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-0a7c20-ar-0a7c209.pkl. "
BLCA,,,,NR,"We have a white female patient with bladder urothelial carcinoma. The transcriptomic profiling of her tumor immune microenvironment from a lymph node biopsy reports a tumor mutational burden (TMB) as ""nan."" Could you help evaluate the likelihood of her responding to atezolizumab therapy given this molecular data?","We have a white female patient with bladder urothelial carcinoma. The transcriptomic profiling of her tumor immune microenvironment from a lymph node biopsy reports a tumor mutational burden (TMB) as ""nan."" Could you help evaluate the likelihood of her responding to atezolizumab therapy given this molecular data? Using the Compass tool, evaluate the patient’s transcriptomic data to predict their response to immune checkpoint inhibitor therapy. Specifically, quantify key immune markers—macrophage activity, interferon-gamma signaling, genomic stability, cell proliferation rates, and cytotoxic T cell levels. Then, integrate these molecular findings with the Compass analysis and the patient’s clinical history to develop a detailed immune profile. Finally, compile a comprehensive report that explains how these combined data might influence the expected benefits of ICI treatment.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-0bdb34-ar-0bdb342.pkl. "
BLCA,9.0,,excluded,NR,"For a white male patient with bladder urothelial carcinoma whose ureter biopsy transcriptomic profiling reveals a tumor mutational burden (TMB) of 9.0, what is the expected likelihood of a favorable response to atezolizumab therapy?","For a white male patient with bladder urothelial carcinoma whose ureter biopsy transcriptomic profiling reveals a tumor mutational burden (TMB) of 9.0, what is the expected likelihood of a favorable response to atezolizumab therapy? Please use the Compass tool to analyze the patient's transcriptomic data with the goal of predicting their response to immune checkpoint inhibitor therapy. In your evaluation, quantify important immune parameters including macrophage activity, interferon-gamma signaling, genomic stability, cell proliferation, and the levels of cytotoxic T cells. Next, combine these molecular findings with the results from the Compass analysis and the patient's clinical history to create a comprehensive immune profile. Finally, prepare a detailed report that outlines how these integrated data might influence the expected outcomes of the ICI treatment.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-0ce9c9-ar-0ce9c98.pkl. "
BLCA,4.0,0.137254902,desert,NR,"For a White female patient diagnosed with bladder urothelial carcinoma, a bladder biopsy revealed a tumor mutational burden (TMB) of 4.0 along with detailed transcriptomic profiling of the immune microenvironment. Could you assess the likelihood of a positive response to Atezolizumab therapy in this case?","For a White female patient diagnosed with bladder urothelial carcinoma, a bladder biopsy revealed a tumor mutational burden (TMB) of 4.0 along with detailed transcriptomic profiling of the immune microenvironment. Could you assess the likelihood of a positive response to Atezolizumab therapy in this case? Using the Compass tool, please assess the patient's transcriptomic data to predict their response to immune checkpoint inhibitor (ICI) therapy. Quantify key immune parameters including macrophage activity, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T cell levels. Integrate these molecular metrics with the Compass analysis and the patient's clinical history to build a comprehensive immune profile. Finally, compile a detailed report discussing how these combined data contribute to the anticipated outcomes of ICI treatment.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-0d855c-ar-0d855cf.pkl. "
BLCA,32.0,4.098039216,excluded,NR,"A white male patient with bladder urothelial carcinoma has a tumor mutational burden of 32 identified via transcriptomic profiling from a ureter biopsy. Based on these findings, what is the likelihood that he will respond to Atezolizumab therapy?","A white male patient with bladder urothelial carcinoma has a tumor mutational burden of 32 identified via transcriptomic profiling from a ureter biopsy. Based on these findings, what is the likelihood that he will respond to Atezolizumab therapy? Please use the Compass tool to evaluate the patient's transcriptomic data for predicting their response to immune checkpoint inhibitor therapy. Measure critical immune factors: macrophage activity, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T cell levels. Combine these molecular data with the Compass analysis and the patient’s clinical history to generate a comprehensive immune profile. Then, prepare a detailed report that explains how these data collectively inform the expected outcomes of ICI treatment.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-0f956e-ar-0f956e7.pkl. "
BLCA,21.0,3.529411765,desert,NR,"In a White male patient with bladder urothelial carcinoma, transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy revealed a tumor mutational burden of 21.0. Based on this information, how likely is the patient to respond to Atezolizumab therapy?","In a White male patient with bladder urothelial carcinoma, transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy revealed a tumor mutational burden of 21.0. Based on this information, how likely is the patient to respond to Atezolizumab therapy? Please use the Compass tool to analyze the patient's transcriptomic data to forecast their response to immune checkpoint inhibitor therapy. Assess key immune parameters including macrophage activity, interferon-gamma signaling, genomic stability, cellular proliferation, and cytotoxic T cell levels. Integrate these molecular findings with the Compass evaluation and the patient’s clinical history to develop a comprehensive immune profile. Finally, generate a detailed report that delineates how these combined data predict the potential outcomes of ICI treatment.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-110501-ar-110501d.pkl. "
BLCA,10.0,1.078431373,inflamed,NR,"In a white male patient with bladder urothelial carcinoma, the transcriptomic profile from a kidney biopsy revealed a tumor mutational burden (TMB) of 10.0. Could you provide your assessment regarding the likelihood of response to Atezolizumab therapy?","In a white male patient with bladder urothelial carcinoma, the transcriptomic profile from a kidney biopsy revealed a tumor mutational burden (TMB) of 10.0. Could you provide your assessment regarding the likelihood of response to Atezolizumab therapy? Utilize the Compass tool to evaluate the patient’s transcriptomic data and predict their response to immune checkpoint inhibitor therapy. Review key immune features, including macrophage activity, interferon-gamma signaling, genomic stability, cellular proliferation, and cytotoxic T cell levels, and integrate these molecular findings with the patient’s clinical history. Then, prepare a detailed report outlining how these combined data inform the likely clinical outcomes of ICI treatment.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-12502d-ar-12502d9.pkl. "
BLCA,38.0,6.68627451,desert,R,I am evaluating a Caucasian male patient with confirmed bladder urothelial carcinoma. A transcriptomic analysis of his tumor immune microenvironment from a bladder biopsy revealed a tumor mutational burden (TMB) of 38. How should we interpret this TMB value in terms of his potential response to Atezolizumab therapy?,"I am evaluating a Caucasian male patient with confirmed bladder urothelial carcinoma. A transcriptomic analysis of his tumor immune microenvironment from a bladder biopsy revealed a tumor mutational burden (TMB) of 38. How should we interpret this TMB value in terms of his potential response to Atezolizumab therapy? Use the Compass tool to analyze the patient's transcriptomic profile and predict their response to immune checkpoint inhibitor therapy. Evaluate key immune parameters—including macrophage activity, interferon-gamma signaling, genomic stability, cellular proliferation, and cytotoxic T cell levels—and integrate these findings with the patient’s clinical history. Then, compile a comprehensive report that explains how these combined data inform the expected clinical outcomes of ICI treatment.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-149386-ar-1493861.pkl. "
BLCA,7.0,0.568627451,excluded,R,"For a white female patient diagnosed with bladder urothelial carcinoma, whose biopsy transcriptomic analysis reveals a tumor mutational burden of 7.0 mutations per megabase, how likely is she to benefit from Atezolizumab therapy?","For a white female patient diagnosed with bladder urothelial carcinoma, whose biopsy transcriptomic analysis reveals a tumor mutational burden of 7.0 mutations per megabase, how likely is she to benefit from Atezolizumab therapy? Please use the Compass tool to evaluate the patient's transcriptomic profile and predict their response to immune checkpoint inhibitor therapy. Begin by assessing specific immune markers, including macrophage activity, interferon-gamma signaling, genomic stability, cellular proliferation, and cytotoxic T cell levels. Then, integrate these molecular findings with the patient's clinical history and prepare a detailed report that explains how these factors together can inform the anticipated outcomes of ICI treatment.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-14df63-ar-14df63a.pkl. "
BLCA,5.0,0.274509804,excluded,NR,"I have a Caucasian male patient diagnosed with bladder urothelial carcinoma. A transcriptomic analysis of his tumor immune microenvironment, obtained via bladder biopsy, revealed a tumor mutational burden of 5.0. Could you evaluate the likelihood of a clinically significant response to Atezolizumab in this case?","I have a Caucasian male patient diagnosed with bladder urothelial carcinoma. A transcriptomic analysis of his tumor immune microenvironment, obtained via bladder biopsy, revealed a tumor mutational burden of 5.0. Could you evaluate the likelihood of a clinically significant response to Atezolizumab in this case? Evaluate the patient's transcriptomic profile using the Compass tool to predict their response to immune checkpoint inhibitor (ICI) therapy. Start by examining key immune markers such as macrophage activity, interferon-gamma signaling, genomic stability, cellular proliferation, and cytotoxic T cell levels. Then, correlate these molecular findings with the patient's clinical history and compile a detailed report on how these combined factors may impact the expected outcomes of ICI treatment.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-166a41-ar-166a419.pkl. "
BLCA,15.0,,desert,NR,"We have a Caucasian male patient diagnosed with bladder urothelial carcinoma. A bladder biopsy of his tumor revealed a transcriptomic profile of the immune microenvironment with a tumor mutation burden (TMB) of 15.0. Based on these findings, what can we infer about his likelihood of responding to Atezolizumab therapy?","We have a Caucasian male patient diagnosed with bladder urothelial carcinoma. A bladder biopsy of his tumor revealed a transcriptomic profile of the immune microenvironment with a tumor mutation burden (TMB) of 15.0. Based on these findings, what can we infer about his likelihood of responding to Atezolizumab therapy? Assess the patient's transcriptomic profile with the Compass tool to estimate their potential response to immune checkpoint inhibitor therapy. Begin by analyzing specific immune markers, including macrophage activity, interferon-gamma signaling, genomic stability, cellular proliferation, and cytotoxic T cell levels. Then, integrate these molecular findings with the patient’s clinical history, and prepare a comprehensive report detailing how these factors might affect the anticipated outcomes of the ICI treatment.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-180398-ar-1803982.pkl. "
BLCA,,0.215686275,excluded,NR,"I have a white male patient with a confirmed diagnosis of bladder urothelial carcinoma. A transcriptomic analysis of his tumor immune microenvironment, obtained from a kidney biopsy, shows that the tumor mutation burden (TMB) is not available. Based on these findings, could you assess whether he is likely to respond to Atezolizumab therapy?","I have a white male patient with a confirmed diagnosis of bladder urothelial carcinoma. A transcriptomic analysis of his tumor immune microenvironment, obtained from a kidney biopsy, shows that the tumor mutation burden (TMB) is not available. Based on these findings, could you assess whether he is likely to respond to Atezolizumab therapy? Using the Compass tool, review the patient's transcriptomic data to predict their response to immune checkpoint inhibitor therapy. Start by examining key immune markers such as macrophage activity, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T cell levels. Then, combine these molecular insights with the patient's clinical history and compile a comprehensive report outlining how these factors might influence the expected treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-181b63-ar-181b638.pkl. "
BLCA,,,,NR,"I have a Caucasian male patient diagnosed with bladder urothelial carcinoma. A transcriptomic analysis of his tumor immune microenvironment, obtained via lung biopsy, did not yield a measurable tumor mutational burden. Based on this information, how likely is he to respond to atezolizumab therapy?","I have a Caucasian male patient diagnosed with bladder urothelial carcinoma. A transcriptomic analysis of his tumor immune microenvironment, obtained via lung biopsy, did not yield a measurable tumor mutational burden. Based on this information, how likely is he to respond to atezolizumab therapy? Please use the Compass tool to analyze the patient’s transcriptomic data and assess their potential response to immune checkpoint inhibitor therapy. Begin by evaluating important immune markers, including macrophage activity, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T cell levels. Then, integrate these findings with the patient’s clinical history to prepare a detailed report that outlines how these factors may affect the anticipated treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-187e05-ar-187e056.pkl. "
BLCA,18.0,2.039215686,excluded,NR,"For a white male patient with bladder urothelial carcinoma whose bladder biopsy transcriptomic analysis shows a tumor mutational burden of 18.0, what is the likelihood that he would respond favorably to atezolizumab therapy?","For a white male patient with bladder urothelial carcinoma whose bladder biopsy transcriptomic analysis shows a tumor mutational burden of 18.0, what is the likelihood that he would respond favorably to atezolizumab therapy? Please use the Compass tool to evaluate the patient's transcriptomic data to determine their likely response to immune checkpoint inhibitor therapy. Start by assessing key immune markers, such as macrophage activity, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T cell levels. After this analysis, combine these results with the patient’s clinical history to generate a comprehensive report detailing how these factors may influence the treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-18a4da-ar-18a4dab.pkl. "
BLCA,7.0,0.392156863,inflamed,NR,"In a Black or African American male patient with bladder urothelial carcinoma, tumor profiling from a ureter biopsy showed a tumor mutation burden of 7.0. Based on these findings, what is the likelihood that this patient will respond to atezolizumab therapy?","In a Black or African American male patient with bladder urothelial carcinoma, tumor profiling from a ureter biopsy showed a tumor mutation burden of 7.0. Based on these findings, what is the likelihood that this patient will respond to atezolizumab therapy? Please use the Compass tool to analyze the patient's transcriptomic data in order to assess their potential response to immune checkpoint inhibitor therapy. Begin by examining key immune markers—specifically macrophage activity, interferon-gamma signaling, genomic stability, cell proliferation rates, and cytotoxic T cell levels. Then, integrate these findings with the patient’s clinical history to compile a detailed report outlining how these factors might impact treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-18b935-ar-18b9351.pkl. "
BLCA,19.0,1.803921569,,NR,"For a white male patient with bladder urothelial carcinoma who has a tumor mutational burden of 19.0 based on transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy, what is the likelihood of a positive therapeutic response to Atezolizumab?","For a white male patient with bladder urothelial carcinoma who has a tumor mutational burden of 19.0 based on transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy, what is the likelihood of a positive therapeutic response to Atezolizumab? Use the Compass tool to review the patient’s transcriptomic data and evaluate their likely response to immune checkpoint inhibitors. Start by analyzing key biomarkers, including macrophage activity, interferon-gamma signaling, genomic stability, proliferation rates, and levels of cytotoxic T cells. Next, correlate these molecular findings with the patient’s clinical history, and prepare a comprehensive report that details how these factors might influence the treatment outcome.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-18bc10-ar-18bc107.pkl. "
BLCA,5.0,0.470588235,excluded,NR,I have a Caucasian male patient with bladder urothelial carcinoma. His bladder biopsy transcriptomic analysis of the tumor immune microenvironment showed a tumor mutational burden (TMB) of 5.0. Could you provide an assessment of his potential response to Atezolizumab therapy?,"I have a Caucasian male patient with bladder urothelial carcinoma. His bladder biopsy transcriptomic analysis of the tumor immune microenvironment showed a tumor mutational burden (TMB) of 5.0. Could you provide an assessment of his potential response to Atezolizumab therapy? Please use the Compass tool to examine the patient's transcriptomic data in order to assess their potential response to immune checkpoint inhibitors. Begin by analyzing critical biomarkers such as macrophage activity, interferon-gamma signaling, genomic stability, proliferation rates, and cytotoxic T cell levels. Then, integrate these molecular insights with the patient’s clinical history, and prepare a detailed report outlining how these factors could influence their treatment outcome.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-18be5b-ar-18be5b3.pkl. "
BLCA,5.0,0.431372549,excluded,NR,"In a white male patient with bladder urothelial carcinoma whose tumor biopsy shows a tumor mutation burden (TMB) of 5.0, what is the likelihood of a positive response to atezolizumab therapy?","In a white male patient with bladder urothelial carcinoma whose tumor biopsy shows a tumor mutation burden (TMB) of 5.0, what is the likelihood of a positive response to atezolizumab therapy? Please use the Compass tool to evaluate the patient’s transcriptomic profile for potential responsiveness to immune checkpoint inhibitors. Focus on quantifying biomarkers such as macrophage activity, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T cell levels. Once these molecular parameters have been assessed, combine the findings with the patient's clinical history and compile a comprehensive report detailing how these factors may impact the treatment outcome.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-19fec8-ar-19fec8f.pkl. "
BLCA,8.0,1.176470588,excluded,NR,I have a Caucasian male patient with bladder urothelial carcinoma. Transcriptomic profiling of his tumor immune microenvironment from a bladder biopsy revealed a tumor mutational burden of 8.0 mutations per megabase. Could you estimate his potential response to atezolizumab therapy based on these findings?,"I have a Caucasian male patient with bladder urothelial carcinoma. Transcriptomic profiling of his tumor immune microenvironment from a bladder biopsy revealed a tumor mutational burden of 8.0 mutations per megabase. Could you estimate his potential response to atezolizumab therapy based on these findings? Use the Compass tool to assess the patient’s transcriptomic profile for potential responsiveness to immune checkpoint inhibitors. Specifically, quantify biomarkers including macrophage activity, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T cell levels. Then, integrate these molecular findings with the patient’s clinical history and prepare a detailed report outlining how these factors might influence the treatment outcome.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-1a87df-ar-1a87df7.pkl. "
BLCA,13.0,0.294117647,desert,NR,"I have a Caucasian female patient diagnosed with bladder urothelial carcinoma (BLCA). A ureter biopsy provided a transcriptomic profile of her tumor immune microenvironment, showing a tumor mutational burden (TMB) of 13.0. Based on these findings, would you expect her to respond favorably to Atezolizumab therapy?","I have a Caucasian female patient diagnosed with bladder urothelial carcinoma (BLCA). A ureter biopsy provided a transcriptomic profile of her tumor immune microenvironment, showing a tumor mutational burden (TMB) of 13.0. Based on these findings, would you expect her to respond favorably to Atezolizumab therapy? Please use the Compass tool to evaluate the patient's transcriptomic profile for indicators of potential response to immune checkpoint inhibitors. Specifically, measure biomarkers such as macrophage activity, interferon-gamma signaling, genomic integrity, cell proliferation rates, and cytotoxic T cell concentrations. Then, correlate these molecular results with the patient's clinical history and compile a comprehensive report detailing how these factors may affect the patient’s treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-1ab1b2-ar-1ab1b28.pkl. "
BLCA,16.0,1.862745098,excluded,R,"For a white male patient with bladder urothelial carcinoma, where transcriptomic analysis of the tumor immune microenvironment from a kidney biopsy revealed a tumor mutational burden of 16, what is the likelihood that he would respond favorably to Atezolizumab therapy?","For a white male patient with bladder urothelial carcinoma, where transcriptomic analysis of the tumor immune microenvironment from a kidney biopsy revealed a tumor mutational burden of 16, what is the likelihood that he would respond favorably to Atezolizumab therapy? Please use the Compass tool to analyze the patient’s transcriptomic profile for markers that may predict a response to immune checkpoint inhibitors. In particular, assess parameters related to macrophage activity, interferon-gamma signaling, genomic integrity, cell proliferation, and cytotoxic T cell levels. Then, integrate these molecular findings with the patient’s clinical history and prepare a comprehensive report outlining how these biomarkers might impact the patient’s treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-1abf01-ar-1abf01d.pkl. "
BLCA,2.0,0.647058824,excluded,NR,"We have a White male patient with bladder urothelial carcinoma. The tumor's immune microenvironment, as profiled via a kidney biopsy, shows a tumor mutational burden (TMB) of 2.0. Based on this information, how likely is the patient to respond to Atezolizumab therapy?","We have a White male patient with bladder urothelial carcinoma. The tumor's immune microenvironment, as profiled via a kidney biopsy, shows a tumor mutational burden (TMB) of 2.0. Based on this information, how likely is the patient to respond to Atezolizumab therapy? Utilize the Compass tool to evaluate the patient’s transcriptomic data for biomarkers that could indicate a response to immune checkpoint inhibitors. Specifically, assess factors such as macrophage function, interferon-gamma signaling, genomic integrity, cell proliferation rates, and cytotoxic T cell activity. Combine these molecular findings with the patient’s clinical history, and prepare a detailed report that explains how these biomarkers may influence the patient’s treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-1ac4e3-ar-1ac4e3d.pkl. "
BLCA,,,excluded,NR,"A Caucasian female patient with a diagnosis of bladder urothelial carcinoma has a tumor immune microenvironment profile from a bladder biopsy showing a tumor mutational burden (TMB) reported as ""nan."" Based on this information, could you evaluate the likelihood of a positive response to Atezolizumab therapy?","A Caucasian female patient with a diagnosis of bladder urothelial carcinoma has a tumor immune microenvironment profile from a bladder biopsy showing a tumor mutational burden (TMB) reported as ""nan."" Based on this information, could you evaluate the likelihood of a positive response to Atezolizumab therapy? Please use the Compass tool to analyze the patient’s transcriptomic data, focusing on identifying biomarkers that predict responsiveness to immune checkpoint inhibitors. In your analysis, evaluate macrophage function, interferon-gamma signaling, genomic stability, cell proliferation rates, and cytotoxic T cell activity. After correlating these molecular indicators with the patient's clinical history, compile a comprehensive report that describes how these biomarkers might affect the treatment outcome.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-1c0ecf-ar-1c0ecfb.pkl. "
BLCA,7.0,0.549019608,excluded,NR,"For a Caucasian male with bladder urothelial carcinoma whose tumor immune microenvironment analysis shows a tumor mutational burden (TMB) of 7.0, what is the likelihood that he would respond to Atezolizumab therapy?","For a Caucasian male with bladder urothelial carcinoma whose tumor immune microenvironment analysis shows a tumor mutational burden (TMB) of 7.0, what is the likelihood that he would respond to Atezolizumab therapy? Please use the Compass tool to analyze the patient’s transcriptomic data with an emphasis on identifying biomarkers that predict response to immune checkpoint inhibitors. In your assessment, specifically evaluate macrophage function, interferon-gamma signaling, genomic stability, cell proliferation rates, and cytotoxic T cell activity. After linking these molecular findings with the patient’s clinical history, generate a detailed report that explains the potential impact of these biomarkers on the treatment outcome.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-1c8b08-ar-1c8b086.pkl. "
BLCA,20.0,4.019607843,desert,NR,"In a white male patient diagnosed with bladder urothelial carcinoma (BLCA), transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy revealed a tumor mutation burden (TMB) of 20.0. Based on this information, how likely is the patient to respond favorably to Atezolizumab therapy?","In a white male patient diagnosed with bladder urothelial carcinoma (BLCA), transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy revealed a tumor mutation burden (TMB) of 20.0. Based on this information, how likely is the patient to respond favorably to Atezolizumab therapy? Please utilize the Compass tool to evaluate the patient’s transcriptomic profile, with a focus on biomarkers that may predict the response to immune checkpoint inhibitors. In your analysis, carefully assess indicators of macrophage function, interferon-gamma signaling, genomic integrity, cell proliferation rates, and the activity of cytotoxic T cells. Then, integrate these molecular findings with the patient's clinical background to prepare a comprehensive report discussing how these biomarkers could impact treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-1dda30-ar-1dda30f.pkl. "
BLCA,5.0,1.431372549,inflamed,NR,"For a white female patient diagnosed with bladder urothelial carcinoma, the transcriptomic profile from a bladder biopsy indicates a tumor mutational burden of 5.0. Based on these findings, would you consider her a likely candidate for Atezolizumab therapy?","For a white female patient diagnosed with bladder urothelial carcinoma, the transcriptomic profile from a bladder biopsy indicates a tumor mutational burden of 5.0. Based on these findings, would you consider her a likely candidate for Atezolizumab therapy? Please use the Compass tool to analyze the patient’s transcriptomic profile, focusing on biomarkers linked to the effectiveness of immune checkpoint inhibitors. Specifically, assess markers of macrophage function, interferon-gamma signaling, genomic integrity, cell proliferation, and cytotoxic T cell activity. Incorporate these molecular findings with the patient’s clinical history and prepare a detailed report discussing how these biomarkers may affect treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-1e9c4d-ar-1e9c4d1.pkl. "
BLCA,38.0,4.509803922,inflamed,R,"In a white male patient with bladder urothelial carcinoma, a bladder biopsy transcriptomic profile revealed a tumor mutational burden of 38.0. Based on these findings, what is the anticipated response to atezolizumab therapy?","In a white male patient with bladder urothelial carcinoma, a bladder biopsy transcriptomic profile revealed a tumor mutational burden of 38.0. Based on these findings, what is the anticipated response to atezolizumab therapy? Please use the Compass tool to perform a detailed analysis of the patient’s transcriptomic profile, with a focus on biomarkers related to immune checkpoint inhibitor efficacy. Specifically, evaluate markers associated with macrophage function, interferon-gamma signaling, genomic integrity, cell proliferation, and cytotoxic T cell activity. Combine these molecular findings with the patient’s clinical history, and prepare a comprehensive report discussing how these biomarkers may influence treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-1f66db-ar-1f66db5.pkl. "
BLCA,6.0,0.549019608,desert,NR,"In a Caucasian male patient diagnosed with bladder urothelial carcinoma, transcriptomic profiling of the tumor immune microenvironment from a kidney biopsy indicates a TMB of 6.0 mutations/megabase. How likely is this patient to respond to atezolizumab therapy?","In a Caucasian male patient diagnosed with bladder urothelial carcinoma, transcriptomic profiling of the tumor immune microenvironment from a kidney biopsy indicates a TMB of 6.0 mutations/megabase. How likely is this patient to respond to atezolizumab therapy? Use the Compass tool to thoroughly evaluate the patient’s transcriptomic profile. Focus your analysis on biomarkers indicative of immune checkpoint inhibitor efficacy, specifically those related to macrophage function, interferon-gamma signaling, genomic integrity, cell proliferation, and cytotoxic T cell activity. Integrate these molecular insights with the patient’s clinical history, and prepare a detailed report discussing the potential impact of these biomarkers on treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-1f83eb-ar-1f83ebd.pkl. "
BLCA,8.0,1.235294118,inflamed,NR,"I have a Caucasian male patient with a diagnosis of bladder urothelial carcinoma. Transcriptomic profiling of his tumor immune microenvironment from a bladder biopsy indicates a tumor mutational burden of 8.0. Based on these findings, how likely is it that he will respond to Atezolizumab therapy?","I have a Caucasian male patient with a diagnosis of bladder urothelial carcinoma. Transcriptomic profiling of his tumor immune microenvironment from a bladder biopsy indicates a tumor mutational burden of 8.0. Based on these findings, how likely is it that he will respond to Atezolizumab therapy? Please utilize the Compass tool to perform a comprehensive assessment of the patient’s transcriptomic data. Concentrate on identifying biomarkers that can predict the effectiveness of immune checkpoint inhibitors, particularly those associated with macrophage activity, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T cell function. Incorporate these molecular findings with the patient’s clinical history and compile a detailed report that evaluates how these biomarkers may influence treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-1fa6bc-ar-1fa6bcb.pkl. "
BLCA,13.0,2.392156863,inflamed,R,"I have a Caucasian male patient diagnosed with bladder urothelial carcinoma (BLCA) whose tumor biopsy transcriptomic analysis of the immune microenvironment revealed a tumor mutation burden (TMB) of 13.0. Based on these findings, what is his likelihood of responding to atezolizumab therapy?","I have a Caucasian male patient diagnosed with bladder urothelial carcinoma (BLCA) whose tumor biopsy transcriptomic analysis of the immune microenvironment revealed a tumor mutation burden (TMB) of 13.0. Based on these findings, what is his likelihood of responding to atezolizumab therapy? Please use the Compass tool to conduct an in‐depth analysis of the patient’s transcriptomic data. In your evaluation, focus on identifying biomarkers that may predict responses to immune checkpoint inhibitors—specifically those related to macrophage function, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T cell activity. Then, integrate these molecular findings with the patient’s clinical history and prepare a detailed report assessing how these biomarkers might influence treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-203dcf-ar-203dcf1.pkl. "
BLCA,5.0,0.294117647,excluded,NR,"For a white male patient with bladder urothelial carcinoma whose tumor immune microenvironment transcriptomic profile from a kidney biopsy reveals a tumor mutational burden of 5.0, what is the likelihood of a positive response to Atezolizumab therapy?","For a white male patient with bladder urothelial carcinoma whose tumor immune microenvironment transcriptomic profile from a kidney biopsy reveals a tumor mutational burden of 5.0, what is the likelihood of a positive response to Atezolizumab therapy? Please use the Compass tool to perform a comprehensive analysis of the patient’s transcriptomic data. Concentrate on identifying biomarkers that could indicate a response to immune checkpoint inhibitors, with particular attention to those linked to macrophage activity, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T cell function. After analyzing these molecular markers, integrate your findings with the patient’s clinical history and compile a detailed report discussing how these biomarkers may impact treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-2070b4-ar-2070b41.pkl. "
BLCA,5.0,0.235294118,desert,NR,"For a white female patient with bladder urothelial carcinoma whose tumor biopsy transcriptomic analysis reveals a tumor mutational burden of 5.0, how likely is it that she will respond to Atezolizumab therapy?","For a white female patient with bladder urothelial carcinoma whose tumor biopsy transcriptomic analysis reveals a tumor mutational burden of 5.0, how likely is it that she will respond to Atezolizumab therapy? Please use the Compass tool to conduct an in-depth analysis of the patient’s transcriptomic data. Focus on identifying biomarkers that may predict the response to immune checkpoint inhibitors, especially those related to macrophage activation, interferon-gamma signaling, genomic integrity, cell proliferation, and cytotoxic T cell function. Once you have completed the molecular assessment, correlate these findings with the patient’s clinical history and prepare a comprehensive report that details how these biomarkers could influence treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-230959-ar-2309593.pkl. "
BLCA,5.0,0.333333333,excluded,NR,"In a Caucasian female with bladder urothelial carcinoma, transcriptomic profiling of the tumor immune microenvironment from a kidney biopsy revealed a tumor mutational burden of 5.0. How might this TMB level influence her likelihood of responding to Atezolizumab therapy?","In a Caucasian female with bladder urothelial carcinoma, transcriptomic profiling of the tumor immune microenvironment from a kidney biopsy revealed a tumor mutational burden of 5.0. How might this TMB level influence her likelihood of responding to Atezolizumab therapy? Please use the Compass tool to thoroughly analyze the patient's transcriptomic data, with a specific emphasis on detecting biomarkers that could indicate how they might respond to immune checkpoint inhibitors. In your assessment, concentrate on factors associated with macrophage activation, interferon-gamma signaling, maintenance of genomic integrity, cell proliferation, and the function of cytotoxic T cells. Once your molecular analysis is complete, integrate these results with the patient’s clinical history and prepare a detailed report outlining the potential impact of these biomarkers on treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-23aa15-ar-23aa15d.pkl. "
BLCA,,1.823529412,desert,R,"We have a white male patient diagnosed with bladder urothelial carcinoma. A transcriptomic analysis of his tumor immune microenvironment from a prior biopsy reported a TMB value as ""nan."" Based on this result, how can we evaluate his potential response to Atezolizumab therapy?","We have a white male patient diagnosed with bladder urothelial carcinoma. A transcriptomic analysis of his tumor immune microenvironment from a prior biopsy reported a TMB value as ""nan."" Based on this result, how can we evaluate his potential response to Atezolizumab therapy? Using the Compass tool, conduct a comprehensive analysis of the patient's transcriptomic data to identify biomarkers relevant to immune checkpoint inhibitor responsiveness. Focus specifically on markers related to macrophage activation, interferon-gamma signaling, genomic integrity maintenance, cell proliferation, and cytotoxic T cell function. Once the molecular analysis is completed, integrate these findings with the patient's clinical history and prepare a detailed report that discusses how these biomarkers might influence treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-25510f-ar-25510f3.pkl. "
BLCA,12.0,1.529411765,inflamed,R,"In a white female patient with a diagnosis of bladder urothelial carcinoma, transcriptomic analysis of the tumor immune microenvironment from a lymph node biopsy revealed a tumor mutation burden of 12. Could you provide an assessment regarding the likelihood of a positive response to atezolizumab therapy?","In a white female patient with a diagnosis of bladder urothelial carcinoma, transcriptomic analysis of the tumor immune microenvironment from a lymph node biopsy revealed a tumor mutation burden of 12. Could you provide an assessment regarding the likelihood of a positive response to atezolizumab therapy? Please use the Compass tool to analyze the patient’s transcriptomic data, paying particular attention to identifying biomarkers associated with response to immune checkpoint inhibitors. Specifically, focus on markers that reflect macrophage activation, interferon-gamma signaling, genomic integrity, cell proliferation, and cytotoxic T cell activity. Once you have completed this molecular analysis, integrate these results with the patient’s clinical history and prepare a detailed report discussing how these biomarkers could impact their treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-2570ff-ar-2570ff4.pkl. "
BLCA,1.0,0.274509804,excluded,NR,"I have an Asian male patient with bladder urothelial carcinoma. A transcriptomic analysis of his tumor immune microenvironment from a bladder biopsy revealed a tumor mutational burden of 1.0. Given these findings, how likely is the patient to respond to Atezolizumab therapy?","I have an Asian male patient with bladder urothelial carcinoma. A transcriptomic analysis of his tumor immune microenvironment from a bladder biopsy revealed a tumor mutational burden of 1.0. Given these findings, how likely is the patient to respond to Atezolizumab therapy? Please employ the Compass tool to evaluate the patient's transcriptomic data. Focus on identifying biomarkers that predict response to immune checkpoint inhibitors, with particular attention to markers indicative of macrophage activation, interferon-gamma signaling, genomic integrity, cell proliferation, and cytotoxic T cell activity. After completing the molecular analysis, integrate these findings with the patient’s clinical history and prepare a comprehensive report detailing how these biomarkers may influence treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-26104d-ar-26104d5.pkl. "
BLCA,6.0,0.431372549,excluded,NR,"For a white male patient diagnosed with bladder urothelial carcinoma (BLCA), whose bladder biopsy transcriptomic analysis shows a tumor mutational burden (TMB) of 6.0, what is the likelihood that he will respond to atezolizumab therapy?","For a white male patient diagnosed with bladder urothelial carcinoma (BLCA), whose bladder biopsy transcriptomic analysis shows a tumor mutational burden (TMB) of 6.0, what is the likelihood that he will respond to atezolizumab therapy? Please use the Compass tool to analyze the patient's transcriptomic data with a focus on biomarkers that may indicate a favorable response to immune checkpoint inhibitors. In particular, assess markers related to macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T cell activity. Once the molecular analysis is complete, correlate these findings with the patient's clinical history and compile a detailed report that explains how these biomarkers could affect treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-262422-ar-2624229.pkl. "
BLCA,8.0,0.745098039,excluded,R,"In a patient diagnosed with bladder urothelial carcinoma, transcriptomic analysis of the tumor immune microenvironment from a bladder biopsy revealed a tumor mutational burden (TMB) of 8.0. Based on this molecular profile, how likely is the patient to respond to Atezolizumab therapy?","In a patient diagnosed with bladder urothelial carcinoma, transcriptomic analysis of the tumor immune microenvironment from a bladder biopsy revealed a tumor mutational burden (TMB) of 8.0. Based on this molecular profile, how likely is the patient to respond to Atezolizumab therapy? Please utilize the Compass tool to examine the patient’s transcriptomic data, focusing on biomarkers that could be indicative of a positive response to immune checkpoint inhibitors. Specifically, evaluate markers of macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T cell activity. Once you complete the molecular analysis, compare these findings with the patient’s clinical history and prepare a comprehensive report that explains how these biomarkers may influence the treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-27299a-ar-27299ae.pkl. "
BLCA,6.0,0.568627451,inflamed,NR,"We have a white male patient with bladder urothelial carcinoma whose tumor immune microenvironment was profiled via a kidney biopsy, revealing a tumor mutation burden of 6.0 mutations per megabase. Based on this transcriptomic data, what is your assessment of the likelihood of response to Atezolizumab therapy?","We have a white male patient with bladder urothelial carcinoma whose tumor immune microenvironment was profiled via a kidney biopsy, revealing a tumor mutation burden of 6.0 mutations per megabase. Based on this transcriptomic data, what is your assessment of the likelihood of response to Atezolizumab therapy? Please use the Compass tool to analyze the patient’s transcriptomic data with emphasis on potential biomarkers for a positive response to immune checkpoint inhibitors. Focus on evaluating indicators of macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T cell activity. After completing the molecular assessment, review the patient’s clinical history and prepare a detailed report outlining how these biomarkers could affect treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-286870-ar-2868703.pkl. "
BLCA,22.0,,desert,NR,"I have a white male patient with bladder urothelial carcinoma whose bladder biopsy transcriptomic analysis indicates a tumor mutational burden of 22.0 mutations per megabase. Based on these findings, how likely is it that he will respond favorably to atezolizumab therapy?","I have a white male patient with bladder urothelial carcinoma whose bladder biopsy transcriptomic analysis indicates a tumor mutational burden of 22.0 mutations per megabase. Based on these findings, how likely is it that he will respond favorably to atezolizumab therapy? Please use the Compass tool to evaluate the patient's transcriptomic data, with an emphasis on identifying biomarkers that may predict a positive response to immune checkpoint inhibitors. Your analysis should focus on assessing indicators of macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T cell activity. Once the molecular assessment is complete, review the patient's clinical history and compile a comprehensive report discussing how these biomarkers might impact treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-28e603-ar-28e6031.pkl. "
BLCA,1.0,,excluded,NR,"I am managing a White male patient with bladder urothelial carcinoma. The transcriptomic analysis of the tumor immune microenvironment from his bladder biopsy indicates a tumor mutational burden of 1.0. Based on these findings, could you assess the likelihood of a favorable response to Atezolizumab therapy?","I am managing a White male patient with bladder urothelial carcinoma. The transcriptomic analysis of the tumor immune microenvironment from his bladder biopsy indicates a tumor mutational burden of 1.0. Based on these findings, could you assess the likelihood of a favorable response to Atezolizumab therapy? Please use the Compass tool to analyze the patient’s transcriptomic data, specifically focusing on biomarkers that could indicate a favorable response to immune checkpoint inhibitors. In your evaluation, assess markers of macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T cell activity. After completing the molecular analysis, review the patient’s clinical history and prepare a detailed report discussing how these biomarkers might influence treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-297c03-ar-297c030.pkl. "
BLCA,,0.490196078,desert,NR,"For a Caucasian female patient with bladder urothelial carcinoma, transcriptomic profiling from a ureter biopsy of the tumor immune microenvironment shows a tumor mutational burden reported as ""nan."" Based on this information, how might her response to atezolizumab therapy be predicted?","For a Caucasian female patient with bladder urothelial carcinoma, transcriptomic profiling from a ureter biopsy of the tumor immune microenvironment shows a tumor mutational burden reported as ""nan."" Based on this information, how might her response to atezolizumab therapy be predicted? Please use the Compass tool to conduct an analysis of the patient’s transcriptomic data, concentrating on biomarkers associated with a likely positive response to immune checkpoint inhibitors. Specifically, evaluate markers related to macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T cell activity. Once the molecular assessment is complete, review the patient's clinical history and prepare a detailed report discussing how these biomarkers might affect treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-29da92-ar-29da928.pkl. "
BLCA,2.0,0.156862745,desert,NR,"In a White male patient diagnosed with bladder urothelial carcinoma, whose tumor immune microenvironment transcriptomic profile obtained from a kidney biopsy indicates a tumor mutational burden (TMB) of 2.0, how likely is it that he will respond to Atezolizumab therapy?","In a White male patient diagnosed with bladder urothelial carcinoma, whose tumor immune microenvironment transcriptomic profile obtained from a kidney biopsy indicates a tumor mutational burden (TMB) of 2.0, how likely is it that he will respond to Atezolizumab therapy? Please use the Compass tool to analyze the patient’s transcriptomic data, with a focus on biomarkers that may predict a positive response to immune checkpoint inhibitors. Specifically, assess indicators of macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T cell activity. After completing the molecular analysis, review the patient's clinical history and compile a comprehensive report discussing how these biomarkers could influence treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-2b672f-ar-2b672f4.pkl. "
BLCA,11.0,1.294117647,excluded,NR,"For a white male patient with bladder urothelial carcinoma, whose bladder biopsy shows a tumor mutation burden of 11.0 based on transcriptomic profiling of the immune microenvironment, how likely is it that he will respond to Atezolizumab therapy?","For a white male patient with bladder urothelial carcinoma, whose bladder biopsy shows a tumor mutation burden of 11.0 based on transcriptomic profiling of the immune microenvironment, how likely is it that he will respond to Atezolizumab therapy? Please use the Compass tool to evaluate the patient’s transcriptomic data, concentrating on biomarkers that might predict a favorable response to immune checkpoint inhibitors. Focus your assessment on indicators of macrophage activation, interferon‐gamma signaling, genomic stability, cell proliferation, and cytotoxic T cell activity. Once the molecular analysis is complete, review the patient’s clinical history and prepare a detailed report that explains how these biomarkers may affect treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-2bba8c-ar-2bba8cb.pkl. "
BLCA,9.0,0.431372549,desert,NR,"I have a white male patient with bladder urothelial carcinoma (BLCA). A transcriptomic analysis of his tumor immune microenvironment from a bladder biopsy revealed a tumor mutational burden (TMB) of 9.0. Based on these findings, what is the likelihood that he will respond favorably to Atezolizumab therapy?","I have a white male patient with bladder urothelial carcinoma (BLCA). A transcriptomic analysis of his tumor immune microenvironment from a bladder biopsy revealed a tumor mutational burden (TMB) of 9.0. Based on these findings, what is the likelihood that he will respond favorably to Atezolizumab therapy? Please use the Compass tool to assess the patient's transcriptomic data, specifically looking for biomarkers that could predict a positive response to immune checkpoint inhibitors. Concentrate on markers related to macrophage activation, interferon‐gamma signaling, genomic stability, cell proliferation, and cytotoxic T cell activity. After completing the molecular analysis, review the patient's clinical history and prepare a detailed report discussing how these biomarkers might influence treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-2c9586-ar-2c95861.pkl. "
BLCA,,,inflamed,NR,"I have a Caucasian male patient with bladder urothelial carcinoma (BLCA) who underwent a kidney biopsy for transcriptomic analysis of his tumor immune microenvironment. The report indicates an indeterminate tumor mutational burden (TMB). Based on these findings, how likely is it that the patient would respond to Atezolizumab therapy?","I have a Caucasian male patient with bladder urothelial carcinoma (BLCA) who underwent a kidney biopsy for transcriptomic analysis of his tumor immune microenvironment. The report indicates an indeterminate tumor mutational burden (TMB). Based on these findings, how likely is it that the patient would respond to Atezolizumab therapy? Please use the Compass tool to analyze this patient's transcriptomic data for biomarkers that might predict a favorable response to immune checkpoint inhibitors. Focus specifically on markers associated with macrophage activation, interferon‐gamma signaling, genomic stability, cell proliferation, and cytotoxic T cell activity. Once the molecular analysis is complete, review the patient's clinical history and prepare a comprehensive report detailing how these biomarkers could impact treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-2dc3f0-ar-2dc3f04.pkl. "
BLCA,14.0,2.705882353,excluded,NR,"A white male patient diagnosed with bladder urothelial carcinoma underwent a kidney biopsy for transcriptomic profiling of his tumor immune microenvironment, which revealed a tumor mutational burden of 14.0 mutations per megabase. Based on these findings, what is the likelihood of a favorable response to atezolizumab therapy?","A white male patient diagnosed with bladder urothelial carcinoma underwent a kidney biopsy for transcriptomic profiling of his tumor immune microenvironment, which revealed a tumor mutational burden of 14.0 mutations per megabase. Based on these findings, what is the likelihood of a favorable response to atezolizumab therapy? Please use the Compass tool to assess this patient's transcriptomic data for biomarkers that could indicate a likely positive response to immune checkpoint inhibitors. In your analysis, pay particular attention to markers related to macrophage activation, interferon‐gamma signaling, genomic stability, cell proliferation, and cytotoxic T cell activity. Once you have completed the molecular evaluation, review the patient's clinical history in detail and compile a thorough report that explains how these biomarkers may influence treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-2e7aa8-ar-2e7aa8f.pkl. "
BLCA,18.0,1.764705882,,R,"In a white male patient with bladder urothelial carcinoma, transcriptomic profiling from a bladder biopsy revealed a tumor mutational burden (TMB) of 18.0. Could this TMB level indicate a likelihood of a favorable response to Atezolizumab therapy?","In a white male patient with bladder urothelial carcinoma, transcriptomic profiling from a bladder biopsy revealed a tumor mutational burden (TMB) of 18.0. Could this TMB level indicate a likelihood of a favorable response to Atezolizumab therapy? Please use the Compass tool to examine this patient's transcriptomic data in order to identify biomarkers that may predict a positive response to immune checkpoint inhibitors. Focus your analysis on markers associated with macrophage activation, interferon‐gamma signaling, genomic stability, cell proliferation, and cytotoxic T cell activity. After completing this molecular evaluation, review the patient’s clinical history thoroughly and prepare a comprehensive report that explains the potential impact of these biomarkers on the patient’s treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-2e9ac0-ar-2e9ac0b.pkl. "
BLCA,13.0,1.137254902,inflamed,R,"I am evaluating a White male patient with bladder urothelial carcinoma. The transcriptomic analysis of his tumor immune microenvironment from a bladder biopsy shows a tumor mutational burden of 13.0. Based on this information, what is the likelihood that he will respond to atezolizumab therapy?","I am evaluating a White male patient with bladder urothelial carcinoma. The transcriptomic analysis of his tumor immune microenvironment from a bladder biopsy shows a tumor mutational burden of 13.0. Based on this information, what is the likelihood that he will respond to atezolizumab therapy? Please use the Compass tool to analyze this patient’s transcriptomic data with the aim of identifying biomarkers that may predict a positive response to immune checkpoint inhibitors. Focus specifically on markers related to macrophage activation, interferon‐gamma signaling, genomic stability, cell proliferation, and cytotoxic T cell activity. Once you have completed the molecular analysis, review the patient’s clinical history and prepare a detailed report discussing how these biomarkers might affect their treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-2eb07d-ar-2eb07de.pkl. "
BLCA,8.0,0.450980392,excluded,NR,"In a Black or African American female patient with bladder urothelial carcinoma, whose tumor immune microenvironment shows a TMB of 8.0 from transcriptomic analysis, what is the likelihood of a clinically significant response to atezolizumab therapy?","In a Black or African American female patient with bladder urothelial carcinoma, whose tumor immune microenvironment shows a TMB of 8.0 from transcriptomic analysis, what is the likelihood of a clinically significant response to atezolizumab therapy? Please utilize the Compass tool to assess this patient’s transcriptomic data in order to identify biomarkers that could predict a favorable response to immune checkpoint inhibitors. Concentrate specifically on markers of macrophage activation, interferon‐gamma signaling, genomic stability, cell proliferation, and cytotoxic T cell activity. Once your molecular analysis is complete, review the patient's clinical history and compile a comprehensive report detailing how these biomarkers may influence treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-2f2289-ar-2f22893.pkl. "
BLCA,6.0,,excluded,R,"I have a Caucasian female patient diagnosed with bladder urothelial carcinoma. The transcriptomic profile of her tumor microenvironment, obtained from a bladder biopsy, indicates a tumor mutational burden of 6.0. Could you provide an assessment of her likely response to Atezolizumab therapy?","I have a Caucasian female patient diagnosed with bladder urothelial carcinoma. The transcriptomic profile of her tumor microenvironment, obtained from a bladder biopsy, indicates a tumor mutational burden of 6.0. Could you provide an assessment of her likely response to Atezolizumab therapy? Please use the Compass tool to analyze this patient's transcriptomic data and identify biomarkers that could indicate a beneficial response to immune checkpoint inhibitors. Specifically, focus your analysis on indicators related to macrophage activation, interferon‐gamma signaling, genomic stability, cell proliferation, and cytotoxic T cell activity. After completing the molecular evaluation, review the patient's clinical history and prepare a detailed report that discusses how these biomarkers might affect treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-30b5c6-ar-30b5c6c.pkl. "
BLCA,,,excluded,NR,"I have a Caucasian male patient diagnosed with bladder urothelial carcinoma. The transcriptomic analysis of his tumor immune microenvironment from a bladder biopsy indicates a TMB value reported as ""nan."" Based on this information, can you evaluate the likelihood of a positive response to Atezolizumab therapy?","I have a Caucasian male patient diagnosed with bladder urothelial carcinoma. The transcriptomic analysis of his tumor immune microenvironment from a bladder biopsy indicates a TMB value reported as ""nan."" Based on this information, can you evaluate the likelihood of a positive response to Atezolizumab therapy? Using the Compass tool, please evaluate the patient’s transcriptomic data to identify biomarkers that may predict a favorable response to immune checkpoint inhibitors. In your analysis, prioritize markers associated with macrophage activation, interferon‐gamma signaling, genomic stability, cell proliferation, and cytotoxic T cell activity. After completing the molecular evaluation, review the patient’s clinical history and compile a comprehensive report discussing the potential impact of these biomarkers on treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-30cf07-ar-30cf07d.pkl. "
BLCA,23.0,4.235294118,inflamed,R,"A white male patient with a diagnosis of bladder urothelial carcinoma underwent a bladder biopsy, and the transcriptomic profile of his tumor immune microenvironment revealed a tumor mutational burden (TMB) of 23.0. Given this information, what is the likelihood of a favorable response to Atezolizumab therapy?","A white male patient with a diagnosis of bladder urothelial carcinoma underwent a bladder biopsy, and the transcriptomic profile of his tumor immune microenvironment revealed a tumor mutational burden (TMB) of 23.0. Given this information, what is the likelihood of a favorable response to Atezolizumab therapy? Please use the Compass tool to analyze the patient's transcriptomic data and identify biomarkers that may predict a positive response to immune checkpoint inhibitors. In your analysis, focus particularly on markers related to macrophage activation, interferon‐gamma signaling, genomic stability, cell proliferation, and cytotoxic T cell activity. After completing the molecular evaluation, review the patient’s clinical history and prepare a detailed report discussing how these biomarkers might affect treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-31d917-ar-31d9176.pkl. "
BLCA,,0.705882353,,NR,"For a Caucasian female patient diagnosed with bladder urothelial carcinoma, the transcriptomic profiling of the tumor immune microenvironment using a lymph node biopsy revealed a non-assessable tumor mutation burden (reported as ""nan""). Based on these results, what is the likelihood that she would respond favorably to Atezolizumab therapy?","For a Caucasian female patient diagnosed with bladder urothelial carcinoma, the transcriptomic profiling of the tumor immune microenvironment using a lymph node biopsy revealed a non-assessable tumor mutation burden (reported as ""nan""). Based on these results, what is the likelihood that she would respond favorably to Atezolizumab therapy? Please use the Compass tool to examine the patient's transcriptomic data and identify biomarkers that could indicate a likely positive response to immune checkpoint inhibitors. In your evaluation, prioritize biomarkers associated with macrophage activation, interferon‐gamma signaling, genomic stability, cell proliferation, and cytotoxic T cell activity. Once you have completed the molecular analysis, review the patient's clinical history and compile a comprehensive report outlining how these biomarkers may influence treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-31f41d-ar-31f41dd.pkl. "
BLCA,2.0,,,NR,"In a Caucasian male with bladder urothelial carcinoma, a lymph node biopsy analysis of the tumor immune microenvironment revealed a tumor mutation burden of 2.0. Based on this profile, would you consider the patient a likely responder to Atezolizumab therapy?","In a Caucasian male with bladder urothelial carcinoma, a lymph node biopsy analysis of the tumor immune microenvironment revealed a tumor mutation burden of 2.0. Based on this profile, would you consider the patient a likely responder to Atezolizumab therapy? Please use the Compass tool to analyze the patient's transcriptomic data and identify biomarkers that may predict a favorable response to immune checkpoint inhibitors. In your evaluation, focus on markers related to macrophage activation, interferon-γ signaling, genomic stability, cell proliferation, and cytotoxic T cell activity. After completing the molecular analysis, review the patient’s clinical history and prepare a comprehensive report discussing how these biomarkers could affect the treatment outcome.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-3330c0-ar-3330c03.pkl. "
BLCA,,,,NR,"I have a Caucasian male patient diagnosed with bladder urothelial carcinoma. A transcriptomic analysis of his tumor immune microenvironment from a bladder biopsy revealed that the tumor mutational burden is not defined. Based on this information, what is the likelihood of a response to Atezolizumab therapy?","I have a Caucasian male patient diagnosed with bladder urothelial carcinoma. A transcriptomic analysis of his tumor immune microenvironment from a bladder biopsy revealed that the tumor mutational burden is not defined. Based on this information, what is the likelihood of a response to Atezolizumab therapy? Please use the Compass tool to examine this patient’s transcriptomic data and identify biomarkers that could indicate a positive response to immune checkpoint inhibitors. Focus specifically on markers that reflect macrophage activation, interferon-γ signaling, genomic stability, cell proliferation, and cytotoxic T cell activity. Once you have completed the molecular analysis, review the patient’s clinical history and compile a comprehensive report detailing how these biomarkers might influence the treatment outcome.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-34430e-ar-34430ef.pkl. "
BLCA,7.0,0.333333333,excluded,NR,"For a white male patient with bladder urothelial carcinoma and a tumor mutation burden of 7.0 derived from the tumor immune microenvironment, how likely is he to respond to Atezolizumab therapy?","For a white male patient with bladder urothelial carcinoma and a tumor mutation burden of 7.0 derived from the tumor immune microenvironment, how likely is he to respond to Atezolizumab therapy? Please use the Compass tool to analyze this patient's transcriptomic data, specifically identifying biomarkers that could predict a favorable response to immune checkpoint inhibitors. Concentrate on biomarkers related to macrophage activation, interferon-γ signaling, genomic stability, cell proliferation, and cytotoxic T cell activity. After completing the molecular analysis, review the patient's clinical history and prepare a comprehensive report discussing how these biomarkers may affect the treatment outcome.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-36851b-ar-36851bc.pkl. "
BLCA,1.0,0.607843137,inflamed,NR,"For an Asian male patient with bladder urothelial carcinoma whose tumor immune microenvironment transcriptomic profiling shows a tumor mutational burden of 1.0, what is the likelihood of a favorable response to Atezolizumab therapy?","For an Asian male patient with bladder urothelial carcinoma whose tumor immune microenvironment transcriptomic profiling shows a tumor mutational burden of 1.0, what is the likelihood of a favorable response to Atezolizumab therapy? Please use the Compass tool to analyze the patient’s transcriptomic data, with a focus on identifying biomarkers that may predict a positive response to immune checkpoint inhibitors. Specifically, evaluate markers related to macrophage activation, interferon-γ signaling, genomic stability, cell proliferation, and cytotoxic T cell function. Once the molecular analysis is complete, review the patient’s clinical history and prepare a detailed report outlining how these findings might influence treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-36a922-ar-36a9225.pkl. "
BLCA,7.0,0.352941176,excluded,NR,"I have a white male patient diagnosed with bladder urothelial carcinoma. A ureter biopsy of his tumor's immune microenvironment revealed a tumor mutational burden of 7.0. Based on these findings, could you provide your assessment on the likelihood of response to Atezolizumab therapy?","I have a white male patient diagnosed with bladder urothelial carcinoma. A ureter biopsy of his tumor's immune microenvironment revealed a tumor mutational burden of 7.0. Based on these findings, could you provide your assessment on the likelihood of response to Atezolizumab therapy? Please use the Compass tool to evaluate the patient's transcriptomic data, focusing on biomarkers that may indicate a favorable response to immune checkpoint inhibitors. Specifically, assess markers associated with macrophage activation, interferon-γ signaling, genomic stability, cell proliferation, and cytotoxic T-cell function. After completing the molecular analysis, review the patient's clinical history and compile a comprehensive report detailing how these findings could impact treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-36d873-ar-36d8739.pkl. "
BLCA,5.0,,excluded,NR,"I have a white male patient diagnosed with bladder urothelial carcinoma. A transcriptomic analysis of his tumor immune microenvironment from a bladder biopsy revealed a tumor mutational burden of 5.0. Based on these findings, would you expect him to respond favorably to atezolizumab therapy?","I have a white male patient diagnosed with bladder urothelial carcinoma. A transcriptomic analysis of his tumor immune microenvironment from a bladder biopsy revealed a tumor mutational burden of 5.0. Based on these findings, would you expect him to respond favorably to atezolizumab therapy? Please use the Compass tool to analyze the patient’s transcriptomic profile, focusing on biomarkers that may predict a positive response to immune checkpoint inhibitors. Specifically, evaluate indicators related to macrophage activation, interferon-γ signaling, genomic stability, cell proliferation, and cytotoxic T-cell function. Once the molecular assessment is complete, review the patient’s clinical history and prepare a detailed report explaining how these findings might influence treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-3894ac-ar-3894ac3.pkl. "
BLCA,6.0,,excluded,NR,"In a white male patient with bladder urothelial carcinoma, transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy indicates a tumor mutational burden of 6.0 mutations per megabase. Based on this molecular profile, what response might be anticipated with atezolizumab therapy?","In a white male patient with bladder urothelial carcinoma, transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy indicates a tumor mutational burden of 6.0 mutations per megabase. Based on this molecular profile, what response might be anticipated with atezolizumab therapy? Please use the Compass tool to evaluate the patient's transcriptomic data with a focus on identifying biomarkers that could predict a favorable response to immune checkpoint inhibitors. Specifically, assess indicators associated with macrophage activation, interferon-γ signaling, genomic stability, cell proliferation, and cytotoxic T-cell function. After completing the molecular analysis, review the patient’s clinical history and prepare a detailed report discussing how these findings may impact treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-39eb94-ar-39eb94f.pkl. "
BLCA,,,,NR,"A  White male patient with bladder urothelial carcinoma underwent transcriptomic profiling of the tumor immune microenvironment from a lung biopsy, and the tumor mutational burden (TMB) was reported as ""nan."" Based on these findings, how likely is he to respond to Atezolizumab therapy?","A  White male patient with bladder urothelial carcinoma underwent transcriptomic profiling of the tumor immune microenvironment from a lung biopsy, and the tumor mutational burden (TMB) was reported as ""nan."" Based on these findings, how likely is he to respond to Atezolizumab therapy? Please use the Compass tool to analyze the patient's transcriptomic profile, concentrating on identifying biomarkers that could forecast a positive response to immune checkpoint inhibitors. Focus specifically on evaluating markers related to macrophage activation, interferon-γ signaling, genomic stability, cell proliferation, and cytotoxic T-cell function. Once the molecular analysis is complete, integrate these findings with the patient's clinical history and prepare a comprehensive report outlining the potential implications for treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-3a1c96-ar-3a1c963.pkl. "
BLCA,2.0,0.176470588,excluded,NR,"For a white male patient with bladder urothelial carcinoma whose lymph node biopsy shows a tumor mutational burden of 2.0, what is the expected likelihood of a favorable response to atezolizumab therapy?","For a white male patient with bladder urothelial carcinoma whose lymph node biopsy shows a tumor mutational burden of 2.0, what is the expected likelihood of a favorable response to atezolizumab therapy? Please use the Compass tool to examine this patient’s transcriptomic profile, with a focus on identifying biomarkers that may predict a favorable response to immune checkpoint inhibitor therapy. Specifically, evaluate markers of macrophage activation, interferon-γ signaling, genomic stability, cell proliferation, and cytotoxic T-cell function. After completing the molecular analysis, integrate these results with the patient’s clinical history to compile a comprehensive report discussing potential treatment outcome implications.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-3b1066-ar-3b1066e.pkl. "
BLCA,44.0,5.823529412,inflamed,R,"A white male patient with bladder urothelial carcinoma has undergone transcriptomic profiling of the tumor immune microenvironment, which revealed a tumor mutational burden (TMB) of 44.0. Based on this profile, could we expect a favorable response to atezolizumab therapy?","A white male patient with bladder urothelial carcinoma has undergone transcriptomic profiling of the tumor immune microenvironment, which revealed a tumor mutational burden (TMB) of 44.0. Based on this profile, could we expect a favorable response to atezolizumab therapy? Please analyze the patient's transcriptomic data using the Compass tool to identify biomarkers that could predict a favorable response to immune checkpoint inhibitor therapy. In your evaluation, focus on markers associated with macrophage activation, interferon-γ signaling, genomic stability, cell proliferation, and cytotoxic T-cell function. Once the molecular analysis is complete, integrate these findings with the patient's clinical history to create a detailed report outlining the potential implications for treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-3b15b4-ar-3b15b4c.pkl. "
BLCA,15.0,2.235294118,excluded,NR,"I have a white male patient diagnosed with bladder urothelial carcinoma. Transcriptomic analysis of his tumor immune microenvironment, obtained via kidney biopsy, shows a tumor mutational burden of 15. Can you provide an assessment of his likely response to Atezolizumab therapy?","I have a white male patient diagnosed with bladder urothelial carcinoma. Transcriptomic analysis of his tumor immune microenvironment, obtained via kidney biopsy, shows a tumor mutational burden of 15. Can you provide an assessment of his likely response to Atezolizumab therapy? Please review the patient’s transcriptomic data with the Compass tool to identify biomarkers that may indicate a positive response to immune checkpoint inhibitor therapy. In your analysis, pay particular attention to markers related to macrophage activation, interferon-γ signaling, genomic stability, cell proliferation, and cytotoxic T-cell function. After completing the molecular evaluation, integrate these findings with the patient’s clinical history to produce a comprehensive report on the potential treatment implications.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-3cb94b-ar-3cb94b0.pkl. "
BLCA,17.0,1.411764706,excluded,R,"In a white male patient with bladder urothelial carcinoma, transcriptomic analysis of a lymph node biopsy shows a tumor mutation burden of 17.0. How likely is this patient to benefit from atezolizumab therapy?","In a white male patient with bladder urothelial carcinoma, transcriptomic analysis of a lymph node biopsy shows a tumor mutation burden of 17.0. How likely is this patient to benefit from atezolizumab therapy? Please examine the patient's transcriptomic data using the Compass tool to identify biomarkers that may predict a favorable response to immune checkpoint inhibitor therapy. Focus specifically on markers associated with macrophage activation, interferon-γ signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. Once your molecular evaluation is complete, correlate these findings with the patient’s clinical history to compile a detailed report on the potential treatment implications.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-3e04eb-ar-3e04eb9.pkl. "
BLCA,11.0,1.215686275,desert,NR,I have a Caucasian male patient with bladder urothelial carcinoma (BLCA) whose transcriptomic analysis of the tumor immune microenvironment from a kidney biopsy revealed a tumor mutational burden (TMB) of 11.0. Could you evaluate the likelihood of a favorable response to Atezolizumab therapy in this context?,"I have a Caucasian male patient with bladder urothelial carcinoma (BLCA) whose transcriptomic analysis of the tumor immune microenvironment from a kidney biopsy revealed a tumor mutational burden (TMB) of 11.0. Could you evaluate the likelihood of a favorable response to Atezolizumab therapy in this context? Please review the patient's transcriptomic data using the Compass tool to identify biomarkers that could indicate a favorable response to immune checkpoint inhibitors. Specifically, analyze markers related to macrophage activation, interferon-γ signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. After completing the molecular assessment, integrate these findings with the patient’s clinical history to prepare a comprehensive report outlining the potential treatment implications.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-3e8baf-ar-3e8baff.pkl. "
BLCA,,,desert,NR,"I have a Caucasian male patient diagnosed with bladder urothelial carcinoma. The transcriptomic analysis of his tumor immune microenvironment from a bladder biopsy indicates a tumor mutational burden (TMB) reported as ""nan."" Could you provide your assessment on whether he is likely to respond to atezolizumab therapy?","I have a Caucasian male patient diagnosed with bladder urothelial carcinoma. The transcriptomic analysis of his tumor immune microenvironment from a bladder biopsy indicates a tumor mutational burden (TMB) reported as ""nan."" Could you provide your assessment on whether he is likely to respond to atezolizumab therapy? Review the patient's transcriptomic data using the Compass tool to identify biomarkers that may predict a favorable response to immune checkpoint inhibitors. Focus on analyzing indicators associated with macrophage activation, interferon-γ signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. Once the molecular assessment is complete, integrate these findings with the patient's clinical history and prepare a detailed report that outlines the potential implications for treatment.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-3ee5dc-ar-3ee5dcd.pkl. "
BLCA,,0.431372549,excluded,NR,"I am managing a white male patient diagnosed with bladder urothelial carcinoma (BLCA). A transcriptomic analysis of the tumor immune microenvironment from his bladder biopsy reported a tumor mutational burden (TMB) value of ""nan."" Based on these findings, what can we infer about his potential response to Atezolizumab therapy?","I am managing a white male patient diagnosed with bladder urothelial carcinoma (BLCA). A transcriptomic analysis of the tumor immune microenvironment from his bladder biopsy reported a tumor mutational burden (TMB) value of ""nan."" Based on these findings, what can we infer about his potential response to Atezolizumab therapy? Examine the patient's transcriptomic profile using the Compass tool to identify biomarkers that may indicate a positive response to immune checkpoint inhibitors. Specifically, assess markers related to macrophage activation, interferon-γ signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. After completing the molecular evaluation, correlate these findings with the patient’s clinical history and compile a comprehensive report outlining the potential treatment implications.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-415f36-ar-415f36a.pkl. "
BLCA,12.0,0.392156863,desert,NR,"For a white male patient with bladder urothelial carcinoma and a tumor mutation burden of 12.0 as determined by transcriptomic analysis of the tumor immune microenvironment from a bladder biopsy, what is the estimated likelihood that he will respond favorably to Atezolizumab therapy?","For a white male patient with bladder urothelial carcinoma and a tumor mutation burden of 12.0 as determined by transcriptomic analysis of the tumor immune microenvironment from a bladder biopsy, what is the estimated likelihood that he will respond favorably to Atezolizumab therapy? Please use the Compass tool to analyze the patient’s transcriptomic data. Your objective is to identify biomarkers predictive of a positive response to immune checkpoint inhibitors by focusing on markers indicative of macrophage activation, interferon-γ signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. Following the molecular assessment, integrate these findings with the patient’s clinical history and prepare a detailed report that outlines the potential implications for treatment.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-4305ab-ar-4305ab9.pkl. "
BLCA,6.0,0.921568627,excluded,NR,"I have a white male patient diagnosed with bladder urothelial carcinoma. Transcriptomic analysis of his tumor immune microenvironment from a bladder biopsy revealed a tumor mutational burden (TMB) of 6.0. Based on this information, what is the likelihood that he will respond to Atezolizumab therapy?","I have a white male patient diagnosed with bladder urothelial carcinoma. Transcriptomic analysis of his tumor immune microenvironment from a bladder biopsy revealed a tumor mutational burden (TMB) of 6.0. Based on this information, what is the likelihood that he will respond to Atezolizumab therapy? Please use the Compass tool to examine the patient's transcriptomic data. Focus on identifying biomarkers that could predict a positive response to immune checkpoint inhibitors—specifically those related to macrophage activation, interferon-γ signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. After completing the molecular evaluation, integrate these findings with the patient's clinical history and prepare a detailed report discussing the treatment implications.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-4501e4-ar-4501e41.pkl. "
BLCA,5.0,1.392156863,inflamed,NR,"In a Caucasian male patient with bladder urothelial carcinoma, tumor transcriptomic profiling from a bladder biopsy reveals a tumor mutational burden (TMB) of 5.0. Based on these findings, how likely is the patient to respond to atezolizumab therapy?","In a Caucasian male patient with bladder urothelial carcinoma, tumor transcriptomic profiling from a bladder biopsy reveals a tumor mutational burden (TMB) of 5.0. Based on these findings, how likely is the patient to respond to atezolizumab therapy? Please utilize the Compass tool to analyze the patient's transcriptomic data with an emphasis on identifying biomarkers that could indicate a favorable response to immune checkpoint inhibitors. Specifically, evaluate markers associated with macrophage activation, interferon-γ signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. After completing this molecular assessment, correlate the findings with the patient’s clinical history and compile a comprehensive report outlining the potential treatment implications.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-45c8e6-ar-45c8e64.pkl. "
BLCA,8.0,,desert,NR,"I have a Caucasian male patient diagnosed with bladder urothelial carcinoma (BLCA). The transcriptomic analysis of his tumor immune microenvironment from a nano biopsy indicates a tumor mutational burden (TMB) of 8.0 mutations per megabase. Based on this data, how likely is it that he will respond to Atezolizumab therapy?","I have a Caucasian male patient diagnosed with bladder urothelial carcinoma (BLCA). The transcriptomic analysis of his tumor immune microenvironment from a nano biopsy indicates a tumor mutational burden (TMB) of 8.0 mutations per megabase. Based on this data, how likely is it that he will respond to Atezolizumab therapy? Using the Compass tool, please analyze the patient's transcriptomic data to identify biomarkers that may predict a positive response to immune checkpoint inhibitors. In your evaluation, focus on markers related to macrophage activation, interferon-γ signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. Once the molecular assessment is complete, compare these findings with the patient's clinical history and prepare a detailed report outlining the potential implications for treatment.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-468a9e-ar-468a9e1.pkl. "
BLCA,8.0,0.803921569,inflamed,NR,"For a white male patient with bladder urothelial carcinoma and a tumor mutational burden of 8.0 determined from a bladder biopsy transcriptomic profile, how likely is it that he will benefit from treatment with atezolizumab?","For a white male patient with bladder urothelial carcinoma and a tumor mutational burden of 8.0 determined from a bladder biopsy transcriptomic profile, how likely is it that he will benefit from treatment with atezolizumab? Please use the Compass tool to analyze the patient's transcriptomic profile to identify biomarkers that might predict a favorable response to immune checkpoint inhibitors. In your evaluation, concentrate on markers associated with macrophage activation, interferon-γ signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. After completing the molecular analysis, integrate these findings with the patient's clinical history and produce a comprehensive report detailing the potential treatment implications.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-47fc46-ar-47fc46c.pkl. "
BLCA,0.0,0.607843137,excluded,NR,"In a patient diagnosed with bladder urothelial carcinoma, where transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy reveals a tumor mutational burden of 0.0, how likely is the patient to respond to Atezolizumab therapy?","In a patient diagnosed with bladder urothelial carcinoma, where transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy reveals a tumor mutational burden of 0.0, how likely is the patient to respond to Atezolizumab therapy? Please utilize the Compass tool to assess the patient’s transcriptomic profile for biomarkers that may indicate a favorable response to immune checkpoint inhibitors. Your analysis should focus on biomarkers related to macrophage activation, interferon-γ signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. Once the molecular evaluation is complete, integrate the results with the patient’s clinical history and compile a detailed report outlining the implications for treatment.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-49d487-ar-49d4875.pkl. "
BLCA,5.0,1.450980392,excluded,NR,"In a white male patient with bladder urothelial carcinoma whose tumor immune microenvironment transcriptomic analysis—obtained via kidney biopsy—reveals a tumor mutational burden of 5.0, what is the expected likelihood of response to Atezolizumab therapy?","In a white male patient with bladder urothelial carcinoma whose tumor immune microenvironment transcriptomic analysis—obtained via kidney biopsy—reveals a tumor mutational burden of 5.0, what is the expected likelihood of response to Atezolizumab therapy? Please use the Compass tool to analyze the patient’s transcriptomic profile for biomarkers that may predict a positive response to immune checkpoint inhibitors. Specifically, concentrate on markers associated with macrophage activation, interferon-γ signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. After completing the molecular evaluation, combine these findings with the patient’s clinical history and prepare a comprehensive report discussing the potential treatment implications.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-49f9b2-ar-49f9b2e.pkl. "
BLCA,6.0,,desert,NR,"I have a Caucasian male patient with bladder urothelial carcinoma. A transcriptomic analysis of the tumor immune microenvironment from a kidney biopsy revealed a tumor mutational burden of 6.0. Based on these findings, how likely is the patient to respond to Atezolizumab therapy?","I have a Caucasian male patient with bladder urothelial carcinoma. A transcriptomic analysis of the tumor immune microenvironment from a kidney biopsy revealed a tumor mutational burden of 6.0. Based on these findings, how likely is the patient to respond to Atezolizumab therapy? Please use the Compass tool to evaluate the patient's transcriptomic profile. Focus on identifying biomarkers that could indicate a favorable response to immune checkpoint inhibitors, with particular attention to markers related to macrophage activation, interferon-γ signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. Once the molecular analysis is complete, integrate these findings with the patient's clinical history and compile a detailed report outlining the potential implications for treatment.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-4b0175-ar-4b0175e.pkl. "
BLCA,,,excluded,NR,"For a White female patient diagnosed with bladder urothelial carcinoma, transcriptomic profiling of the tumor immune microenvironment from a kidney biopsy indicates a tumor mutational burden (TMB) result of ""nan."" Based on this data, how likely is it that the patient would respond to Atezolizumab therapy?","For a White female patient diagnosed with bladder urothelial carcinoma, transcriptomic profiling of the tumor immune microenvironment from a kidney biopsy indicates a tumor mutational burden (TMB) result of ""nan."" Based on this data, how likely is it that the patient would respond to Atezolizumab therapy? Please use the Compass tool to analyze the patient's transcriptomic profile, focusing on biomarkers that may predict a positive response to immune checkpoint inhibitors. Specifically, assess indicators related to macrophage activation, interferon-γ signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. After completing the molecular analysis, integrate the results with the patient's clinical history and prepare a detailed report on the potential treatment implications.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-4b7ea0-ar-4b7ea01.pkl. "
BLCA,59.0,11.68627451,excluded,R,"For a white male patient diagnosed with bladder urothelial carcinoma (BLCA), whose ureter biopsy transcriptomic profile reveals a tumor mutational burden (TMB) of 59.0, how likely is he to respond to Atezolizumab therapy?","For a white male patient diagnosed with bladder urothelial carcinoma (BLCA), whose ureter biopsy transcriptomic profile reveals a tumor mutational burden (TMB) of 59.0, how likely is he to respond to Atezolizumab therapy? Please employ the Compass tool to evaluate the patient's transcriptomic profile, emphasizing biomarkers that may indicate a favorable response to immune checkpoint inhibitors. In your analysis, prioritize assessments of macrophage activation, interferon-γ signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. Once you complete the molecular analysis, correlate these findings with the patient's clinical history, and compile a comprehensive report outlining the treatment implications.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-4caabd-ar-4caabd6.pkl. "
BLCA,13.0,0.31372549,desert,NR,"Given a white male patient with bladder urothelial carcinoma whose transcriptomic analysis from a kidney biopsy shows a tumor mutational burden of 13.0, would you consider this profile indicative of a likely positive response to atezolizumab therapy?","Given a white male patient with bladder urothelial carcinoma whose transcriptomic analysis from a kidney biopsy shows a tumor mutational burden of 13.0, would you consider this profile indicative of a likely positive response to atezolizumab therapy? Please utilize the Compass tool to analyze the patient's transcriptomic profile, with particular focus on biomarkers associated with a positive response to immune checkpoint inhibitors. Specifically, evaluate indicators such as macrophage activation, interferon-γ signaling, genomic integrity, cell proliferation rates, and cytotoxic T-cell activity. After completing this molecular analysis, integrate these results with the patient's clinical history and prepare a detailed report discussing the potential treatment implications.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-523468-ar-5234688.pkl. "
BLCA,12.0,0.745098039,excluded,NR,"I have a female patient diagnosed with bladder urothelial carcinoma (BLCA). A ureter biopsy provided a transcriptomic profile of her tumor immune microenvironment, revealing a tumor mutational burden (TMB) of 12.0. Based on these findings, how likely is she to respond to Atezolizumab therapy?","I have a female patient diagnosed with bladder urothelial carcinoma (BLCA). A ureter biopsy provided a transcriptomic profile of her tumor immune microenvironment, revealing a tumor mutational burden (TMB) of 12.0. Based on these findings, how likely is she to respond to Atezolizumab therapy? Please use the Compass tool to review the patient's transcriptomic profile. Concentrate on biomarkers that predict a favorable response to immune checkpoint inhibitors, such as markers of macrophage activation, interferon-γ signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. Once you have completed the molecular analysis, combine these findings with the patient's clinical history and compile a detailed report that outlines the potential implications for treatment.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-52500c-ar-52500ca.pkl. "
BLCA,4.0,0.254901961,,NR,"We have a white male patient with bladder urothelial carcinoma whose lymph node biopsy transcriptomic analysis shows a tumor mutational burden of 4.0. Based on these findings, how likely is the patient to respond to Atezolizumab therapy?","We have a white male patient with bladder urothelial carcinoma whose lymph node biopsy transcriptomic analysis shows a tumor mutational burden of 4.0. Based on these findings, how likely is the patient to respond to Atezolizumab therapy? Please utilize the Compass tool to analyze the patient's transcriptomic data. Focus particularly on identifying biomarkers that indicate a likelihood of a positive response to immune checkpoint therapy, including those associated with macrophage activation, interferon-γ signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. After completing the molecular assessment, integrate these findings with the patient’s clinical history and prepare a comprehensive report outlining the potential treatment implications.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-52e3fa-ar-52e3fa3.pkl. "
BLCA,11.0,1.823529412,desert,R,I have a white male patient diagnosed with bladder urothelial carcinoma (BLCA) whose tumor transcriptomic analysis reveals a TMB of 11.0. Could these findings suggest a likely response to Atezolizumab therapy?,"I have a white male patient diagnosed with bladder urothelial carcinoma (BLCA) whose tumor transcriptomic analysis reveals a TMB of 11.0. Could these findings suggest a likely response to Atezolizumab therapy? Please use the Compass tool to examine the patient’s transcriptomic data and identify biomarkers that may predict a favorable response to immune checkpoint therapy. Specifically, look for indicators related to macrophage activation, interferon-γ signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. Once you complete the molecular evaluation, integrate these results with the patient’s clinical history and prepare a detailed report on the potential implications for treatment.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-548551-ar-548551e.pkl. "
BLCA,5.0,,desert,NR,"A Caucasian male with bladder urothelial carcinoma has a transcriptomic profile from a biopsy that shows a tumor mutation burden of 5.0. Based on these findings, would this patient likely respond favorably to Atezolizumab therapy?","A Caucasian male with bladder urothelial carcinoma has a transcriptomic profile from a biopsy that shows a tumor mutation burden of 5.0. Based on these findings, would this patient likely respond favorably to Atezolizumab therapy? Please use the Compass tool to analyze the patient’s transcriptomic data and identify biomarkers that may indicate a positive response to immune checkpoint therapy. Focus on markers of macrophage activation, interferon-γ signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. After completing the molecular analysis, integrate these findings with the patient’s clinical history and prepare a comprehensive report outlining potential treatment implications.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-54e58f-ar-54e58f1.pkl. "
BLCA,,,,NR,"A white female patient with bladder urothelial carcinoma underwent transcriptomic profiling of her tumor immune microenvironment via a kidney biopsy, which reported a tumor mutational burden value of ""nan."" How should we interpret this finding in terms of her likelihood of responding to Atezolizumab therapy?","A white female patient with bladder urothelial carcinoma underwent transcriptomic profiling of her tumor immune microenvironment via a kidney biopsy, which reported a tumor mutational burden value of ""nan."" How should we interpret this finding in terms of her likelihood of responding to Atezolizumab therapy? Please analyze the patient's transcriptomic data using the Compass tool to identify biomarkers associated with a favorable response to immune checkpoint therapy. Specifically, assess indicators related to macrophage activation, interferon-γ signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. Once the molecular analysis is complete, integrate these results with the patient's clinical history and prepare a detailed report discussing the potential treatment implications.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-553c3c-ar-553c3c3.pkl. "
BLCA,5.0,,excluded,NR,I am managing a white male patient diagnosed with bladder urothelial carcinoma. A ureter biopsy with transcriptomic profiling of the tumor immune microenvironment revealed a tumor mutational burden of 5.0 mutations per megabase. Could you please provide your perspective on the likelihood of this patient responding to Atezolizumab therapy?,"I am managing a white male patient diagnosed with bladder urothelial carcinoma. A ureter biopsy with transcriptomic profiling of the tumor immune microenvironment revealed a tumor mutational burden of 5.0 mutations per megabase. Could you please provide your perspective on the likelihood of this patient responding to Atezolizumab therapy? Please evaluate the patient's transcriptomic data using the Compass tool to pinpoint biomarkers linked to a positive response to immune checkpoint therapy. Specifically, focus your assessment on markers related to macrophage activation, interferon-γ signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. Once your molecular analysis is complete, integrate these findings with the patient's clinical history and prepare a comprehensive report outlining the potential implications for treatment.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-557dde-ar-557dde1.pkl. "
BLCA,19.0,0.647058824,inflamed,R,"For a Native Hawaiian or other Pacific Islander patient with bladder urothelial carcinoma who has a tumor mutational burden of 19.0 based on transcriptomic profiling of the tumor immune microenvironment, how likely is it that they will respond to atezolizumab therapy?","For a Native Hawaiian or other Pacific Islander patient with bladder urothelial carcinoma who has a tumor mutational burden of 19.0 based on transcriptomic profiling of the tumor immune microenvironment, how likely is it that they will respond to atezolizumab therapy? Please analyze the patient's transcriptomic data using the Compass tool to identify biomarkers associated with a favorable response to immune checkpoint therapy. Focus specifically on markers indicative of macrophage activation, interferon-γ signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. After you complete the molecular analysis, integrate the results with the patient's clinical history and prepare a detailed report outlining the treatment implications.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-560f23-ar-560f23d.pkl. "
BLCA,,0.607843137,,NR,"For a white male patient with bladder urothelial carcinoma, a transcriptomic analysis of his tumor biopsy indicated a tumor mutational burden (TMB) reported as ""nan."" How should we interpret this finding in terms of his potential response to Atezolizumab therapy?","For a white male patient with bladder urothelial carcinoma, a transcriptomic analysis of his tumor biopsy indicated a tumor mutational burden (TMB) reported as ""nan."" How should we interpret this finding in terms of his potential response to Atezolizumab therapy? Analyze the patient's transcriptomic data with the Compass tool to detect biomarkers that predict a favorable response to immune checkpoint therapy. Concentrate on indicators of macrophage activation, interferon-γ signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. Once the molecular analysis is complete, integrate these findings with the patient’s clinical history and compile a comprehensive report detailing the implications for treatment.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-563d62-ar-563d623.pkl. "
BLCA,,,,NR,"We have a white female patient diagnosed with bladder urothelial carcinoma. Transcriptomic profiling of her tumor microenvironment from a bladder biopsy did not yield a measurable tumor mutational burden (TMB). Based on this finding, how might we predict her response to Atezolizumab therapy?","We have a white female patient diagnosed with bladder urothelial carcinoma. Transcriptomic profiling of her tumor microenvironment from a bladder biopsy did not yield a measurable tumor mutational burden (TMB). Based on this finding, how might we predict her response to Atezolizumab therapy? Review the patient's transcriptomic data using the Compass tool to identify biomarkers that indicate a likely positive response to immune checkpoint therapy. Specifically, focus on markers of macrophage activation, interferon-γ signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. After completing the molecular analysis, integrate these findings with the patient’s clinical history, and prepare a detailed report outlining the potential treatment implications.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-568ce1-ar-568ce16.pkl. "
BLCA,33.0,5.509803922,excluded,R,"A white male patient with bladder urothelial carcinoma has a transcriptomic profile of the tumor immune microenvironment from a kidney biopsy showing a tumor mutational burden of 33.0. Based on these findings, is it reasonable to expect a positive response to Atezolizumab therapy?","A white male patient with bladder urothelial carcinoma has a transcriptomic profile of the tumor immune microenvironment from a kidney biopsy showing a tumor mutational burden of 33.0. Based on these findings, is it reasonable to expect a positive response to Atezolizumab therapy? Please analyze the patient's transcriptomic data using the Compass tool to identify biomarkers associated with a positive response to immune checkpoint therapy. Concentrate on evaluating markers related to macrophage activation, interferon-γ signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. Once the molecular analysis is complete, correlate these findings with the patient’s clinical history and compile a comprehensive report that outlines the potential implications for treatment.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-572f19-ar-572f197.pkl. "
BLCA,32.0,,excluded,R,"A White male patient with bladder urothelial carcinoma has a transcriptomic tumor immune microenvironment profile showing a tumor mutational burden of 32.0 based on a recent biopsy. Based on these findings, is he likely to respond favorably to atezolizumab therapy?","A White male patient with bladder urothelial carcinoma has a transcriptomic tumor immune microenvironment profile showing a tumor mutational burden of 32.0 based on a recent biopsy. Based on these findings, is he likely to respond favorably to atezolizumab therapy? Please use the Compass tool to analyze the patient's transcriptomic data and identify biomarkers that may predict a favorable response to immune checkpoint therapy. Focus on markers that indicate macrophage activation, interferon-γ signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. After completing the molecular analysis, correlate these findings with the patient’s clinical history and prepare a detailed report outlining the potential treatment implications.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-5767dd-ar-5767dd7.pkl. "
BLCA,2.0,0.333333333,desert,R,"For a white male patient with bladder urothelial carcinoma whose tumor transcriptomic analysis from a bladder biopsy shows a TMB of 2.0, how predictive is this biomarker for response to Atezolizumab therapy?","For a white male patient with bladder urothelial carcinoma whose tumor transcriptomic analysis from a bladder biopsy shows a TMB of 2.0, how predictive is this biomarker for response to Atezolizumab therapy? Please use the Compass tool to analyze the patient’s transcriptomic data. Your main goal is to identify biomarkers—specifically those related to macrophage activation, interferon-γ signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity—that could predict a favorable response to immune checkpoint therapy. After completing the molecular analysis, integrate these results with the patient’s clinical history and prepare a comprehensive report detailing the potential implications for treatment.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-58e783-ar-58e7832.pkl. "
BLCA,14.0,,excluded,NR,"I have a patient diagnosed with bladder urothelial carcinoma whose bladder biopsy transcriptomic analysis reveals a tumor mutation burden of 14. Based on these findings, what is the likelihood of a favorable response to Atezolizumab therapy?","I have a patient diagnosed with bladder urothelial carcinoma whose bladder biopsy transcriptomic analysis reveals a tumor mutation burden of 14. Based on these findings, what is the likelihood of a favorable response to Atezolizumab therapy? Use the Compass tool to evaluate the patient’s transcriptomic profile. Your objective is to identify biomarkers associated with macrophage activation, interferon-γ signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity that may indicate a favorable response to immune checkpoint therapy. Once the molecular analysis is complete, integrate these findings with the patient’s clinical history and prepare a detailed report that outlines the potential treatment implications.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-59f392-ar-59f3928.pkl. "
BLCA,,,,NR,"I have a white male patient diagnosed with bladder urothelial carcinoma (BLCA) whose tumor immune microenvironment was profiled using transcriptomic analysis from a nan biopsy. The analysis reported a TMB value (currently noted as unavailable). Based on these findings, can you help evaluate the likelihood of a clinically meaningful response to atezolizumab therapy?","I have a white male patient diagnosed with bladder urothelial carcinoma (BLCA) whose tumor immune microenvironment was profiled using transcriptomic analysis from a nan biopsy. The analysis reported a TMB value (currently noted as unavailable). Based on these findings, can you help evaluate the likelihood of a clinically meaningful response to atezolizumab therapy? Please use the Compass tool to analyze the patient’s transcriptomic profile. Specifically, assess biomarkers related to macrophage activation, interferon‐γ signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity, as these may predict a positive response to immune checkpoint therapy. Once you’ve completed the molecular analysis, please integrate these findings with the patient’s clinical history and compile a comprehensive report that outlines the potential treatment implications.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-59fda9-ar-59fda90.pkl. "
BLCA,9.0,1.333333333,desert,NR,"For a white male patient diagnosed with bladder urothelial carcinoma, whose tumor microenvironment transcriptomic profile from a bladder biopsy shows a TMB of 9.0, what is the likelihood of a favorable response to Atezolizumab therapy?","For a white male patient diagnosed with bladder urothelial carcinoma, whose tumor microenvironment transcriptomic profile from a bladder biopsy shows a TMB of 9.0, what is the likelihood of a favorable response to Atezolizumab therapy? Please use the Compass tool to evaluate the patient's transcriptomic profile, focusing on biomarkers for macrophage activation, interferon‐γ signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. These biomarkers may help predict a favorable response to immune checkpoint therapy. After completing the molecular analysis, integrate these results with the patient's clinical history and produce a detailed report outlining the implications for treatment.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-5a2347-ar-5a2347c.pkl. "
BLCA,12.0,,,NR,"In an Asian female patient with bladder urothelial carcinoma, a ureter biopsy of the tumor immune microenvironment showed a tumor mutational burden (TMB) of 12.0 mutations/Mb. Based on these findings, would you expect this patient to respond favorably to Atezolizumab therapy?","In an Asian female patient with bladder urothelial carcinoma, a ureter biopsy of the tumor immune microenvironment showed a tumor mutational burden (TMB) of 12.0 mutations/Mb. Based on these findings, would you expect this patient to respond favorably to Atezolizumab therapy? Please use the Compass tool to analyze the patient's transcriptomic profile, paying particular attention to biomarkers related to macrophage activation, interferon‐γ signaling, genomic stability, cell proliferation, and cytotoxic T‐cell activity. These markers can potentially indicate a favorable responsiveness to immune checkpoint inhibition. Upon completing this molecular evaluation, please compile a comprehensive report that incorporates these findings with the patient’s clinical history and clearly outlines the treatment implications.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-5b57e4-ar-5b57e47.pkl. "
BLCA,,,excluded,NR,"In a white male patient with bladder urothelial carcinoma, the transcriptomic analysis of the tumor immune microenvironment from a bladder biopsy revealed an indeterminate (nan) tumor mutational burden. Based on these findings, what is the likelihood that the patient will respond to Atezolizumab therapy?","In a white male patient with bladder urothelial carcinoma, the transcriptomic analysis of the tumor immune microenvironment from a bladder biopsy revealed an indeterminate (nan) tumor mutational burden. Based on these findings, what is the likelihood that the patient will respond to Atezolizumab therapy? Please use the Compass tool to conduct an in-depth analysis of the patient’s transcriptomic profile. Focus on evaluating biomarkers that are indicative of macrophage activation, interferon-γ signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity, as these factors may predict a positive response to immune checkpoint inhibition. Once the analysis is complete, compile a detailed report that integrates these molecular findings with the patient’s clinical history and clearly outlines the implications for treatment.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-5c139c-ar-5c139c5.pkl. "
BLCA,11.0,0.411764706,desert,NR,"We have a White male patient diagnosed with bladder urothelial carcinoma. The transcriptomic analysis from his bladder biopsy shows a tumor mutation burden of 11.0. Based on these findings, what is the likelihood that he will respond to Atezolizumab therapy?","We have a White male patient diagnosed with bladder urothelial carcinoma. The transcriptomic analysis from his bladder biopsy shows a tumor mutation burden of 11.0. Based on these findings, what is the likelihood that he will respond to Atezolizumab therapy? Please use the Compass tool to perform a thorough analysis of the patient’s transcriptomic data. Specifically, assess biomarkers associated with macrophage activation, interferon-γ signaling, genomic integrity, cell proliferation, and cytotoxic T-cell activity, as these may indicate a favorable response to immune checkpoint inhibitors. After completing the analysis, integrate the molecular findings with the patient's clinical history and prepare a comprehensive report outlining the potential treatment implications.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-5cc2d9-ar-5cc2d90.pkl. "
BLCA,10.0,1.215686275,,NR,"For a white male patient with bladder urothelial carcinoma, transcriptomic analysis of the tumor immune microenvironment from a liver biopsy revealed a tumor mutational burden of 10. How likely is this patient to respond to atezolizumab therapy?","For a white male patient with bladder urothelial carcinoma, transcriptomic analysis of the tumor immune microenvironment from a liver biopsy revealed a tumor mutational burden of 10. How likely is this patient to respond to atezolizumab therapy? Utilize the Compass tool to conduct a comprehensive evaluation of the patient’s transcriptomic data. Focus on biomarkers related to macrophage activation, interferon-γ signaling, genomic integrity, cell proliferation, and cytotoxic T-cell function, as these may suggest a favorable response to immune checkpoint inhibitors. Once the analysis is complete, correlate these molecular findings with the patient's clinical history and compile a detailed report outlining the treatment implications.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-5cfa16-ar-5cfa169.pkl. "
BLCA,12.0,,,NR,"In a white male patient with bladder urothelial carcinoma, transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy revealed a tumor mutational burden of 12.0. Could this TMB value indicate a likely response to atezolizumab therapy?","In a white male patient with bladder urothelial carcinoma, transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy revealed a tumor mutational burden of 12.0. Could this TMB value indicate a likely response to atezolizumab therapy? Please use the Compass tool to perform a detailed analysis of the patient’s transcriptomic data with a particular focus on biomarkers associated with macrophage activation, interferon-γ signaling, genomic stability, cell proliferation, and cytotoxic T-cell function. These biomarkers may indicate a potential positive response to immune checkpoint inhibitors. After completing the analysis, integrate these molecular findings with the patient’s clinical history, and prepare a comprehensive report that outlines the potential treatment implications.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-5d1dfd-ar-5d1dfd5.pkl. "
BLCA,13.0,1.411764706,desert,NR,"For a patient with bladder urothelial carcinoma (BLCA) who has a tumor mutational burden (TMB) of 13.0 based on transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy, how might we assess their likelihood of responding to atezolizumab therapy?","For a patient with bladder urothelial carcinoma (BLCA) who has a tumor mutational burden (TMB) of 13.0 based on transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy, how might we assess their likelihood of responding to atezolizumab therapy? Please use the Compass tool to thoroughly analyze the patient's transcriptomic data, paying special attention to biomarkers related to macrophage activation, interferon-γ signaling, genomic stability, cell proliferation, and cytotoxic T-cell function. These biomarkers may help predict a favorable response to immune checkpoint inhibitors. After completing the analysis, integrate your molecular findings with the patient's clinical history to prepare a detailed report that outlines the potential implications for treatment.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-5d989c-ar-5d989c8.pkl. "
BLCA,6.0,0.823529412,excluded,NR,"I have a white male patient with bladder urothelial carcinoma (BLCA). A transcriptomic analysis of the tumor immune microenvironment obtained from a kidney biopsy revealed a tumor mutational burden (TMB) of 6.0. Based on these findings, could you evaluate his likelihood of responding to Atezolizumab therapy?","I have a white male patient with bladder urothelial carcinoma (BLCA). A transcriptomic analysis of the tumor immune microenvironment obtained from a kidney biopsy revealed a tumor mutational burden (TMB) of 6.0. Based on these findings, could you evaluate his likelihood of responding to Atezolizumab therapy? Utilize the Compass tool to perform a detailed analysis of the patient's transcriptomic data. Focus on biomarkers associated with macrophage activation, interferon-γ signaling, genomic stability, cell proliferation, and cytotoxic T-cell function, as these may indicate a positive response to immune checkpoint inhibitors. Once the analysis is complete, integrate your molecular findings with the patient's clinical history and compile a comprehensive report outlining the potential treatment implications.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-5e3bae-ar-5e3bae0.pkl. "
BLCA,21.0,3.823529412,inflamed,NR,"In a Caucasian male diagnosed with bladder urothelial carcinoma, transcriptomic analysis of the tumor microenvironment from a ureter biopsy revealed a tumor mutational burden of 21.0. Considering this profile, how likely is the patient to respond to Atezolizumab therapy?","In a Caucasian male diagnosed with bladder urothelial carcinoma, transcriptomic analysis of the tumor microenvironment from a ureter biopsy revealed a tumor mutational burden of 21.0. Considering this profile, how likely is the patient to respond to Atezolizumab therapy? Use the Compass tool to perform a comprehensive analysis of the patient's transcriptomic profile. Focus specifically on biomarkers related to macrophage activation, interferon-γ signaling, genomic stability, cell proliferation, and cytotoxic T-cell function, as these may help predict a positive response to immune checkpoint inhibitors. Once the analysis is complete, integrate these molecular findings with the patient’s clinical history and prepare a detailed report outlining the potential implications for treatment.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-5fe7a8-ar-5fe7a81.pkl. "
BLCA,14.0,,inflamed,R,"For a white male with bladder urothelial carcinoma and a tumor mutational burden of 14.0 from a bladder biopsy transcriptomic analysis, what is the likelihood that he will respond to Atezolizumab therapy?","For a white male with bladder urothelial carcinoma and a tumor mutational burden of 14.0 from a bladder biopsy transcriptomic analysis, what is the likelihood that he will respond to Atezolizumab therapy? Please use the Compass tool to conduct an in‐depth analysis of the patient’s transcriptomic profile. Your examination should particularly assess biomarkers that indicate macrophage activation, interferon‐γ signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity, as these markers may be useful for predicting a favorable response to immune checkpoint inhibitors. After completing the analysis, integrate the molecular data with the patient’s clinical history and compile a detailed report that discusses the potential treatment implications based on these findings.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-6083aa-ar-6083aac.pkl. "
BLCA,9.0,1.803921569,desert,R,"For a white male patient with bladder urothelial carcinoma whose bladder biopsy transcriptomic analysis shows a tumor mutational burden of 9.0, how likely is it that he will respond favorably to atezolizumab therapy?","For a white male patient with bladder urothelial carcinoma whose bladder biopsy transcriptomic analysis shows a tumor mutational burden of 9.0, how likely is it that he will respond favorably to atezolizumab therapy? Use the Compass tool to perform a thorough analysis of the patient’s transcriptomic profile. Focus on biomarkers for macrophage activation, interferon-γ signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity, as these may help predict a positive response to immune checkpoint inhibitors. Once the analysis is complete, combine the molecular findings with the patient’s clinical history and prepare a detailed report outlining the potential treatment implications based on these results.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-6157c8-ar-6157c8f.pkl. "
BLCA,27.0,5.882352941,inflamed,NR,"We have a white male patient with bladder urothelial carcinoma. A transcriptomic analysis of his tumor immune microenvironment from a bladder biopsy revealed a tumor mutational burden of 27.0. Based on this data, what is the likelihood that he will respond favorably to Atezolizumab therapy?","We have a white male patient with bladder urothelial carcinoma. A transcriptomic analysis of his tumor immune microenvironment from a bladder biopsy revealed a tumor mutational burden of 27.0. Based on this data, what is the likelihood that he will respond favorably to Atezolizumab therapy? Please use the Compass tool to conduct a detailed analysis of the patient’s transcriptomic profile. Focus on evaluating biomarkers related to macrophage activation, interferon-γ signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity, as these may indicate a likelihood of a favorable response to immune checkpoint inhibitors. After completing the analysis, correlate the molecular findings with the patient’s clinical history and compile a comprehensive report that outlines the potential treatment implications based on these results.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-61b9d4-ar-61b9d4d.pkl. "
BLCA,,,desert,NR,"For a white female patient with bladder urothelial carcinoma whose lymph node biopsy transcriptomic profiling of the tumor immune microenvironment reported a TMB value of ""nan"", how might we interpret her likelihood of responding to Atezolizumab therapy?","For a white female patient with bladder urothelial carcinoma whose lymph node biopsy transcriptomic profiling of the tumor immune microenvironment reported a TMB value of ""nan"", how might we interpret her likelihood of responding to Atezolizumab therapy? Please use the Compass tool to perform a comprehensive transcriptomic analysis. Specifically, evaluate biomarkers associated with macrophage activation, interferon-γ signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity, as these may predict responsiveness to immune checkpoint inhibitors. Once the analysis is complete, integrate these molecular insights with the patient’s clinical history and prepare a detailed report that discusses the potential treatment implications.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-61baf9-ar-61baf91.pkl. "
BLCA,5.0,0.784313725,,NR,"For a white female patient with bladder urothelial carcinoma (BLCA) whose tumor profiling via kidney biopsy shows a tumor mutational burden of 5.0 mutations per megabase, how likely is she to respond to Atezolizumab therapy?","For a white female patient with bladder urothelial carcinoma (BLCA) whose tumor profiling via kidney biopsy shows a tumor mutational burden of 5.0 mutations per megabase, how likely is she to respond to Atezolizumab therapy? Use the Compass tool to conduct an in-depth transcriptomic analysis, focusing on biomarkers linked to macrophage activation, interferon-γ signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. These markers may help predict the patient’s response to immune checkpoint inhibitors. After completing the analysis, please integrate these molecular findings with the patient’s clinical history and prepare a detailed report discussing the potential treatment implications.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-62fb13-ar-62fb138.pkl. "
BLCA,,0.156862745,,NR,"For a Caucasian male patient diagnosed with bladder urothelial carcinoma, whose bladder biopsy transcriptomic analysis reports an undefined tumor mutational burden, can we predict his likelihood of responding to Atezolizumab therapy?","For a Caucasian male patient diagnosed with bladder urothelial carcinoma, whose bladder biopsy transcriptomic analysis reports an undefined tumor mutational burden, can we predict his likelihood of responding to Atezolizumab therapy? Please use the Compass tool to perform a comprehensive transcriptomic analysis. Concentrate on biomarkers associated with macrophage activation, interferon-γ signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity, as these may help predict the patient’s response to immune checkpoint inhibitors. Once the analysis is complete, combine these molecular findings with the patient’s clinical history and compile a detailed report outlining the implications for treatment options.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-63405b-ar-63405b0.pkl. "
BLCA,14.0,0.980392157,desert,NR,"For a white male patient diagnosed with bladder urothelial carcinoma, whose tumor immune microenvironment transcriptomic profile from a bladder biopsy shows a tumor mutational burden of 14.0, what is your assessment of his likely response to atezolizumab therapy?","For a white male patient diagnosed with bladder urothelial carcinoma, whose tumor immune microenvironment transcriptomic profile from a bladder biopsy shows a tumor mutational burden of 14.0, what is your assessment of his likely response to atezolizumab therapy? Please use the Compass tool to conduct a thorough transcriptomic analysis, with special emphasis on biomarkers linked to macrophage activation, interferon-γ signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. These markers may help predict the patient's response to immune checkpoint inhibitors. Once the analysis is complete, integrate the molecular findings with the patient's clinical history and prepare a comprehensive report outlining the potential implications for treatment options.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-63b218-ar-63b2189.pkl. "
BLCA,4.0,0.294117647,excluded,NR,"In a Caucasian male with bladder urothelial carcinoma, transcriptomic analysis of the tumor immune microenvironment from a bladder biopsy revealed a tumor mutational burden of 4.0. Based on this information, what is the likelihood that he will respond to atezolizumab therapy?","In a Caucasian male with bladder urothelial carcinoma, transcriptomic analysis of the tumor immune microenvironment from a bladder biopsy revealed a tumor mutational burden of 4.0. Based on this information, what is the likelihood that he will respond to atezolizumab therapy? Please use the Compass tool to perform a comprehensive transcriptomic analysis that focuses on the biomarkers related to macrophage activation, interferon-γ signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. These biomarkers could provide valuable insights into how the patient might respond to immune checkpoint inhibitors. After completing the analysis, integrate the results with the patient's clinical history and prepare a detailed report outlining the potential treatment implications.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-65afda-ar-65afda2.pkl. "
BLCA,5.0,0.490196078,inflamed,NR,"For a White male patient with bladder urothelial carcinoma, whose tumor immune microenvironment transcriptomic analysis shows a tumor mutational burden (TMB) of 5.0, how should we interpret the likelihood of a meaningful clinical response to atezolizumab?","For a White male patient with bladder urothelial carcinoma, whose tumor immune microenvironment transcriptomic analysis shows a tumor mutational burden (TMB) of 5.0, how should we interpret the likelihood of a meaningful clinical response to atezolizumab? Please use the Compass tool to conduct a detailed transcriptomic analysis targeting key biomarkers, such as those involved in macrophage activation, interferon-γ signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. These biomarkers may offer important insights regarding the patient’s potential response to immune checkpoint inhibitors. Once the analysis is complete, please correlate the results with the patient’s clinical history and compile a comprehensive report that outlines the treatment implications.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-6662f5-ar-6662f51.pkl. "
BLCA,15.0,2.68627451,excluded,R,"In a White female patient with bladder urothelial carcinoma, using tumor immune microenvironment transcriptomic profiling that shows a tumor mutational burden (TMB) of 15 mutations per megabase, how likely is it that the patient will respond to Atezolizumab therapy?","In a White female patient with bladder urothelial carcinoma, using tumor immune microenvironment transcriptomic profiling that shows a tumor mutational burden (TMB) of 15 mutations per megabase, how likely is it that the patient will respond to Atezolizumab therapy? Please use the Compass tool to perform a comprehensive transcriptomic evaluation concentrating on key biomarkers—specifically those related to macrophage activation, interferon-γ signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. These biomarkers can help predict the patient’s response to immune checkpoint inhibitors. After completing the evaluation, integrate the findings with the patient’s clinical history and prepare a detailed report outlining the treatment implications.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-670649-ar-670649e.pkl. "
BLCA,13.0,1.254901961,desert,NR,"In a white male patient with bladder urothelial carcinoma, the transcriptomic profile of his bladder biopsy reveals a tumor mutational burden (TMB) of 13.0. Based on these findings, how would you evaluate his likelihood of responding to atezolizumab therapy?","In a white male patient with bladder urothelial carcinoma, the transcriptomic profile of his bladder biopsy reveals a tumor mutational burden (TMB) of 13.0. Based on these findings, how would you evaluate his likelihood of responding to atezolizumab therapy? Please use the Compass tool to conduct a detailed transcriptomic analysis, focusing on biomarkers related to macrophage activation, interferon-γ signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. These markers are intended to assist in forecasting the patient’s response to immune checkpoint therapy. Once the analysis is complete, integrate the results with the patient’s clinical history and compile a comprehensive report that outlines the potential treatment implications.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-675a12-ar-675a12a.pkl. "
BLCA,14.0,2.549019608,inflamed,NR,"A white female patient has been diagnosed with bladder urothelial carcinoma. Tumor immune microenvironment analysis from a bladder biopsy revealed a tumor mutational burden of 14.0. Based on these findings, what is the likelihood that she will respond favorably to Atezolizumab therapy?","A white female patient has been diagnosed with bladder urothelial carcinoma. Tumor immune microenvironment analysis from a bladder biopsy revealed a tumor mutational burden of 14.0. Based on these findings, what is the likelihood that she will respond favorably to Atezolizumab therapy? Please use the Compass tool to perform an in-depth transcriptomic analysis, with an emphasis on biomarkers tied to macrophage activation, interferon-γ signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. These biomarkers are critical for predicting the patient's response to immune checkpoint therapy. Once you have completed the analysis, please integrate the findings with the patient's clinical history and prepare a detailed report outlining the therapeutic implications.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-6780ed-ar-6780ed4.pkl. "
BLCA,17.0,1.117647059,desert,NR,"For a Black or African American male patient diagnosed with bladder urothelial carcinoma, whose tumor biopsy transcriptomic analysis shows a tumor mutation burden (TMB) of 17.0, how likely is he to benefit from Atezolizumab therapy?","For a Black or African American male patient diagnosed with bladder urothelial carcinoma, whose tumor biopsy transcriptomic analysis shows a tumor mutation burden (TMB) of 17.0, how likely is he to benefit from Atezolizumab therapy? Please use the Compass tool to conduct a comprehensive transcriptomic analysis. Focus on evaluating biomarkers associated with macrophage activation, interferon-γ signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity, as these are key indicators for predicting the response to immune checkpoint therapy. Once the analysis is complete, correlate these findings with the patient’s clinical history and produce a detailed report that outlines the potential therapeutic implications.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-6792d6-ar-6792d6e.pkl. "
BLCA,7.0,1.862745098,excluded,R,"I have a White male patient with bladder urothelial carcinoma whose tumor microenvironment was characterized using transcriptomic profiling of a bladder biopsy, revealing a tumor mutational burden (TMB) of 7.0. Could you evaluate the likelihood of his responding to Atezolizumab therapy?","I have a White male patient with bladder urothelial carcinoma whose tumor microenvironment was characterized using transcriptomic profiling of a bladder biopsy, revealing a tumor mutational burden (TMB) of 7.0. Could you evaluate the likelihood of his responding to Atezolizumab therapy? Please perform a comprehensive transcriptomic analysis using the Compass tool, with an emphasis on assessing biomarkers related to macrophage activation, interferon-γ signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity—all key indicators for predicting response to immune checkpoint therapy. After completing the analysis, correlate the results with the patient’s clinical history and prepare a detailed report outlining the potential therapeutic implications.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-681e4b-ar-681e4bf.pkl. "
BLCA,5.0,1.176470588,,NR,"In a white male patient with bladder urothelial carcinoma, a transcriptomic analysis from a bladder biopsy revealed a tumor mutational burden (TMB) of 5.0. Based on these findings, what is the likelihood that the patient will respond favorably to Atezolizumab therapy?","In a white male patient with bladder urothelial carcinoma, a transcriptomic analysis from a bladder biopsy revealed a tumor mutational burden (TMB) of 5.0. Based on these findings, what is the likelihood that the patient will respond favorably to Atezolizumab therapy? Please conduct a comprehensive transcriptomic analysis using the Compass tool, focusing specifically on biomarkers associated with macrophage activation, interferon-γ signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity—these are pivotal in assessing the likelihood of a favorable response to immune checkpoint therapy. Once the analysis is complete, integrate the findings with the patient’s clinical history and compile a detailed report that outlines the potential therapeutic implications.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-6964a6-ar-6964a6d.pkl. "
BLCA,20.0,1.039215686,desert,R,"In a white male patient with bladder urothelial carcinoma, a lung biopsy of the tumor immune microenvironment revealed a tumor mutation burden of 20.0. Based on these findings, how likely is it that the patient will respond to atezolizumab therapy?","In a white male patient with bladder urothelial carcinoma, a lung biopsy of the tumor immune microenvironment revealed a tumor mutation burden of 20.0. Based on these findings, how likely is it that the patient will respond to atezolizumab therapy? Please perform a detailed transcriptomic analysis using the Compass tool, with a focus on biomarkers linked to macrophage activation, interferon-γ signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. These biomarkers are critical for evaluating the probability of a positive response to immune checkpoint therapy. After completing the analysis, combine the results with the patient’s clinical history and prepare a comprehensive report that highlights the potential therapeutic implications.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-6cb230-ar-6cb230f.pkl. "
BLCA,3.0,0.960784314,inflamed,NR,"We have a White male patient diagnosed with bladder urothelial carcinoma. Transcriptomic profiling of his tumor immune microenvironment from a bladder biopsy reveals a tumor mutational burden (TMB) of 3.0. Based on this information, could you comment on the likelihood of his responding to Atezolizumab therapy?","We have a White male patient diagnosed with bladder urothelial carcinoma. Transcriptomic profiling of his tumor immune microenvironment from a bladder biopsy reveals a tumor mutational burden (TMB) of 3.0. Based on this information, could you comment on the likelihood of his responding to Atezolizumab therapy? Please conduct an in-depth transcriptomic analysis using the Compass tool, emphasizing biomarkers associated with macrophage activation, interferon-γ signaling, genomic stability, cell proliferation, and cytotoxic T-cell function. These biomarkers are essential for assessing the likelihood of a favorable response to immune checkpoint therapy. Once the analysis is complete, integrate these findings with the patient's clinical history and prepare a detailed report outlining the potential therapeutic implications.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-6cbc10-ar-6cbc10a.pkl. "
BLCA,,,excluded,NR,"I have a Black or African American male patient diagnosed with bladder urothelial carcinoma (BLCA). A transcriptomic analysis of the tumor immune microenvironment from a lymph node biopsy reported a non-available tumor mutational burden (TMB). Based on these findings, could you provide guidance on whether this patient might respond to Atezolizumab therapy?","I have a Black or African American male patient diagnosed with bladder urothelial carcinoma (BLCA). A transcriptomic analysis of the tumor immune microenvironment from a lymph node biopsy reported a non-available tumor mutational burden (TMB). Based on these findings, could you provide guidance on whether this patient might respond to Atezolizumab therapy? Please perform a comprehensive transcriptomic analysis using the Compass tool, focusing on biomarkers linked to macrophage activation, interferon-γ signaling, genomic stability, cell proliferation, and cytotoxic T-cell function. These markers are critical in evaluating the probability of a positive response to immune checkpoint therapy. After completing the analysis, integrate the data with the patient's clinical history and compile a detailed report that outlines the potential therapeutic implications.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-6d2ae0-ar-6d2ae0c.pkl. "
BLCA,,3.568627451,,NR,"I have a white male patient diagnosed with bladder urothelial carcinoma whose transcriptomic analysis of the tumor immune microenvironment from a bladder biopsy indicates a tumor mutational burden reported as ""nan."" Could you provide insights on his likely response to Atezolizumab therapy?","I have a white male patient diagnosed with bladder urothelial carcinoma whose transcriptomic analysis of the tumor immune microenvironment from a bladder biopsy indicates a tumor mutational burden reported as ""nan."" Could you provide insights on his likely response to Atezolizumab therapy? Please use the Compass tool to conduct a full transcriptomic evaluation, focusing on biomarkers that indicate macrophage activation, interferon-γ signaling, genomic stability, cell proliferation, and cytotoxic T-cell function. These markers are essential for assessing the likelihood of a favorable response to immune checkpoint therapy. Once the analysis is complete, correlate these molecular findings with the patient’s clinical history and prepare a comprehensive report that details the therapeutic implications.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-6dd7ad-ar-6dd7ad1.pkl. "
BLCA,8.0,2.078431373,,R,"For a white female patient diagnosed with bladder urothelial carcinoma (BLCA) whose tumor immune microenvironment transcriptomic profile, obtained via a nanobiopsy, reveals a tumor mutational burden of 8.0, how likely is she to respond to atezolizumab therapy?","For a white female patient diagnosed with bladder urothelial carcinoma (BLCA) whose tumor immune microenvironment transcriptomic profile, obtained via a nanobiopsy, reveals a tumor mutational burden of 8.0, how likely is she to respond to atezolizumab therapy? Please use the Compass tool to perform a comprehensive transcriptomic analysis, with an emphasis on markers for macrophage activation, interferon-γ signaling, genomic stability, cell proliferation, and cytotoxic T-cell function. These biomarkers are key to predicting a positive response to immune checkpoint therapy. After completing the analysis, integrate the molecular findings with the patient’s clinical history, and prepare a detailed report outlining the clinical and therapeutic implications.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-6f2a10-ar-6f2a102.pkl. "
BLCA,6.0,1.039215686,excluded,R,"A  white patient diagnosed with bladder urothelial carcinoma has a tumor transcriptomic profile from a kidney biopsy indicating a tumor mutational burden of 6.0. Based on this information, how likely is the patient to respond to atezolizumab therapy?","A  white patient diagnosed with bladder urothelial carcinoma has a tumor transcriptomic profile from a kidney biopsy indicating a tumor mutational burden of 6.0. Based on this information, how likely is the patient to respond to atezolizumab therapy? Please use the Compass tool to conduct a comprehensive transcriptomic analysis, focusing on markers of macrophage activation, interferon-γ signaling, genomic stability, cell proliferation, and cytotoxic T-cell function. These biomarkers are critical for predicting a favorable response to immune checkpoint therapy. Once the analysis is complete, integrate the molecular findings with the patient’s clinical history and prepare a detailed report outlining the clinical and therapeutic implications.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-6ff654-ar-6ff654a.pkl. "
BLCA,17.0,2.176470588,,NR,"For a white male patient diagnosed with bladder urothelial carcinoma, whose tumor immune microenvironment transcriptomic analysis from a bladder biopsy indicates a TMB of 17.0, what is your assessment regarding his potential response to atezolizumab therapy?","For a white male patient diagnosed with bladder urothelial carcinoma, whose tumor immune microenvironment transcriptomic analysis from a bladder biopsy indicates a TMB of 17.0, what is your assessment regarding his potential response to atezolizumab therapy? Please use the Compass tool to perform a detailed transcriptomic analysis emphasizing markers related to macrophage activation, interferon-γ signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. These markers are important in identifying patients who may benefit from immune checkpoint therapies. After completing the analysis, correlate the molecular insights with the patient’s clinical history and produce a comprehensive report discussing the clinical and therapeutic implications.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-7114d9-ar-7114d99.pkl. "
BLCA,6.0,1.568627451,,NR,"For a white male patient with bladder urothelial carcinoma who underwent a kidney biopsy for transcriptomic profiling of the tumor microenvironment, revealing a tumor mutational burden of 6.0, how likely is he to respond to atezolizumab therapy?","For a white male patient with bladder urothelial carcinoma who underwent a kidney biopsy for transcriptomic profiling of the tumor microenvironment, revealing a tumor mutational burden of 6.0, how likely is he to respond to atezolizumab therapy? Please utilize the Compass tool to conduct a comprehensive transcriptomic analysis focusing on biomarkers associated with macrophage activation, interferon-γ signaling, genomic stability, cellular proliferation, and cytotoxic T-cell activity. These biomarkers can help identify patients who might respond favorably to immune checkpoint therapies. Upon completion of the analysis, integrate these molecular findings with the patient’s clinical history and compile a detailed report outlining the implications for diagnosis and therapeutic strategies.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-716f54-ar-716f54e.pkl. "
BLCA,1.0,0.333333333,,R,"I have a white male patient with bladder urothelial carcinoma (BLCA) whose tumor immune microenvironment was assessed using a lymph node biopsy, showing a tumor mutational burden (TMB) of 1.0. Based on this profile, could you advise on the likelihood of a favorable response to Atezolizumab therapy?","I have a white male patient with bladder urothelial carcinoma (BLCA) whose tumor immune microenvironment was assessed using a lymph node biopsy, showing a tumor mutational burden (TMB) of 1.0. Based on this profile, could you advise on the likelihood of a favorable response to Atezolizumab therapy? Please use the Compass tool to perform a comprehensive transcriptomic evaluation, specifically analyzing biomarkers related to macrophage activation, interferon-γ signaling, genomic integrity, cellular proliferation, and cytotoxic T-cell function. These markers are important for identifying patients who might benefit from immune checkpoint therapies. After completing the analysis, incorporate the molecular data with the patient’s clinical history and prepare a detailed report that outlines the diagnostic and therapeutic implications.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-727c0e-ar-727c0e9.pkl. "
BLCA,,,excluded,R,"We have a white male patient diagnosed with bladder urothelial carcinoma. His tumor immune microenvironment transcriptomic profile, obtained from a kidney biopsy, showed an unavailable TMB value. Could you evaluate whether he is likely to benefit from Atezolizumab therapy?","We have a white male patient diagnosed with bladder urothelial carcinoma. His tumor immune microenvironment transcriptomic profile, obtained from a kidney biopsy, showed an unavailable TMB value. Could you evaluate whether he is likely to benefit from Atezolizumab therapy? Please use the Compass tool to conduct a comprehensive transcriptomic analysis focused on biomarkers of macrophage activation, interferon-γ signaling, genomic integrity, cellular proliferation, and cytotoxic T-cell function. These biomarkers are key in identifying patients who may benefit from immune checkpoint therapies. Once the analysis is complete, integrate the molecular findings with the patient’s clinical history, and prepare a detailed report outlining both diagnostic insights and therapeutic recommendations.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-73663e-ar-73663ee.pkl. "
BLCA,7.0,0.274509804,excluded,NR,"For a white female patient with bladder urothelial carcinoma, a transcriptomic analysis of the tumor immune microenvironment from a kidney biopsy revealed a tumor mutational burden (TMB) of 7.0. Given this TMB level, do you consider her likely to respond favorably to atezolizumab therapy?","For a white female patient with bladder urothelial carcinoma, a transcriptomic analysis of the tumor immune microenvironment from a kidney biopsy revealed a tumor mutational burden (TMB) of 7.0. Given this TMB level, do you consider her likely to respond favorably to atezolizumab therapy? Please employ the Compass tool to perform a detailed transcriptomic analysis that centers on biomarkers related to macrophage activation, interferon-γ signaling, genomic integrity, cellular proliferation, and cytotoxic T-cell function. These biomarkers are instrumental in identifying potentially responsive patients for immune checkpoint therapies. After completing the analysis, integrate these molecular findings with the patient’s clinical history and compile a comprehensive report that outlines your diagnostic conclusions along with therapeutic recommendations.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-75142f-ar-75142fc.pkl. "
BLCA,21.0,2.392156863,inflamed,NR,"In a white female patient with bladder urothelial carcinoma, transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy indicates a tumor mutational burden (TMB) of 21.0. Based on this information, what is the expected likelihood of a response to Atezolizumab therapy?","In a white female patient with bladder urothelial carcinoma, transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy indicates a tumor mutational burden (TMB) of 21.0. Based on this information, what is the expected likelihood of a response to Atezolizumab therapy? Please use the Compass tool to conduct a comprehensive transcriptomic analysis focusing on biomarkers of macrophage activation, interferon-γ signaling, genomic integrity, cell proliferation, and cytotoxic T-cell function. These biomarkers are crucial for identifying candidates who may benefit from immune checkpoint therapies. Once the analysis is complete, merge these molecular results with the patient's clinical history and prepare a detailed report that includes your diagnostic findings and treatment recommendations.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-7538ad-ar-7538ad9.pkl. "
BLCA,7.0,,excluded,NR,"A White male patient with bladder urothelial carcinoma has a tumor immune microenvironment transcriptomic profile from a ureteral biopsy showing a TMB of 7.0. Based on this information, what is the likelihood that he will respond to Atezolizumab therapy?","A White male patient with bladder urothelial carcinoma has a tumor immune microenvironment transcriptomic profile from a ureteral biopsy showing a TMB of 7.0. Based on this information, what is the likelihood that he will respond to Atezolizumab therapy? Use the Compass tool to perform an in-depth transcriptomic evaluation, specifically examining biomarkers linked to macrophage activation, interferon-γ signaling, genomic integrity, cell proliferation, and cytotoxic T-cell function. These factors are key for identifying patients who might respond well to immune checkpoint therapies. After completing the molecular analysis, combine these results with the patient's clinical history and create a comprehensive report that details your diagnostic conclusions along with treatment recommendations.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-753d4b-ar-753d4bb.pkl. "
BLCA,6.0,0.333333333,inflamed,NR,"We have a white male patient with bladder urothelial carcinoma whose lung biopsy transcriptomic profile reveals a tumor mutation burden of 6.0. Based on these findings, how likely is the patient to respond to Atezolizumab therapy?","We have a white male patient with bladder urothelial carcinoma whose lung biopsy transcriptomic profile reveals a tumor mutation burden of 6.0. Based on these findings, how likely is the patient to respond to Atezolizumab therapy? Please use the Compass tool to conduct a detailed transcriptomic analysis with a focus on biomarkers related to macrophage activation, interferon-γ signaling, genomic stability, cell proliferation, and cytotoxic T-cell function. These markers are crucial for identifying patients likely to benefit from immune checkpoint inhibitors. Once the molecular analysis is complete, integrate these findings with the patient's clinical history to compile a thorough report outlining your diagnostic conclusions and treatment recommendations.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-75f12d-ar-75f12d1.pkl. "
BLCA,6.0,0.215686275,inflamed,NR,"In a white male patient with bladder urothelial carcinoma, transcriptomic analysis of the tumor immune microenvironment from a kidney biopsy revealed a tumor mutational burden (TMB) of 6.0. How likely is this patient to respond to atezolizumab therapy?","In a white male patient with bladder urothelial carcinoma, transcriptomic analysis of the tumor immune microenvironment from a kidney biopsy revealed a tumor mutational burden (TMB) of 6.0. How likely is this patient to respond to atezolizumab therapy? Utilize the Compass tool to perform an in-depth transcriptomic analysis, concentrating on biomarkers such as those indicative of macrophage activation, interferon-γ signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. These markers are essential for pinpointing patients who may respond favorably to immune checkpoint inhibitors. After completing the molecular assessment, please correlate these results with the patient’s clinical history and prepare a comprehensive report that includes your diagnostic interpretation and recommended treatment plan.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-76a431-ar-76a431b.pkl. "
BLCA,,0.215686275,inflamed,R,"For a white male patient diagnosed with bladder urothelial carcinoma, the tumor immune microenvironment analysis from a bladder biopsy indicates that the tumor mutational burden is not available. Based on this information, how might we assess the likelihood of a response to Atezolizumab therapy?","For a white male patient diagnosed with bladder urothelial carcinoma, the tumor immune microenvironment analysis from a bladder biopsy indicates that the tumor mutational burden is not available. Based on this information, how might we assess the likelihood of a response to Atezolizumab therapy? Please use the Compass tool to conduct a detailed transcriptomic analysis that evaluates key biomarkers, including indicators of macrophage activation, interferon-γ signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. These markers are critical for identifying patients who may benefit from immune checkpoint inhibitor therapy. Once the molecular analysis is complete, review the results alongside the patient’s clinical history and compile a comprehensive report that presents your diagnostic interpretation and treatment recommendations.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-771445-ar-771445e.pkl. "
BLCA,3.0,0.745098039,inflamed,NR,"For a Caucasian male patient diagnosed with bladder urothelial carcinoma, whose tumor immune microenvironment transcriptomic analysis from a bladder biopsy indicates a tumor mutational burden of 3.0 mutations per megabase, what is the likelihood of a positive response to Atezolizumab therapy?","For a Caucasian male patient diagnosed with bladder urothelial carcinoma, whose tumor immune microenvironment transcriptomic analysis from a bladder biopsy indicates a tumor mutational burden of 3.0 mutations per megabase, what is the likelihood of a positive response to Atezolizumab therapy? Utilize the Compass tool to conduct a transcriptomic evaluation of key biomarkers associated with macrophage activation, interferon-γ signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. These markers are essential for identifying candidates for immune checkpoint inhibitor therapy. After completing the molecular analysis, review the findings in the context of the patient’s clinical history and create a detailed report that outlines your diagnostic interpretation along with treatment recommendations.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-7829a3-ar-7829a34.pkl. "
BLCA,5.0,0.941176471,,NR,"In an Asian male patient with bladder urothelial carcinoma, whose bladder biopsy transcriptomic analysis of the tumor immune microenvironment shows a tumor mutation burden of 5.0, how likely is it that he will respond to atezolizumab therapy?","In an Asian male patient with bladder urothelial carcinoma, whose bladder biopsy transcriptomic analysis of the tumor immune microenvironment shows a tumor mutation burden of 5.0, how likely is it that he will respond to atezolizumab therapy? Use the Compass tool to analyze transcriptomic data for biomarkers that reflect macrophage activation, interferon-γ signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. These markers are key for determining eligibility for immune checkpoint inhibitor therapy. After completing the molecular analysis, integrate your findings with the patient's clinical history and compile a comprehensive report that includes your diagnostic interpretation and treatment recommendations.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-789319-ar-7893196.pkl. "
BLCA,,1.039215686,excluded,NR,"I have a white male patient diagnosed with bladder urothelial carcinoma. Transcriptomic analysis from his bladder biopsy indicates a tumor mutational burden (TMB) reported as ""nan."" Could you please assess his likelihood of benefiting from Atezolizumab therapy based on this data?","I have a white male patient diagnosed with bladder urothelial carcinoma. Transcriptomic analysis from his bladder biopsy indicates a tumor mutational burden (TMB) reported as ""nan."" Could you please assess his likelihood of benefiting from Atezolizumab therapy based on this data? Please use the Compass tool to examine transcriptomic data for biomarkers associated with macrophage activation, interferon-γ signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. These biomarkers are critical for assessing whether a patient is eligible for immune checkpoint inhibitor therapy. Once you complete the molecular analysis, review it in the context of the patient’s clinical history and prepare a detailed report outlining your diagnostic interpretation along with your treatment recommendations.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-7aa01f-ar-7aa01fc.pkl. "
BLCA,12.0,,,R,"For a Caucasian female patient with bladder urothelial carcinoma, whose tumor immune microenvironment transcriptomic analysis from a ureter biopsy indicates a tumor mutation burden of 12.0, how likely is she to respond to Atezolizumab therapy?","For a Caucasian female patient with bladder urothelial carcinoma, whose tumor immune microenvironment transcriptomic analysis from a ureter biopsy indicates a tumor mutation burden of 12.0, how likely is she to respond to Atezolizumab therapy? Please use the Compass tool to evaluate transcriptomic data focusing on biomarkers indicative of macrophage activation, interferon-γ signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. These biomarkers are essential for determining a patient’s eligibility for immune checkpoint inhibitor therapy. Once your molecular analysis is complete, integrate the findings with the patient’s clinical history and prepare a comprehensive report detailing your diagnostic interpretation along with treatment recommendations.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-7b4000-ar-7b40007.pkl. "
BLCA,,0.725490196,,NR,"I have a white male patient diagnosed with bladder urothelial carcinoma. A ureter biopsy of his tumor immune microenvironment revealed a tumor mutational burden (TMB) value reported as 'nan'. Based on this finding, how should we interpret his potential response to Atezolizumab therapy, and what additional factors might we need to assess in this context?","I have a white male patient diagnosed with bladder urothelial carcinoma. A ureter biopsy of his tumor immune microenvironment revealed a tumor mutational burden (TMB) value reported as 'nan'. Based on this finding, how should we interpret his potential response to Atezolizumab therapy, and what additional factors might we need to assess in this context? Use the Compass tool to analyze transcriptomic data with a focus on biomarkers for macrophage activation, interferon-γ signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. These markers are critical for assessing a patient’s suitability for immune checkpoint inhibitor therapy. After completing the molecular analysis, please integrate the results with the patient’s clinical history and compile a comprehensive report that outlines your diagnostic interpretation along with treatment recommendations.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-7bff23-ar-7bff231.pkl. "
BLCA,5.0,0.529411765,,NR,"For a Caucasian female patient with bladder urothelial carcinoma, whose tumor biopsy transcriptomic profile shows a tumor mutational burden of 5.0, how likely is it that she would respond to Atezolizumab therapy?","For a Caucasian female patient with bladder urothelial carcinoma, whose tumor biopsy transcriptomic profile shows a tumor mutational burden of 5.0, how likely is it that she would respond to Atezolizumab therapy? Please use the Compass tool to evaluate the transcriptomic data, placing emphasis on biomarkers related to macrophage activation, interferon-γ signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. These markers are essential for determining whether a patient is a good candidate for immune checkpoint inhibitor therapy. Once the molecular analysis is complete, integrate these findings with the patient’s clinical history and prepare a detailed report that includes your diagnostic interpretation and suggested treatment options.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-7c67b0-ar-7c67b05.pkl. "
BLCA,4.0,0.156862745,inflamed,NR,"In a Caucasian male patient with bladder urothelial carcinoma, whose lymph node biopsy transcriptomic profiling reveals a tumor mutational burden of 4.0, what is the likelihood of a favorable response to Atezolizumab therapy?","In a Caucasian male patient with bladder urothelial carcinoma, whose lymph node biopsy transcriptomic profiling reveals a tumor mutational burden of 4.0, what is the likelihood of a favorable response to Atezolizumab therapy? Please use the Compass tool to analyze the transcriptomic data, focusing specifically on biomarkers for macrophage activation, interferon-γ signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. These biomarkers are crucial in assessing the suitability of a patient for immune checkpoint inhibitor therapy. After completing the molecular analysis, integrate these results with the patient's clinical history to prepare a detailed report that includes your diagnostic interpretation and recommended treatment strategies.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-7d2dfb-ar-7d2dfba.pkl. "
BLCA,8.0,2.098039216,excluded,R,"For a white male patient with bladder urothelial carcinoma, a transcriptomic analysis of the tumor immune microenvironment from a bladder biopsy indicated a tumor mutational burden of 8.0. Based on this information, could you provide an assessment of his potential response to Atezolizumab therapy?","For a white male patient with bladder urothelial carcinoma, a transcriptomic analysis of the tumor immune microenvironment from a bladder biopsy indicated a tumor mutational burden of 8.0. Based on this information, could you provide an assessment of his potential response to Atezolizumab therapy? Utilize the Compass tool to examine the transcriptomic dataset, concentrating on biomarkers associated with macrophage activation, interferon-γ signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. These markers are key for evaluating a patient's eligibility for immune checkpoint inhibitor therapy. Once the molecular analysis is complete, integrate the findings with the patient's clinical history and compile a comprehensive report that includes your diagnostic interpretation along with recommended treatment strategies.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-7d7c54-ar-7d7c546.pkl. "
BLCA,,,excluded,NR,"I have a white male patient diagnosed with bladder urothelial carcinoma. His bladder biopsy transcriptomic profile reports an indeterminate tumor mutational burden (TMB is not available). Based on these findings, how can we assess the likelihood of a positive response to Atezolizumab therapy?","I have a white male patient diagnosed with bladder urothelial carcinoma. His bladder biopsy transcriptomic profile reports an indeterminate tumor mutational burden (TMB is not available). Based on these findings, how can we assess the likelihood of a positive response to Atezolizumab therapy? Please use the Compass tool to analyze the transcriptomic dataset with a focus on biomarkers relevant to macrophage activation, interferon-γ signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. These biomarkers are critical for determining the patient’s suitability for immune checkpoint inhibitor therapy. After completing the molecular analysis, review the patient’s clinical history and prepare a detailed report that includes your diagnostic assessment and treatment recommendations.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-7f0d9c-ar-7f0d9cc.pkl. "
BLCA,1.0,,excluded,NR,"For a Black/African American male patient diagnosed with bladder urothelial carcinoma, a bladder biopsy transcriptomic analysis revealed a tumor mutational burden of 1.0. Based on this information, what is the likelihood that he would benefit from Atezolizumab therapy?","For a Black/African American male patient diagnosed with bladder urothelial carcinoma, a bladder biopsy transcriptomic analysis revealed a tumor mutational burden of 1.0. Based on this information, what is the likelihood that he would benefit from Atezolizumab therapy? Please utilize the Compass tool to perform a transcriptomic analysis focusing on biomarkers associated with macrophage activation, interferon-γ signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. These biomarkers are essential for assessing the patient’s potential response to immune checkpoint inhibitor therapy. Once the molecular evaluation is complete, review the patient’s clinical history and compile a comprehensive report that includes your diagnostic conclusions and personalized treatment recommendations.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-7fb698-ar-7fb6987.pkl. "
BLCA,11.0,0.764705882,excluded,NR,"In an Asian male patient with bladder urothelial carcinoma and a tumor mutational burden of 11.0 determined from transcriptomic profiling of the tumor immune microenvironment (via kidney biopsy), how likely is a favorable response to atezolizumab therapy?","In an Asian male patient with bladder urothelial carcinoma and a tumor mutational burden of 11.0 determined from transcriptomic profiling of the tumor immune microenvironment (via kidney biopsy), how likely is a favorable response to atezolizumab therapy? Please use the Compass tool to conduct a transcriptomic analysis that targets biomarkers related to macrophage activation, interferon-γ signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. These markers are critical for evaluating the patient's potential response to immune checkpoint inhibitor therapy. After completing the molecular analysis, review the patient's clinical history and prepare a detailed report that outlines your diagnostic findings and tailored treatment recommendations.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-7fb7a1-ar-7fb7a13.pkl. "
BLCA,8.0,0.215686275,inflamed,NR,"I have a White male patient diagnosed with bladder urothelial carcinoma. A transcriptomic analysis of his tumor immune microenvironment from a kidney biopsy revealed a tumor mutation burden of 8.0. Based on these findings, can you provide insight into his potential responsiveness to Atezolizumab therapy?","I have a White male patient diagnosed with bladder urothelial carcinoma. A transcriptomic analysis of his tumor immune microenvironment from a kidney biopsy revealed a tumor mutation burden of 8.0. Based on these findings, can you provide insight into his potential responsiveness to Atezolizumab therapy? Use the Compass tool to perform a transcriptomic analysis focusing on biomarkers associated with macrophage activation, interferon-γ signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. These biomarkers are important for assessing the patient's responsiveness to immune checkpoint inhibitor therapy. After completing the molecular analysis, review the patient's clinical history and compile a comprehensive report detailing your diagnostic findings along with personalized treatment recommendations.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-80c618-ar-80c6183.pkl. "
BLCA,7.0,1.078431373,,NR,"For a white female patient diagnosed with bladder urothelial carcinoma whose bladder biopsy reveals a tumor mutational burden (TMB) of 7.0 via transcriptomic profiling of the tumor immune microenvironment, what is the likelihood that she will respond to atezolizumab therapy?","For a white female patient diagnosed with bladder urothelial carcinoma whose bladder biopsy reveals a tumor mutational burden (TMB) of 7.0 via transcriptomic profiling of the tumor immune microenvironment, what is the likelihood that she will respond to atezolizumab therapy? Utilize the Compass tool for a transcriptomic analysis concentrating on biomarkers of macrophage activation, interferon-γ signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. These biomarkers are crucial for evaluating the patient's likely response to immune checkpoint inhibitor therapy. Once the molecular analysis is complete, review the patient's clinical history and prepare a detailed diagnostic report that includes personalized treatment recommendations.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-81b715-ar-81b7152.pkl. "
BLCA,,1.098039216,desert,NR,"In a white male patient diagnosed with bladder urothelial carcinoma, transcriptomic profiling of the tumor immune microenvironment from a separate biopsy yielded an indeterminate tumor mutational burden value. Based on these findings, can we estimate the likelihood of the patient responding to atezolizumab therapy?","In a white male patient diagnosed with bladder urothelial carcinoma, transcriptomic profiling of the tumor immune microenvironment from a separate biopsy yielded an indeterminate tumor mutational burden value. Based on these findings, can we estimate the likelihood of the patient responding to atezolizumab therapy? Please use the Compass tool to perform a transcriptomic analysis focusing on biomarkers related to macrophage activation, interferon-γ signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. These markers are vital for predicting how a patient may respond to immune checkpoint inhibitor therapy. After completing the molecular analysis, review the patient’s clinical history and compile a comprehensive diagnostic report that includes tailored treatment recommendations.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-822b22-ar-822b226.pkl. "
BLCA,5.0,1.725490196,desert,R,"For a white male patient with bladder urothelial carcinoma whose bladder tumor biopsy shows a transcriptomic profile with a tumor mutational burden of 5.0, how likely is his tumor to respond to atezolizumab therapy?","For a white male patient with bladder urothelial carcinoma whose bladder tumor biopsy shows a transcriptomic profile with a tumor mutational burden of 5.0, how likely is his tumor to respond to atezolizumab therapy? Utilize the Compass tool to conduct a transcriptomic analysis targeting key biomarkers—including those associated with macrophage activation, interferon-γ signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity—to assess potential responsiveness to immune checkpoint inhibitor therapy. Once the molecular analysis is complete, carefully review the patient’s clinical history and prepare a detailed diagnostic report that incorporates customized treatment recommendations.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-8533e5-ar-8533e5e.pkl. "
BLCA,8.0,0.274509804,excluded,NR,I have a white male patient diagnosed with bladder urothelial carcinoma (BLCA). A lung biopsy of the tumor immune microenvironment revealed a tumor mutational burden (TMB) of 8.0 mutations per megabase. How likely is it that this patient will respond to Atezolizumab therapy?,"I have a white male patient diagnosed with bladder urothelial carcinoma (BLCA). A lung biopsy of the tumor immune microenvironment revealed a tumor mutational burden (TMB) of 8.0 mutations per megabase. How likely is it that this patient will respond to Atezolizumab therapy? Use the Compass tool to perform a transcriptomic evaluation focusing on biomarkers relevant to macrophage activation, interferon-γ signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. This analysis will help determine the likelihood of a positive response to immune checkpoint inhibitor therapy. Once you have completed the molecular assessment, review the patient's clinical history in detail and compile a comprehensive diagnostic report that includes tailored treatment recommendations.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-85f0a3-ar-85f0a3a.pkl. "
BLCA,14.0,0.31372549,excluded,NR,"We have a white female patient with a diagnosis of Bladder Urothelial Carcinoma (BLCA). A bladder biopsy provided a transcriptomic profile of her tumor immune microenvironment, which revealed a tumor mutational burden (TMB) of 14.0. Based on this information, could you assess the likelihood of her responding to Atezolizumab therapy?","We have a white female patient with a diagnosis of Bladder Urothelial Carcinoma (BLCA). A bladder biopsy provided a transcriptomic profile of her tumor immune microenvironment, which revealed a tumor mutational burden (TMB) of 14.0. Based on this information, could you assess the likelihood of her responding to Atezolizumab therapy? Please use the Compass tool to carry out a transcriptomic analysis with an emphasis on biomarkers linked to macrophage activation, interferon-γ signaling, genomic stability, cell proliferation, and cytotoxic T‐cell activity. This evaluation is intended to assess the patient’s potential for a positive response to immune checkpoint inhibitor therapy. After completing the molecular assessment, thoroughly review the patient’s clinical history and prepare a detailed diagnostic report that includes personalized treatment recommendations.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-87a8e1-ar-87a8e18.pkl. "
BLCA,13.0,6.0,inflamed,R,"In a white male patient with bladder urothelial carcinoma displaying a tumor mutational burden of 13.0 on biopsy, what is the likelihood that he will respond to Atezolizumab therapy?","In a white male patient with bladder urothelial carcinoma displaying a tumor mutational burden of 13.0 on biopsy, what is the likelihood that he will respond to Atezolizumab therapy? Please use the Compass tool to perform a transcriptomic analysis focusing on key biomarkers related to macrophage activation, interferon-γ signaling, genomic stability, cell proliferation, and cytotoxic T‐cell activity. This analysis is intended to gauge the patient's likelihood of responding well to immune checkpoint inhibitors. Once the molecular data have been obtained, review the patient’s clinical history and compile a comprehensive diagnostic report that includes personalized treatment recommendations.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-8884fe-ar-8884fe4.pkl. "
BLCA,14.0,0.843137255,desert,R,"Given an Asian male patient diagnosed with bladder urothelial carcinoma, with a tumor mutational burden of 14.0 as determined from a bladder biopsy transcriptomic analysis, could we expect a favorable response to Atezolizumab therapy?","Given an Asian male patient diagnosed with bladder urothelial carcinoma, with a tumor mutational burden of 14.0 as determined from a bladder biopsy transcriptomic analysis, could we expect a favorable response to Atezolizumab therapy? Please use the Compass tool to conduct a transcriptomic analysis that specifically examines biomarkers associated with macrophage activation, interferon-γ signaling, genomic integrity, cell proliferation, and cytotoxic T-cell function. The purpose of this analysis is to assess the likelihood that the patient will benefit from immune checkpoint inhibitor therapy. After you have obtained the molecular data, review the patient’s clinical history thoroughly and prepare a detailed diagnostic report that includes personalized treatment recommendations.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-8a1b0e-ar-8a1b0e0.pkl. "
BLCA,7.0,1.0,excluded,NR,"In a white male patient with bladder urothelial carcinoma, a kidney biopsy analysis of the tumor immune microenvironment revealed a tumor mutation burden of 7.0. Could this TMB value suggest a favorable response to Atezolizumab therapy?","In a white male patient with bladder urothelial carcinoma, a kidney biopsy analysis of the tumor immune microenvironment revealed a tumor mutation burden of 7.0. Could this TMB value suggest a favorable response to Atezolizumab therapy? Use the Compass tool to perform a transcriptomic analysis that targets biomarkers for macrophage activation, interferon-γ signaling, genomic integrity, cell proliferation, and cytotoxic T-cell function. This analysis will help determine the patient's potential responsiveness to immune checkpoint inhibitor therapy. Once you have gathered the molecular data, please review the patient's clinical history in detail and compile a comprehensive diagnostic report that includes tailored treatment recommendations.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-8b4b8b-ar-8b4b8b0.pkl. "
BLCA,6.0,,excluded,NR,"In a White male patient with bladder urothelial carcinoma, whose bladder biopsy transcriptomic analysis shows a tumor mutation burden of 6.0, how likely is it that he will respond to Atezolizumab therapy?","In a White male patient with bladder urothelial carcinoma, whose bladder biopsy transcriptomic analysis shows a tumor mutation burden of 6.0, how likely is it that he will respond to Atezolizumab therapy? Please use the Compass tool to carry out a transcriptomic analysis, specifically targeting biomarkers related to macrophage activation, interferon-γ signaling, genomic integrity, cell proliferation, and cytotoxic T-cell function. This analysis is intended to help evaluate the patient’s potential responsiveness to immune checkpoint inhibitors. Once you have obtained the molecular data, thoroughly review the patient's clinical history and prepare a detailed diagnostic report that includes personalized treatment recommendations.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-8e4698-ar-8e46983.pkl. "
BLCA,6.0,0.509803922,desert,NR,"A Caucasian male patient with bladder urothelial carcinoma has undergone kidney biopsy, and transcriptomic analysis of the tumor immune microenvironment reveals a tumor mutational burden of 6.0 mutations per megabase. What is the likelihood that this patient will benefit from Atezolizumab therapy?","A Caucasian male patient with bladder urothelial carcinoma has undergone kidney biopsy, and transcriptomic analysis of the tumor immune microenvironment reveals a tumor mutational burden of 6.0 mutations per megabase. What is the likelihood that this patient will benefit from Atezolizumab therapy? Please use the Compass tool to conduct a transcriptomic analysis focusing on biomarkers related to macrophage activation, interferon-γ signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. This analysis will help determine the patient’s potential response to immune checkpoint inhibitors. After obtaining the molecular data, review the patient's clinical history and compile a comprehensive diagnostic report that includes personalized treatment recommendations.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-8e8ef2-ar-8e8ef23.pkl. "
BLCA,5.0,,desert,NR,"For a white male with bladder urothelial carcinoma whose tumor immune microenvironment transcriptomic profile from a bladder biopsy reveals a TMB of 5.0, how likely is it that he will respond to Atezolizumab therapy?","For a white male with bladder urothelial carcinoma whose tumor immune microenvironment transcriptomic profile from a bladder biopsy reveals a TMB of 5.0, how likely is it that he will respond to Atezolizumab therapy? Please use the Compass tool to perform a transcriptomic evaluation concentrating on biomarkers such as macrophage activation, interferon-γ signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. This analysis is intended to assess the patient's potential responsiveness to immune checkpoint inhibitors. After acquiring the molecular data, review the patient's clinical history and prepare a detailed diagnostic report that incorporates personalized treatment recommendations.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-8f2275-ar-8f2275c.pkl. "
BLCA,49.0,2.705882353,inflamed,R,"I have a white male patient with bladder urothelial carcinoma whose tumor transcriptomic profile reveals a tumor mutational burden of 49.0. Based on this data, what is the likelihood that he would respond favorably to atezolizumab treatment?","I have a white male patient with bladder urothelial carcinoma whose tumor transcriptomic profile reveals a tumor mutational burden of 49.0. Based on this data, what is the likelihood that he would respond favorably to atezolizumab treatment? Please use the Compass tool to conduct a transcriptomic analysis focusing on biomarkers such as macrophage activation, interferon-γ signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. This evaluation is designed to help determine the patient's potential responsiveness to immune checkpoint inhibitors. Once you have obtained the molecular data, review the patient's clinical history and compile a comprehensive diagnostic report that includes personalized treatment recommendations.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-91c47b-ar-91c47b0.pkl. "
BLCA,12.0,2.235294118,inflamed,NR,"For a white male patient with bladder urothelial carcinoma, whose tumor transcriptomic analysis reveals a tumor mutational burden of 12.0 mutations per megabase, how might this TMB level inform our prediction of his response to atezolizumab therapy?","For a white male patient with bladder urothelial carcinoma, whose tumor transcriptomic analysis reveals a tumor mutational burden of 12.0 mutations per megabase, how might this TMB level inform our prediction of his response to atezolizumab therapy? Please use the Compass tool to perform a transcriptomic analysis focused on biomarkers including macrophage activation, interferon-γ signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. This analysis is intended to assess the patient’s potential response to immune checkpoint inhibitors. After obtaining the molecular data, review the patient’s clinical history and prepare a detailed diagnostic report that includes personalized treatment recommendations.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-9306c5-ar-9306c5c.pkl. "
BLCA,,,,NR,"I have a white male patient diagnosed with bladder urothelial carcinoma (BLCA). The transcriptomic profiling of his tumor immune microenvironment from a bladder biopsy indicates a tumor mutational burden (TMB) value of ""nan."" Could you help assess whether this patient is likely to respond to Atezolizumab therapy?","I have a white male patient diagnosed with bladder urothelial carcinoma (BLCA). The transcriptomic profiling of his tumor immune microenvironment from a bladder biopsy indicates a tumor mutational burden (TMB) value of ""nan."" Could you help assess whether this patient is likely to respond to Atezolizumab therapy? Please utilize the Compass platform to conduct a transcriptomic analysis targeting specific biomarkers—namely macrophage activation, interferon-γ signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. This evaluation is aimed at determining the patient’s potential responsiveness to immune checkpoint inhibitors. Following the acquisition of molecular data, integrate these findings with the patient’s clinical history and create a comprehensive diagnostic report that includes personalized treatment recommendations.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-9410b8-ar-9410b86.pkl. "
BLCA,5.0,0.117647059,desert,NR,"I have a white male patient with bladder urothelial carcinoma. The transcriptomic profile of the tumor immune microenvironment obtained from a bladder biopsy indicates a tumor mutational burden of 5.0. Based on this information, how likely is he to respond to atezolizumab therapy?","I have a white male patient with bladder urothelial carcinoma. The transcriptomic profile of the tumor immune microenvironment obtained from a bladder biopsy indicates a tumor mutational burden of 5.0. Based on this information, how likely is he to respond to atezolizumab therapy? Please use the Compass platform to perform a transcriptomic analysis, specifically targeting biomarkers of macrophage activation, interferon-γ signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. The goal is to assess the patient’s potential responsiveness to immune checkpoint inhibitors. After obtaining the molecular data, integrate these results with the patient's clinical history and prepare a comprehensive diagnostic report that includes personalized treatment recommendations.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-943df5-ar-943df5c.pkl. "
BLCA,11.0,0.215686275,excluded,NR,"I have a Black/African American male patient diagnosed with bladder urothelial carcinoma (BLCA). A transcriptomic analysis of his tumor immune microenvironment from a kidney biopsy revealed a tumor mutational burden (TMB) of 11.0. Based on these findings, what is the likelihood that he will respond to Atezolizumab therapy?","I have a Black/African American male patient diagnosed with bladder urothelial carcinoma (BLCA). A transcriptomic analysis of his tumor immune microenvironment from a kidney biopsy revealed a tumor mutational burden (TMB) of 11.0. Based on these findings, what is the likelihood that he will respond to Atezolizumab therapy? Please use the Compass platform to conduct a transcriptomic analysis that assesses biomarkers related to macrophage activation, interferon-γ signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. This evaluation will help determine the patient’s potential responsiveness to immune checkpoint inhibitors. Once you have obtained the molecular data, integrate these findings with the patient's clinical history and prepare a detailed diagnostic report that includes individualized treatment recommendations.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-94859b-ar-94859b4.pkl. "
BLCA,,0.431372549,desert,NR,"I have a white male patient diagnosed with bladder urothelial carcinoma. A transcriptomic analysis of his tumor immune microenvironment from a bladder biopsy revealed a tumor mutation burden (TMB) reported as ""nan."" Based on this finding, could you provide guidance on whether Atezolizumab therapy is likely to be effective for this patient?","I have a white male patient diagnosed with bladder urothelial carcinoma. A transcriptomic analysis of his tumor immune microenvironment from a bladder biopsy revealed a tumor mutation burden (TMB) reported as ""nan."" Based on this finding, could you provide guidance on whether Atezolizumab therapy is likely to be effective for this patient? Use the Compass platform to perform a transcriptomic analysis focusing on biomarkers associated with macrophage activation, interferon-γ signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. This analysis should inform us about the patient's likelihood of responding to immune checkpoint inhibitors. After obtaining the molecular data, please correlate these findings with the patient’s clinical history and prepare a comprehensive diagnostic report that includes personalized treatment recommendations.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-9539a4-ar-9539a4f.pkl. "
BLCA,,0.196078431,excluded,NR,"In a white male patient with bladder urothelial carcinoma, transcriptomic profiling of the tumor immune microenvironment from a ureter biopsy revealed an undefined tumor mutational burden. Based on these findings, would you expect the patient to respond favorably to Atezolizumab therapy?","In a white male patient with bladder urothelial carcinoma, transcriptomic profiling of the tumor immune microenvironment from a ureter biopsy revealed an undefined tumor mutational burden. Based on these findings, would you expect the patient to respond favorably to Atezolizumab therapy? Please use the Compass platform to conduct a transcriptomic analysis with a focus on biomarkers related to macrophage activation, interferon-γ signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. The results of this analysis will help determine the patient’s potential response to immune checkpoint inhibitors. Once the molecular data is collected, integrate these findings with the patient’s clinical history and compile a detailed diagnostic report that includes tailored treatment recommendations.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-957378-ar-957378b.pkl. "
BLCA,17.0,1.725490196,excluded,NR,"In a white male patient with bladder urothelial carcinoma and a TMB of 17.0 determined from a transcriptomic profile obtained via bladder biopsy, what is the likelihood that this patient will respond to Atezolizumab therapy?","In a white male patient with bladder urothelial carcinoma and a TMB of 17.0 determined from a transcriptomic profile obtained via bladder biopsy, what is the likelihood that this patient will respond to Atezolizumab therapy? Please perform a transcriptomic analysis using the Compass platform, specifically assessing biomarkers for macrophage activation, interferon-γ signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. Use these results to evaluate the patient’s likely response to immune checkpoint inhibitors. After obtaining the molecular data, integrate these findings with the patient’s clinical history and prepare a comprehensive diagnostic report that includes personalized treatment recommendations.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-961d04-ar-961d04c.pkl. "
BLCA,22.0,4.431372549,desert,NR,"In a white male patient with bladder urothelial carcinoma whose tumor transcriptomic profile reveals a tumor mutational burden of 22.0, how likely is it that the patient will benefit from Atezolizumab therapy?","In a white male patient with bladder urothelial carcinoma whose tumor transcriptomic profile reveals a tumor mutational burden of 22.0, how likely is it that the patient will benefit from Atezolizumab therapy? Please perform a transcriptomic analysis using the Compass platform, focusing on biomarkers associated with macrophage activation, interferon-γ signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. Use the data obtained to assess the patient’s potential response to immune checkpoint inhibitors. After completing the molecular analysis, review the results alongside the patient’s clinical history and compile a comprehensive diagnostic report that includes personalized treatment recommendations.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-972530-ar-9725303.pkl. "
BLCA,,1.921568627,excluded,NR,"In a white male patient diagnosed with bladder urothelial carcinoma, transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy revealed a tumor mutation burden (TMB) reported as ""nan."" Given this result, can we reliably predict the patient's likelihood of responding to atezolizumab therapy?","In a white male patient diagnosed with bladder urothelial carcinoma, transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy revealed a tumor mutation burden (TMB) reported as ""nan."" Given this result, can we reliably predict the patient's likelihood of responding to atezolizumab therapy? Please conduct a transcriptomic analysis using the Compass platform to evaluate biomarkers related to macrophage activation, interferon-γ signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. Use these data to estimate the patient’s likely response to immune checkpoint inhibitors. Once the molecular analysis is complete, integrate the findings with the patient’s clinical history and prepare a detailed diagnostic report that includes individualized treatment recommendations.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-978a58-ar-978a587.pkl. "
BLCA,18.0,2.862745098,excluded,R,I have a patient diagnosed with bladder urothelial carcinoma (BLCA) whose kidney biopsy transcriptomic analysis of the tumor immune microenvironment indicates a tumor mutational burden (TMB) of 18. Could you provide insight on the likelihood of response to Atezolizumab therapy in this context?,"I have a patient diagnosed with bladder urothelial carcinoma (BLCA) whose kidney biopsy transcriptomic analysis of the tumor immune microenvironment indicates a tumor mutational burden (TMB) of 18. Could you provide insight on the likelihood of response to Atezolizumab therapy in this context? Please perform a transcriptomic analysis using the Compass platform to assess biomarkers associated with macrophage activation, interferon-γ signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. Use the resulting data to predict the patient’s potential response to immune checkpoint inhibitors. After completing the molecular analysis, integrate these findings with the patient's clinical history and compile a comprehensive diagnostic report that includes personalized treatment recommendations.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-97a00e-ar-97a00e0.pkl. "
BLCA,5.0,0.725490196,excluded,NR,"A white male patient diagnosed with bladder urothelial carcinoma underwent a kidney biopsy for transcriptomic profiling of his tumor immune microenvironment, which revealed a tumor mutational burden of 5.0 mutations per megabase. Based on these findings, is he likely to benefit from atezolizumab therapy?","A white male patient diagnosed with bladder urothelial carcinoma underwent a kidney biopsy for transcriptomic profiling of his tumor immune microenvironment, which revealed a tumor mutational burden of 5.0 mutations per megabase. Based on these findings, is he likely to benefit from atezolizumab therapy? Please conduct a transcriptomic analysis on the Compass platform to evaluate biomarkers related to macrophage activation, interferon-γ signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. Use the data obtained to predict the patient's likely response to immune checkpoint inhibitors. Then, combine these molecular findings with the patient's clinical history to prepare a comprehensive diagnostic report that includes individualized treatment recommendations.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-99a46b-ar-99a46b9.pkl. "
BLCA,4.0,0.862745098,inflamed,NR,"For a white male patient with bladder urothelial carcinoma, whose biopsy transcriptomic analysis reveals a tumor mutation burden (TMB) of 4.0 mutations per megabase, would you consider Atezolizumab therapy to be a potentially effective treatment option?","For a white male patient with bladder urothelial carcinoma, whose biopsy transcriptomic analysis reveals a tumor mutation burden (TMB) of 4.0 mutations per megabase, would you consider Atezolizumab therapy to be a potentially effective treatment option? Please perform a transcriptomic assay using the Compass platform to assess biomarkers indicative of macrophage activation, interferon-γ signaling, genomic stability, cell proliferation, and cytotoxic T-cell function. Utilize these data to estimate the patient’s potential response to immune checkpoint inhibitor therapy. Finally, integrate these molecular findings with the patient's clinical history to construct a detailed diagnostic report that includes personalized treatment recommendations.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-9a2cf3-ar-9a2cf3c.pkl. "
BLCA,5.0,0.647058824,excluded,NR,"In a white male patient with bladder urothelial carcinoma, a kidney biopsy revealed a tumor immune microenvironment transcriptomic profile with a tumor mutational burden of 5.0. Based on these findings, what is the likelihood of a favorable response to atezolizumab therapy?","In a white male patient with bladder urothelial carcinoma, a kidney biopsy revealed a tumor immune microenvironment transcriptomic profile with a tumor mutational burden of 5.0. Based on these findings, what is the likelihood of a favorable response to atezolizumab therapy? Please use the Compass platform to conduct a transcriptomic assay, focusing on biomarkers related to macrophage activation, interferon-γ signaling, genomic stability, cell proliferation, and cytotoxic T-cell function. Based on these molecular findings, assess the patient’s likely response to immune checkpoint inhibitor therapy. Then, combine this information with the patient’s clinical history to develop a detailed diagnostic report that includes tailored treatment recommendations.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-9aa6a0-ar-9aa6a09.pkl. "
BLCA,12.0,0.588235294,inflamed,NR,"A  White male patient with bladder urothelial carcinoma (BLCA) has a tumor mutational burden of 12.0 based on transcriptomic analysis from a kidney biopsy. Given this profile, how might we assess his potential response to atezolizumab therapy? ","A  White male patient with bladder urothelial carcinoma (BLCA) has a tumor mutational burden of 12.0 based on transcriptomic analysis from a kidney biopsy. Given this profile, how might we assess his potential response to atezolizumab therapy?  Using the Compass platform, please perform a transcriptomic assay that targets biomarkers associated with macrophage activation, interferon-γ signaling, genomic stability, cell proliferation, and cytotoxic T-cell function. Evaluate these molecular findings to predict the patient’s potential response to immune checkpoint inhibitor therapy. Then, integrate this data with the patient’s clinical history to create a comprehensive diagnostic report that includes individualized treatment recommendations.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-9cafb9-ar-9cafb90.pkl. "
BLCA,,,,NR,"A white male patient with a diagnosis of bladder urothelial carcinoma underwent a liver biopsy for transcriptomic profiling of the tumor immune microenvironment, which reported a TMB value of ""nan."" Based on these findings, how would you assess his likelihood of responding to Atezolizumab therapy?","A white male patient with a diagnosis of bladder urothelial carcinoma underwent a liver biopsy for transcriptomic profiling of the tumor immune microenvironment, which reported a TMB value of ""nan."" Based on these findings, how would you assess his likelihood of responding to Atezolizumab therapy? Please use the Compass platform to carry out a transcriptomic assay that measures key biomarkers for macrophage activation, interferon-γ signaling, genomic stability, cell proliferation, and cytotoxic T-cell function. Analyze these molecular results to evaluate the patient’s potential responsiveness to immune checkpoint inhibitor therapy. Finally, integrate these findings with the patient’s clinical history and prepare a detailed diagnostic report that includes personalized treatment recommendations.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-9d2494-ar-9d24941.pkl. "
BLCA,,,desert,NR,I have a white female patient with bladder urothelial carcinoma. Transcriptomic analysis of the tumor immune microenvironment from a kidney biopsy yielded a tumor mutational burden (TMB) value reported as “nan.” Could you provide insights on whether she is likely to respond to Atezolizumab therapy?,"I have a white female patient with bladder urothelial carcinoma. Transcriptomic analysis of the tumor immune microenvironment from a kidney biopsy yielded a tumor mutational burden (TMB) value reported as “nan.” Could you provide insights on whether she is likely to respond to Atezolizumab therapy? Please use the Compass platform to perform a transcriptomic assay that quantifies key biomarkers related to macrophage activation, interferon-γ signaling, genomic integrity, cell proliferation, and cytotoxic T-cell function. Assess these molecular findings to determine the patient’s potential response to immune checkpoint inhibitor therapy. Then, combine the assay results with the patient’s clinical history and produce a comprehensive diagnostic report that includes personalized treatment recommendations.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-9dacca-ar-9daccaf.pkl. "
BLCA,10.0,,inflamed,NR,"For a white male patient diagnosed with bladder urothelial carcinoma who has a tumor mutation burden (TMB) of 10 as determined by transcriptomic analysis of the tumor immune microenvironment from a bladder biopsy, what is the likelihood that he will respond to Atezolizumab therapy?","For a white male patient diagnosed with bladder urothelial carcinoma who has a tumor mutation burden (TMB) of 10 as determined by transcriptomic analysis of the tumor immune microenvironment from a bladder biopsy, what is the likelihood that he will respond to Atezolizumab therapy? Please use the Compass platform to run a transcriptomic assay that quantitatively measures biomarkers associated with macrophage activation, interferon-γ signaling, genomic stability, cell proliferation, and cytotoxic T-cell function. Evaluate these molecular findings to estimate the patient’s likelihood of responding to immune checkpoint inhibitor therapy. Finally, integrate the assay data with the patient’s clinical history to produce a detailed diagnostic report that includes individualized treatment recommendations.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-9e11ec-ar-9e11ec6.pkl. "
BLCA,6.0,0.431372549,desert,NR,"Given a white female patient diagnosed with bladder urothelial carcinoma, with a bladder biopsy transcriptomic profile showing a tumor mutational burden (TMB) of 6.0, how likely is she to respond to Atezolizumab therapy?","Given a white female patient diagnosed with bladder urothelial carcinoma, with a bladder biopsy transcriptomic profile showing a tumor mutational burden (TMB) of 6.0, how likely is she to respond to Atezolizumab therapy? Utilize the Compass platform to conduct a transcriptomic assay that quantitatively evaluates biomarkers related to macrophage activation, interferon-γ signaling, genomic stability, cell proliferation, and cytotoxic T-cell function. Based on these molecular findings, assess the patient’s potential responsiveness to immune checkpoint inhibitor therapy. Finally, integrate the assay results with the patient’s clinical history to develop a comprehensive diagnostic report that includes personalized treatment recommendations.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-9fb814-ar-9fb814c.pkl. "
BLCA,,3.333333333,desert,NR,"We have a Caucasian female patient diagnosed with bladder urothelial carcinoma (BLCA). The transcriptomic profile of her tumor immune microenvironment, obtained via bladder biopsy, indicates a tumor mutational burden (TMB) reported as ""nan."" Could you advise on the likelihood of a favorable response to Atezolizumab therapy in this situation?","We have a Caucasian female patient diagnosed with bladder urothelial carcinoma (BLCA). The transcriptomic profile of her tumor immune microenvironment, obtained via bladder biopsy, indicates a tumor mutational burden (TMB) reported as ""nan."" Could you advise on the likelihood of a favorable response to Atezolizumab therapy in this situation? Use the Compass platform to perform a transcriptomic assay that measures biomarkers involved in macrophage activation, interferon-γ signaling, genomic stability, cell proliferation, and cytotoxic T-cell function. Then, evaluate these molecular results to determine the patient’s likelihood of responding to immune checkpoint inhibitor therapy. Finally, combine these assay findings with the patient’s clinical history to create a detailed diagnostic report that includes personalized treatment recommendations.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-a1871f-ar-a1871f4.pkl. "
BLCA,15.0,0.921568627,inflamed,NR,We have a white female patient with bladder urothelial carcinoma whose tumor biopsy showed a tumor mutational burden of 15. Can we assess the likelihood of her responding to atezolizumab therapy based on this immune profiling data?,"We have a white female patient with bladder urothelial carcinoma whose tumor biopsy showed a tumor mutational burden of 15. Can we assess the likelihood of her responding to atezolizumab therapy based on this immune profiling data? Utilize the Compass platform to conduct a transcriptomic assay that quantifies biomarkers involved in macrophage activation, interferon-γ signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. After obtaining the molecular data, assess these results to estimate the patient’s potential response to immune checkpoint inhibitor therapy. Finally, integrate these findings with the patient’s clinical history to compile a comprehensive diagnostic report that includes tailored treatment recommendations.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-a1e62d-ar-a1e62d3.pkl. "
BLCA,8.0,1.411764706,excluded,NR,"A white male patient diagnosed with bladder urothelial carcinoma (BLCA) underwent a lymph node biopsy, and the transcriptomic profile of his tumor immune microenvironment revealed a tumor mutational burden (TMB) of 8.0. Based on these findings, how likely is this patient to respond to Atezolizumab therapy?","A white male patient diagnosed with bladder urothelial carcinoma (BLCA) underwent a lymph node biopsy, and the transcriptomic profile of his tumor immune microenvironment revealed a tumor mutational burden (TMB) of 8.0. Based on these findings, how likely is this patient to respond to Atezolizumab therapy? Please use the Compass platform to perform a transcriptomic assay that quantifies biomarkers related to macrophage activation, interferon-γ signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. After obtaining the molecular data, analyze it to determine the patient’s potential response to immune checkpoint inhibitor therapy. Finally, combine these results with the patient's clinical history to generate a detailed diagnostic report that includes personalized treatment recommendations.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-a32177-ar-a321770.pkl. "
BLCA,6.0,0.68627451,,NR,"For a white male patient with bladder urothelial carcinoma, whose bladder biopsy transcriptomic profile shows a tumor mutational burden (TMB) of 6.0, how likely is it that he will respond favorably to Atezolizumab therapy?","For a white male patient with bladder urothelial carcinoma, whose bladder biopsy transcriptomic profile shows a tumor mutational burden (TMB) of 6.0, how likely is it that he will respond favorably to Atezolizumab therapy? Utilize the Compass platform to run a transcriptomic assay that measures biomarkers indicative of macrophage activation, interferon-γ signaling, genomic integrity, cell proliferation, and cytotoxic T-cell activity. After gathering the molecular data, assess it to estimate the patient's likely response to immune checkpoint inhibitor therapy. Finally, incorporate this analysis with the patient's clinical history to prepare a comprehensive diagnostic report that includes individualized treatment recommendations.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-a424c7-ar-a424c75.pkl. "
BLCA,19.0,0.882352941,,R,"I have a white male patient with bladder urothelial carcinoma whose bladder biopsy transcriptomic profile indicates a tumor mutation burden of 19.0. Based on this data, what are the expectations regarding his response to atezolizumab therapy?","I have a white male patient with bladder urothelial carcinoma whose bladder biopsy transcriptomic profile indicates a tumor mutation burden of 19.0. Based on this data, what are the expectations regarding his response to atezolizumab therapy? Please use the Compass platform to perform a transcriptomic assay that quantifies biomarkers linked to macrophage activation, interferon‐γ signaling, genomic stability, cell proliferation, and cytotoxic T-cell function. Once the molecular data are obtained, review the results to project the patient’s potential responsiveness to immune checkpoint inhibitor therapy. Finally, integrate these findings with the patient’s clinical history to produce a thorough diagnostic report with personalized treatment recommendations.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-a535fc-ar-a535fcd.pkl. "
BLCA,12.0,0.725490196,,NR,"I have a white male patient with bladder urothelial carcinoma, and a recent biopsy of his tumor immune microenvironment revealed a tumor mutational burden (TMB) of 12.0. Could you help assess whether this patient is likely to respond to atezolizumab therapy?","I have a white male patient with bladder urothelial carcinoma, and a recent biopsy of his tumor immune microenvironment revealed a tumor mutational burden (TMB) of 12.0. Could you help assess whether this patient is likely to respond to atezolizumab therapy? Please use the Compass platform to conduct a transcriptomic assay that measures biomarkers associated with macrophage activation, interferon‐γ signaling, genomic stability, cell proliferation, and cytotoxic T-cell function. After acquiring the molecular data, review the results to estimate the patient’s likely response to immune checkpoint inhibitor therapy. Finally, combine these findings with the patient’s clinical history to create a detailed diagnostic report that includes personalized treatment recommendations.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-a90d73-ar-a90d73f.pkl. "
BLCA,,1.529411765,excluded,NR,"I have a Caucasian male patient diagnosed with bladder urothelial carcinoma. His tumor’s immune microenvironment was profiled using transcriptomic analysis from a kidney biopsy, and the report indicated a tumor mutational burden (TMB) value of ""nan."" Based on this data, could you advise on the likelihood of his response to Atezolizumab therapy?","I have a Caucasian male patient diagnosed with bladder urothelial carcinoma. His tumor’s immune microenvironment was profiled using transcriptomic analysis from a kidney biopsy, and the report indicated a tumor mutational burden (TMB) value of ""nan."" Based on this data, could you advise on the likelihood of his response to Atezolizumab therapy? Utilize the Compass platform to perform a transcriptomic assay that evaluates biomarkers related to macrophage activation, interferon‐γ signaling, genomic stability, cell proliferation, and cytotoxic T-cell function. Once the molecular data are obtained, assess the results to predict the patient’s potential response to immune checkpoint inhibitor therapy. Lastly, integrate these molecular insights with the patient's clinical history to compile a comprehensive diagnostic report that outlines personalized treatment recommendations.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-a913c6-ar-a913c61.pkl. "
BLCA,3.0,0.352941176,,NR,"For a white male patient with bladder urothelial carcinoma whose bladder biopsy transcriptomic analysis of the tumor immune microenvironment shows a tumor mutational burden of 3.0, what can be inferred about his likely response to Atezolizumab therapy?","For a white male patient with bladder urothelial carcinoma whose bladder biopsy transcriptomic analysis of the tumor immune microenvironment shows a tumor mutational burden of 3.0, what can be inferred about his likely response to Atezolizumab therapy? Use the Compass platform to conduct a transcriptomic assay examining biomarkers linked to macrophage activation, interferon‐γ signaling, genomic stability, cell proliferation, and cytotoxic T-cell function. After obtaining the molecular data, evaluate the results to forecast the patient’s likelihood of responding to immune checkpoint inhibitors. Finally, combine these molecular findings with the patient’s clinical history to create a detailed diagnostic report that outlines personalized treatment recommendations.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-a9ca85-ar-a9ca853.pkl. "
BLCA,18.0,2.0,,NR,"A white male patient with bladder urothelial carcinoma has undergone a lymph node biopsy, and transcriptomic analysis of the tumor immune microenvironment revealed a tumor mutational burden (TMB) of 18.0 mutations per megabase. Based on these findings, what is the likelihood of a favorable response to Atezolizumab therapy?","A white male patient with bladder urothelial carcinoma has undergone a lymph node biopsy, and transcriptomic analysis of the tumor immune microenvironment revealed a tumor mutational burden (TMB) of 18.0 mutations per megabase. Based on these findings, what is the likelihood of a favorable response to Atezolizumab therapy? Please use the Compass platform to perform a transcriptomic assay that targets biomarkers related to macrophage activation, interferon‐γ signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. Once you have obtained the molecular data, analyze it to predict the patient's potential response to immune checkpoint inhibitor therapy. Finally, integrate these molecular findings with the patient's clinical history to create a comprehensive diagnostic report that outlines personalized treatment recommendations.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-aabf4a-ar-aabf4af.pkl. "
BLCA,15.0,1.725490196,excluded,R,"For a Caucasian male patient diagnosed with bladder urothelial carcinoma, a kidney biopsy provided a transcriptomic profile of the tumor immune microenvironment indicating a tumor mutation burden of 15 mutations/Mb. Could you assess whether this patient is likely to benefit from Atezolizumab therapy?","For a Caucasian male patient diagnosed with bladder urothelial carcinoma, a kidney biopsy provided a transcriptomic profile of the tumor immune microenvironment indicating a tumor mutation burden of 15 mutations/Mb. Could you assess whether this patient is likely to benefit from Atezolizumab therapy? Please use the Compass platform to conduct a transcriptomic assay focused on key biomarkers—specifically those involved in macrophage activation, interferon‐γ signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. Once you have the molecular data, analyze it to estimate how the patient might respond to immune checkpoint inhibitor therapy. Finally, combine these molecular findings with the patient's clinical history to produce a detailed diagnostic report with personalized treatment recommendations.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-aaf505-ar-aaf505c.pkl. "
BLCA,,0.039215686,inflamed,NR,"In a white male patient diagnosed with bladder urothelial carcinoma, transcriptomic profiling of the tumor immune microenvironment from a lymph node biopsy reported a tumor mutation burden (TMB) value of 'nan'. How does this result influence the likelihood of a positive response to atezolizumab therapy?","In a white male patient diagnosed with bladder urothelial carcinoma, transcriptomic profiling of the tumor immune microenvironment from a lymph node biopsy reported a tumor mutation burden (TMB) value of 'nan'. How does this result influence the likelihood of a positive response to atezolizumab therapy? Please use the Compass platform to perform a transcriptomic assay that targets key biomarkers related to macrophage activation, interferon‐γ signaling, genomic maintenance, cell proliferation, and cytotoxic T-cell function. After obtaining the molecular profile, analyze the data to predict the patient’s potential response to immune checkpoint inhibitor therapy. Finally, integrate these molecular results with the patient’s clinical history to generate a comprehensive diagnostic report with tailored treatment recommendations.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-ab8052-ar-ab8052a.pkl. "
BLCA,,,excluded,NR,"I have a Caucasian female patient diagnosed with bladder urothelial carcinoma (BLCA). The transcriptomic analysis of her tumor immune microenvironment, obtained via bladder biopsy, did not provide a measurable tumor mutational burden (TMB). Could you provide your assessment regarding her potential response to Atezolizumab therapy?","I have a Caucasian female patient diagnosed with bladder urothelial carcinoma (BLCA). The transcriptomic analysis of her tumor immune microenvironment, obtained via bladder biopsy, did not provide a measurable tumor mutational burden (TMB). Could you provide your assessment regarding her potential response to Atezolizumab therapy? Please use the Compass platform to perform a transcriptomic assay that focuses on biomarkers associated with macrophage activation, interferon‐gamma signaling, genomic stability, cell proliferation, and cytotoxic T‐cell activity. Once you have obtained the molecular profile, analyze the data to assess the patient’s likely response to immune checkpoint inhibitor therapy. Finally, incorporate these molecular findings with the patient’s clinical history to prepare a detailed diagnostic report that includes personalized treatment recommendations.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-abc151-ar-abc151b.pkl. "
BLCA,6.0,0.745098039,,NR,"In a Caucasian male with bladder urothelial carcinoma (BLCA), a kidney biopsy revealed a tumor mutation burden (TMB) of 6.0 in the tumor immune microenvironment. Based on this profile, how likely is the patient to respond to atezolizumab therapy?","In a Caucasian male with bladder urothelial carcinoma (BLCA), a kidney biopsy revealed a tumor mutation burden (TMB) of 6.0 in the tumor immune microenvironment. Based on this profile, how likely is the patient to respond to atezolizumab therapy? Please use the Compass platform to conduct a transcriptomic assay that evaluates biomarkers related to macrophage activation, interferon‐gamma signaling, genomic stability, cell proliferation, and cytotoxic T‐cell activity. Once you have generated the molecular profile, analyze the results to predict the patient’s response to immune checkpoint inhibitor therapy. Finally, combine these molecular findings with the patient’s clinical history to develop a comprehensive diagnostic report that includes tailored treatment recommendations.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-ad83c9-ar-ad83c9c.pkl. "
BLCA,,,,NR,"I have a white female patient diagnosed with bladder urothelial carcinoma. A kidney biopsy of her tumor immune microenvironment yielded a transcriptomic profile, which reported a tumor mutational burden (TMB) of ""nan."" Can this information help predict her likelihood of responding to atezolizumab therapy?","I have a white female patient diagnosed with bladder urothelial carcinoma. A kidney biopsy of her tumor immune microenvironment yielded a transcriptomic profile, which reported a tumor mutational burden (TMB) of ""nan."" Can this information help predict her likelihood of responding to atezolizumab therapy? Please use the Compass platform to perform a transcriptomic analysis focused on biomarkers indicative of macrophage activation, interferon‐gamma signaling, genomic stability, cell proliferation, and cytotoxic T‐cell activity. After generating the molecular profile, review the data to assess the patient’s potential responsiveness to immune checkpoint inhibitors. Finally, integrate these molecular insights with the patient’s clinical history to create a detailed diagnostic report that includes personalized treatment recommendations.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-ae0262-ar-ae02629.pkl. "
BLCA,,,,NR,"I have an African American male patient diagnosed with bladder urothelial carcinoma (BLCA). Transcriptomic profiling from a ureter biopsy assessing the tumor immune microenvironment did not yield a measurable tumor mutational burden (TMB). Given these findings, could this patient be expected to respond favorably to atezolizumab therapy?","I have an African American male patient diagnosed with bladder urothelial carcinoma (BLCA). Transcriptomic profiling from a ureter biopsy assessing the tumor immune microenvironment did not yield a measurable tumor mutational burden (TMB). Given these findings, could this patient be expected to respond favorably to atezolizumab therapy? Please use the Compass platform to conduct a transcriptomic analysis that specifically examines biomarkers related to macrophage activation, interferon‐gamma signaling, genomic stability, cell proliferation, and cytotoxic T‐cell activity. Once you have generated the molecular profile, analyze the data to assess the patient's likely responsiveness to immune checkpoint inhibitors. Finally, integrate these molecular findings with the patient's clinical history to develop a comprehensive diagnostic report that includes personalized treatment recommendations.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-ae1690-ar-ae16904.pkl. "
BLCA,,,,NR,"I have a White female patient diagnosed with bladder urothelial carcinoma. The transcriptomic analysis of her tumor’s immune microenvironment from a bladder biopsy shows that the tumor mutational burden is not available. Based on this information, how should I assess her likelihood of responding to Atezolizumab therapy?","I have a White female patient diagnosed with bladder urothelial carcinoma. The transcriptomic analysis of her tumor’s immune microenvironment from a bladder biopsy shows that the tumor mutational burden is not available. Based on this information, how should I assess her likelihood of responding to Atezolizumab therapy? Please use the Compass platform to perform a transcriptomic analysis that focuses on biomarkers indicative of macrophage activation, interferon‐gamma signaling, genomic stability, cell proliferation, and cytotoxic T‐cell activity. Once you have generated the molecular profile, review the data to determine the patient's potential responsiveness to immune checkpoint inhibitors. Finally, combine these molecular insights with the patient’s clinical history to prepare a detailed diagnostic report that includes tailored treatment recommendations.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-ae4da2-ar-ae4da27.pkl. "
BLCA,4.0,,excluded,R,"A white male patient with bladder urothelial carcinoma underwent a ureter biopsy, revealing a tumor microenvironment transcriptomic profile with a tumor mutation burden (TMB) of 4.0. Based on this TMB value, how likely is he to respond to atezolizumab therapy?","A white male patient with bladder urothelial carcinoma underwent a ureter biopsy, revealing a tumor microenvironment transcriptomic profile with a tumor mutation burden (TMB) of 4.0. Based on this TMB value, how likely is he to respond to atezolizumab therapy? Use the Compass platform to conduct a transcriptomic analysis that evaluates biomarkers for macrophage activation, interferon‐gamma signaling, genomic integrity, cellular proliferation, and cytotoxic T‐cell activity. After generating the molecular profile, assess the data to determine the patient's likelihood of responding to immune checkpoint inhibitors. Then, integrate these molecular findings with the patient’s clinical history to develop a comprehensive diagnostic report that includes personalized treatment recommendations.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-aec738-ar-aec7380.pkl. "
BLCA,14.0,2.196078431,inflamed,NR,"In a white male patient diagnosed with bladder urothelial carcinoma, transcriptomic profiling of a bladder biopsy revealed a tumor mutational burden of 14.0. Is he likely to benefit from Atezolizumab therapy, and what additional factors should be considered when assessing his response?","In a white male patient diagnosed with bladder urothelial carcinoma, transcriptomic profiling of a bladder biopsy revealed a tumor mutational burden of 14.0. Is he likely to benefit from Atezolizumab therapy, and what additional factors should be considered when assessing his response? Please use the Compass platform to perform a transcriptomic analysis that evaluates biomarkers associated with macrophage activation, interferon‐gamma signaling, genomic integrity, cellular proliferation, and cytotoxic T‐cell activity. Once you have generated the molecular profile, review the data to assess the patient's potential responsiveness to immune checkpoint inhibitors. Finally, combine these molecular findings with the patient’s clinical history to create a detailed diagnostic report that includes individualized treatment recommendations.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-af42c1-ar-af42c15.pkl. "
BLCA,7.0,0.352941176,,NR,"For a white male patient with bladder urothelial carcinoma whose lung biopsy transcriptomic analysis shows a TMB of 7.0, how likely is it that he will respond to Atezolizumab therapy?","For a white male patient with bladder urothelial carcinoma whose lung biopsy transcriptomic analysis shows a TMB of 7.0, how likely is it that he will respond to Atezolizumab therapy? Please use the Compass platform to perform a transcriptomic analysis that examines biomarkers related to macrophage activation, interferon‐gamma signaling, genomic integrity, cellular proliferation, and cytotoxic T‐cell activity. Once you have generated the molecular profile, review the data to determine the patient’s likely response to immune checkpoint inhibitors. Finally, integrate these molecular findings with the patient’s clinical history to prepare a detailed diagnostic report that includes personalized treatment recommendations.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-b0a83e-ar-b0a83e5.pkl. "
BLCA,3.0,0.843137255,inflamed,NR,"For a white female patient with bladder urothelial carcinoma whose tumor immune microenvironment transcriptomic profile from a lung biopsy shows a tumor mutational burden of 3.0 mutations per megabase, what is the likelihood of a favorable response to Atezolizumab therapy?","For a white female patient with bladder urothelial carcinoma whose tumor immune microenvironment transcriptomic profile from a lung biopsy shows a tumor mutational burden of 3.0 mutations per megabase, what is the likelihood of a favorable response to Atezolizumab therapy? Please use the Compass platform to perform a transcriptomic analysis targeting biomarkers for macrophage activation, interferon‐gamma signaling, genomic integrity, cellular proliferation, and cytotoxic T‐cell activity. After creating the patient’s molecular profile, review the results to evaluate their potential response to immune checkpoint inhibitors. Finally, combine these molecular insights with the patient’s clinical history to develop a comprehensive diagnostic report with personalized treatment recommendations.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-b0d11d-ar-b0d11db.pkl. "
BLCA,11.0,1.509803922,,R,"In a white male patient with bladder urothelial carcinoma, transcriptomic analysis of the tumor immune microenvironment from a bladder biopsy revealed a tumor mutational burden (TMB) of 11.0. Based on this finding, how likely is the patient to respond to Atezolizumab therapy?","In a white male patient with bladder urothelial carcinoma, transcriptomic analysis of the tumor immune microenvironment from a bladder biopsy revealed a tumor mutational burden (TMB) of 11.0. Based on this finding, how likely is the patient to respond to Atezolizumab therapy? Use the Compass platform to conduct a transcriptomic analysis focusing on biomarkers related to macrophage activation, interferon‐gamma signaling, genomic integrity, cellular proliferation, and cytotoxic T‐cell activity. Once the molecular profile is established, evaluate the findings to predict the patient’s likely response to immune checkpoint inhibitors. Finally, combine these molecular insights with the patient’s clinical history to create a thorough diagnostic report that includes personalized treatment recommendations.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-b15ac6-ar-b15ac6e.pkl. "
BLCA,4.0,,excluded,NR,"In a White female patient with bladder urothelial carcinoma, a transcriptomic analysis of the tumor immune microenvironment from a bladder biopsy revealed a tumor mutational burden (TMB) of 4.0. What is the likelihood that she will respond favorably to Atezolizumab therapy?","In a White female patient with bladder urothelial carcinoma, a transcriptomic analysis of the tumor immune microenvironment from a bladder biopsy revealed a tumor mutational burden (TMB) of 4.0. What is the likelihood that she will respond favorably to Atezolizumab therapy? Please utilize the Compass platform to perform a transcriptomic analysis that targets biomarkers associated with macrophage activation, interferon‐gamma signaling, genomic integrity, cell proliferation, and cytotoxic T‐cell activity. After establishing the molecular profile, review the results with the goal of predicting the patient’s potential response to immune checkpoint inhibitors. Finally, integrate these molecular insights with the patient’s clinical history to compile a detailed diagnostic report that includes tailored treatment recommendations.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-b15ad0-ar-b15ad09.pkl. "
BLCA,,,,NR,I have a Caucasian female patient diagnosed with bladder urothelial carcinoma. The transcriptomic analysis of her tumor microenvironment from a bladder biopsy indicates that the tumor mutational burden data is not available. Could you evaluate her likely response to Atezolizumab therapy based on this information?,"I have a Caucasian female patient diagnosed with bladder urothelial carcinoma. The transcriptomic analysis of her tumor microenvironment from a bladder biopsy indicates that the tumor mutational burden data is not available. Could you evaluate her likely response to Atezolizumab therapy based on this information? Please use the Compass platform to conduct a transcriptomic analysis focusing on biomarkers related to macrophage activation, interferon‐gamma signaling, genomic stability, cell proliferation, and cytotoxic T‐cell activity. Once the molecular profile is established, review the findings to estimate the patient’s potential response to immune checkpoint inhibitor therapy. Finally, combine these molecular data with the patient’s clinical history to produce a comprehensive diagnostic report that includes personalized treatment recommendations.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-b2e4a0-ar-b2e4a08.pkl. "
BLCA,,0.862745098,desert,R,"In a white male patient with bladder urothelial carcinoma whose tumor biopsy transcriptomic analysis reports a TMB value of ""nan,"" how might this influence his likelihood of responding to Atezolizumab therapy?","In a white male patient with bladder urothelial carcinoma whose tumor biopsy transcriptomic analysis reports a TMB value of ""nan,"" how might this influence his likelihood of responding to Atezolizumab therapy? Please utilize the Compass platform to perform a transcriptomic analysis that examines biomarkers associated with macrophage activation, interferon‐gamma signaling, genomic stability, cell proliferation, and cytotoxic T‐cell activity. After establishing the molecular profile, carefully evaluate the results to predict the patient’s potential response to immune checkpoint inhibitor therapy. Finally, integrate these molecular findings with the patient’s clinical history to prepare a comprehensive diagnostic report that includes tailored treatment recommendations.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-b2f1d0-ar-b2f1d0e.pkl. "
BLCA,18.0,,desert,R,"In a white male patient with bladder urothelial carcinoma, transcriptomic profiling of the tumor immune microenvironment from a biopsy indicated a tumor mutational burden (TMB) of 18.0 mutations per megabase. Based on this finding, what is the likelihood of a favorable response to atezolizumab therapy?","In a white male patient with bladder urothelial carcinoma, transcriptomic profiling of the tumor immune microenvironment from a biopsy indicated a tumor mutational burden (TMB) of 18.0 mutations per megabase. Based on this finding, what is the likelihood of a favorable response to atezolizumab therapy? Using the Compass platform, conduct a transcriptomic analysis focused on biomarkers for macrophage activation, interferon‐gamma signaling, genomic stability, cell proliferation, and cytotoxic T‐cell activity. Once you have established the molecular profile, assess these findings to predict the patient's likely response to immune checkpoint inhibitor therapy. Finally, combine the molecular data with the patient's clinical history to produce a comprehensive diagnostic report that includes personalized treatment recommendations.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-b3c022-ar-b3c0229.pkl. "
BLCA,19.0,,excluded,R,"Given a white male patient with bladder urothelial carcinoma whose transcriptomic analysis from a bladder biopsy indicates a tumor mutational burden (TMB) of 19.0, what is the likelihood that this patient will respond to Atezolizumab therapy?","Given a white male patient with bladder urothelial carcinoma whose transcriptomic analysis from a bladder biopsy indicates a tumor mutational burden (TMB) of 19.0, what is the likelihood that this patient will respond to Atezolizumab therapy? Use the Compass platform to perform a transcriptomic analysis targeting biomarkers linked to macrophage activation, interferon‐gamma signaling, genomic stability, cell proliferation, and cytotoxic T‐cell activity. After establishing a detailed molecular profile, evaluate the biomarker data to predict the patient's potential response to immune checkpoint inhibitor therapy. Finally, combine these molecular insights with the patient's clinical history to compile a comprehensive diagnostic report that includes personalized treatment recommendations.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-b419a8-ar-b419a8f.pkl. "
BLCA,35.0,,excluded,R,"I have a White male patient with bladder urothelial carcinoma whose bladder biopsy transcriptomic analysis shows a tumor mutational burden of 35. Based on this profile, what can we infer about his likely response to Atezolizumab therapy?","I have a White male patient with bladder urothelial carcinoma whose bladder biopsy transcriptomic analysis shows a tumor mutational burden of 35. Based on this profile, what can we infer about his likely response to Atezolizumab therapy? Please use the Compass platform to conduct a transcriptomic analysis focusing on biomarkers related to macrophage activation, interferon‐gamma signaling, genomic integrity, cell proliferation, and cytotoxic T‐cell function. Once you establish a detailed molecular profile, assess the biomarker results to forecast the patient’s likelihood of responding to immune checkpoint inhibitors. Finally, integrate these molecular findings with the patient’s clinical history to create a comprehensive diagnostic report that offers personalized treatment recommendations.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-b470eb-ar-b470eb8.pkl. "
BLCA,5.0,,inflamed,NR,"In a white male patient diagnosed with bladder urothelial carcinoma, a kidney biopsy of the tumor immune microenvironment has revealed a tumor mutational burden (TMB) of 5.0. Is there sufficient evidence to suggest that this patient would likely respond favorably to Atezolizumab therapy?","In a white male patient diagnosed with bladder urothelial carcinoma, a kidney biopsy of the tumor immune microenvironment has revealed a tumor mutational burden (TMB) of 5.0. Is there sufficient evidence to suggest that this patient would likely respond favorably to Atezolizumab therapy? Please use the Compass platform to perform a transcriptomic analysis that targets biomarkers associated with macrophage activation, interferon‐gamma signaling, genomic stability, cell proliferation, and cytotoxic T‐cell activity. After generating a detailed molecular profile, evaluate the biomarker data to predict the patient's likely response to immune checkpoint inhibitors. Finally, combine these molecular insights with the patient's clinical history to develop a comprehensive diagnostic report that includes personalized treatment recommendations.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-b4c7a0-ar-b4c7a00.pkl. "
BLCA,5.0,0.333333333,desert,NR,"I have a white male patient diagnosed with bladder urothelial carcinoma. His tumor biopsy transcriptomic analysis indicates a tumor mutational burden (TMB) of 5.0. Based on these findings, can we assess his likelihood of responding to Atezolizumab therapy?","I have a white male patient diagnosed with bladder urothelial carcinoma. His tumor biopsy transcriptomic analysis indicates a tumor mutational burden (TMB) of 5.0. Based on these findings, can we assess his likelihood of responding to Atezolizumab therapy? Utilize the Compass platform to conduct a transcriptomic analysis focusing on biomarkers related to macrophage activation, interferon‐gamma signaling, genomic stability, cell proliferation, and cytotoxic T‐cell activity. Once you generate a detailed molecular profile, assess the biomarker data to estimate the patient’s potential response to immune checkpoint inhibitors. Finally, integrate these molecular findings with the patient’s clinical history to create a thorough diagnostic report that includes tailored treatment recommendations.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-b8070b-ar-b8070b7.pkl. "
BLCA,16.0,3.764705882,inflamed,NR,"I have a white male patient diagnosed with bladder urothelial carcinoma. His tumor transcriptomic analysis from a bladder biopsy shows a tumor mutational burden (TMB) of 16.0. Based on these findings, what is the likelihood that he will respond to Atezolizumab therapy?","I have a white male patient diagnosed with bladder urothelial carcinoma. His tumor transcriptomic analysis from a bladder biopsy shows a tumor mutational burden (TMB) of 16.0. Based on these findings, what is the likelihood that he will respond to Atezolizumab therapy? Please use the Compass platform to perform a transcriptomic analysis that targets biomarkers for macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. After generating a comprehensive molecular profile, evaluate the biomarker data to predict the patient’s likelihood of responding to immune checkpoint inhibitors. Finally, combine these molecular insights with the patient's clinical history to develop a detailed diagnostic report that includes personalized treatment recommendations.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-b8101c-ar-b8101c5.pkl. "
BLCA,8.0,0.882352941,excluded,NR,"For a patient with bladder urothelial carcinoma whose bladder biopsy transcriptomic profiling reveals a tumor mutation burden of 8.0, how likely is it that they will respond favorably to atezolizumab therapy?","For a patient with bladder urothelial carcinoma whose bladder biopsy transcriptomic profiling reveals a tumor mutation burden of 8.0, how likely is it that they will respond favorably to atezolizumab therapy? Please use the Compass platform to carry out a transcriptomic analysis that focuses on biomarkers related to macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. Once you have developed a detailed molecular profile, assess the biomarker data to estimate the patient's potential responsiveness to immune checkpoint inhibitors. Finally, integrate these molecular findings with the patient's clinical history to prepare a comprehensive diagnostic report that includes personalized treatment recommendations.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-b963dd-ar-b963dda.pkl. "
BLCA,5.0,0.901960784,inflamed,NR,"I have a Caucasian male patient diagnosed with bladder urothelial carcinoma. A bladder biopsy revealed a transcriptomic profile of the tumor immune microenvironment with a tumor mutation burden (TMB) of 5.0. Based on this molecular profile, how likely is this patient to respond to Atezolizumab therapy?","I have a Caucasian male patient diagnosed with bladder urothelial carcinoma. A bladder biopsy revealed a transcriptomic profile of the tumor immune microenvironment with a tumor mutation burden (TMB) of 5.0. Based on this molecular profile, how likely is this patient to respond to Atezolizumab therapy? Using the Compass platform, perform a transcriptomic analysis that targets biomarkers involved in macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell function. After generating a detailed molecular profile, evaluate the biomarker data to assess the likelihood of the patient's response to immune checkpoint inhibitors. Finally, correlate these molecular insights with the patient’s clinical history to compile a comprehensive diagnostic report that provides tailored treatment recommendations.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-ba1a34-ar-ba1a34b.pkl. "
BLCA,5.0,,excluded,NR,"For a White female patient with bladder urothelial carcinoma, transcriptomic profiling of the tumor immune microenvironment from a kidney biopsy showed a tumor mutational burden of 5.0. How does this TMB value inform your assessment of her likely response to atezolizumab therapy?","For a White female patient with bladder urothelial carcinoma, transcriptomic profiling of the tumor immune microenvironment from a kidney biopsy showed a tumor mutational burden of 5.0. How does this TMB value inform your assessment of her likely response to atezolizumab therapy? Using the Compass platform, conduct a transcriptomic analysis to evaluate biomarkers associated with macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell function. Once you have generated a comprehensive molecular profile, assess these biomarkers to determine the patient's potential response to immune checkpoint inhibitors. Finally, integrate these molecular findings with the patient’s clinical history to develop a detailed diagnostic report that includes personalized treatment recommendations.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-ba7176-ar-ba7176a.pkl. "
BLCA,7.0,0.745098039,desert,NR,"Given a white female patient with bladder urothelial carcinoma whose bladder biopsy revealed a tumor mutational burden (TMB) of 7.0 as part of the transcriptomic profiling of the tumor immune microenvironment, what is the likelihood that she will respond to Atezolizumab therapy?","Given a white female patient with bladder urothelial carcinoma whose bladder biopsy revealed a tumor mutational burden (TMB) of 7.0 as part of the transcriptomic profiling of the tumor immune microenvironment, what is the likelihood that she will respond to Atezolizumab therapy? Use the Compass platform to perform a transcriptomic analysis that identifies biomarkers involved in macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell function. After generating this detailed molecular profile, evaluate these biomarkers to predict the patient's potential response to immune checkpoint inhibitors. Finally, combine these molecular results with the patient’s clinical history to create a comprehensive diagnostic report that includes tailored treatment recommendations.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-bc8dc3-ar-bc8dc3a.pkl. "
BLCA,,,excluded,NR,"For a Caucasian male patient diagnosed with Bladder Urothelial Carcinoma, with a tumor transcriptomic profile from a bladder biopsy indicating a TMB value of ""nan,"" what is the likelihood that he will respond to Atezolizumab therapy?","For a Caucasian male patient diagnosed with Bladder Urothelial Carcinoma, with a tumor transcriptomic profile from a bladder biopsy indicating a TMB value of ""nan,"" what is the likelihood that he will respond to Atezolizumab therapy? Please use the Compass platform to conduct a transcriptomic analysis that detects biomarkers associated with macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell function. Once the molecular profile is generated, assess these biomarkers to estimate the patient’s likelihood of responding to immune checkpoint inhibitors. Lastly, integrate these molecular findings with the patient’s clinical history to prepare a comprehensive diagnostic report that includes personalized treatment recommendations.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-bcb07b-ar-bcb07ba.pkl. "
BLCA,9.0,,desert,NR,"For a white male patient with bladder urothelial carcinoma and a tumor mutation burden of 9.0 identified from a biopsy transcriptomic analysis, how likely is he to respond to Atezolizumab treatment?","For a white male patient with bladder urothelial carcinoma and a tumor mutation burden of 9.0 identified from a biopsy transcriptomic analysis, how likely is he to respond to Atezolizumab treatment? Please use the Compass platform to perform a transcriptomic analysis that evaluates biomarkers related to macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell function. Once you generate the molecular profile, review these biomarkers to assess the patient’s potential responsiveness to immune checkpoint inhibitors. Finally, combine the molecular findings with the patient’s clinical history to prepare a comprehensive diagnostic report with personalized treatment recommendations.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-bcbc79-ar-bcbc795.pkl. "
BLCA,20.0,1.254901961,inflamed,NR,"In a white female patient diagnosed with bladder urothelial carcinoma with a tumor mutational burden (TMB) of 20.0 identified via transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy, how should we assess her potential response to Atezolizumab therapy?","In a white female patient diagnosed with bladder urothelial carcinoma with a tumor mutational burden (TMB) of 20.0 identified via transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy, how should we assess her potential response to Atezolizumab therapy? Use the Compass platform to conduct a transcriptomic analysis that examines biomarkers indicative of macrophage activation, interferon-gamma signaling, genomic integrity, cell proliferation, and cytotoxic T-cell activity. After obtaining the molecular profile, review these biomarkers to evaluate the patient's potential responsiveness to immune checkpoint inhibitors. Finally, integrate these molecular findings with the patient's clinical history to create a comprehensive diagnostic report that includes personalized treatment recommendations.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-bda79f-ar-bda79f9.pkl. "
BLCA,10.0,0.784313725,excluded,NR,"I have a white female patient diagnosed with bladder urothelial carcinoma. A lymph node biopsy of her tumor immune microenvironment revealed a tumor mutational burden (TMB) of 10.0. Based on these findings, what is the likelihood that she would respond to atezolizumab therapy?","I have a white female patient diagnosed with bladder urothelial carcinoma. A lymph node biopsy of her tumor immune microenvironment revealed a tumor mutational burden (TMB) of 10.0. Based on these findings, what is the likelihood that she would respond to atezolizumab therapy? Please use the Compass platform to perform a transcriptomic analysis focused on detecting critical biomarkers related to macrophage activation, interferon-gamma signaling, genomic integrity, cell proliferation, and cytotoxic T-cell activity. Once you have obtained the molecular profile, evaluate these biomarkers to assess the likelihood of a positive response to immune checkpoint inhibitors. Finally, combine these molecular insights with the patient’s clinical history to generate a detailed diagnostic report that includes tailored treatment recommendations.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-be83ea-ar-be83eae.pkl. "
BLCA,35.0,3.745098039,excluded,R,"For a Caucasian male patient with bladder urothelial carcinoma whose bladder biopsy transcriptomic profile indicates a tumor mutational burden (TMB) of 35, what is the likelihood of a favorable response to Atezolizumab therapy?","For a Caucasian male patient with bladder urothelial carcinoma whose bladder biopsy transcriptomic profile indicates a tumor mutational burden (TMB) of 35, what is the likelihood of a favorable response to Atezolizumab therapy? Use the Compass platform to conduct a transcriptomic analysis targeting key biomarkers, including those related to macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-lymphocyte activity. Evaluate these markers to determine the likelihood of a positive response to immune checkpoint inhibitor therapy. Finally, integrate this molecular data with the patient’s clinical history to produce a comprehensive diagnostic report that includes personalized treatment recommendations.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-bf1a3a-ar-bf1a3ae.pkl. "
BLCA,6.0,1.450980392,excluded,NR,"In a white female patient diagnosed with bladder urothelial carcinoma, transcriptomic profiling of the tumor’s immune microenvironment from a bladder biopsy revealed a tumor mutational burden of 6.0. Based on these findings, could you assess the likelihood that the patient will benefit from Atezolizumab therapy?","In a white female patient diagnosed with bladder urothelial carcinoma, transcriptomic profiling of the tumor’s immune microenvironment from a bladder biopsy revealed a tumor mutational burden of 6.0. Based on these findings, could you assess the likelihood that the patient will benefit from Atezolizumab therapy? Please use the Compass platform to perform a transcriptomic analysis that focuses on key biomarkers, such as those associated with macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-lymphocyte function. Assess these biomarkers to estimate the likelihood of a positive response to immune checkpoint inhibitor therapy. Finally, merge the resulting molecular data with the patient’s clinical history to prepare a detailed diagnostic report that includes tailor-made treatment recommendations.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-bfdffb-ar-bfdffb9.pkl. "
BLCA,3.0,0.294117647,desert,NR,"For a white female patient with bladder urothelial carcinoma whose tumor biopsy shows a tumor mutation burden (TMB) of 3.0, how might this TMB level influence her response to Atezolizumab therapy?","For a white female patient with bladder urothelial carcinoma whose tumor biopsy shows a tumor mutation burden (TMB) of 3.0, how might this TMB level influence her response to Atezolizumab therapy? Please utilize the Compass platform to conduct a transcriptomic analysis targeting key biomarkers, including those linked to macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-lymphocyte function. Evaluate these markers to gauge the potential efficacy of immune checkpoint inhibitor therapy. Then, combine the molecular data with the patient’s clinical history to develop a comprehensive diagnostic report that outlines personalized treatment recommendations.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-c0d625-ar-c0d625a.pkl. "
BLCA,5.0,1.176470588,desert,NR,"In a white male patient diagnosed with bladder urothelial carcinoma, who exhibits a tumor mutation burden (TMB) of 5.0 based on transcriptomic analysis of the tumor immune microenvironment from a bladder biopsy, what is the likelihood that he will respond to Atezolizumab therapy?","In a white male patient diagnosed with bladder urothelial carcinoma, who exhibits a tumor mutation burden (TMB) of 5.0 based on transcriptomic analysis of the tumor immune microenvironment from a bladder biopsy, what is the likelihood that he will respond to Atezolizumab therapy? Please use the Compass platform to perform a transcriptomic analysis, focusing specifically on biomarkers related to macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-lymphocyte function. Assess these markers to determine the likely response to immune checkpoint inhibitor therapy. Afterwards, integrate the molecular findings with the patient’s clinical history to develop a thorough diagnostic report that provides individualized treatment recommendations.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-c0da5d-ar-c0da5d4.pkl. "
BLCA,5.0,0.960784314,desert,NR,"I have a white male patient diagnosed with bladder urothelial carcinoma. A nanobiopsy of his tumor has revealed a transcriptomic profile with a tumor mutational burden of 5.0. Based on this information, can we expect him to respond favorably to Atezolizumab therapy?","I have a white male patient diagnosed with bladder urothelial carcinoma. A nanobiopsy of his tumor has revealed a transcriptomic profile with a tumor mutational burden of 5.0. Based on this information, can we expect him to respond favorably to Atezolizumab therapy? Please use the Compass platform to conduct a transcriptomic analysis that specifically examines biomarkers associated with macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-lymphocyte function. Evaluate these biomarkers to predict the patient’s response to immune checkpoint inhibitor therapy. Then, combine these molecular insights with the patient’s clinical history to create a comprehensive diagnostic report that includes personalized treatment recommendations.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-c0ef41-ar-c0ef41a.pkl. "
BLCA,5.0,1.098039216,excluded,R,"I have a white male patient diagnosed with bladder urothelial carcinoma. A transcriptomic analysis of his bladder biopsy revealed a tumor mutational burden of 5.0. Based on this information, what is the likelihood that he will respond to Atezolizumab therapy?","I have a white male patient diagnosed with bladder urothelial carcinoma. A transcriptomic analysis of his bladder biopsy revealed a tumor mutational burden of 5.0. Based on this information, what is the likelihood that he will respond to Atezolizumab therapy? Please access the Compass platform and perform a transcriptomic analysis to focus on biomarkers related to macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-lymphocyte function. Assess these biomarkers as potential predictors of the patient's response to immune checkpoint inhibitor therapy. Then, integrate these molecular findings with the patient’s clinical history to develop a detailed diagnostic report that also outlines personalized treatment recommendations.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-c1251c-ar-c1251c7.pkl. "
BLCA,5.0,1.411764706,excluded,R,"A Caucasian male patient with bladder urothelial carcinoma has a tumor mutational burden of 5.0 based on transcriptomic profiling obtained from a kidney biopsy. Based on these findings, is he likely to benefit from Atezolizumab therapy?","A Caucasian male patient with bladder urothelial carcinoma has a tumor mutational burden of 5.0 based on transcriptomic profiling obtained from a kidney biopsy. Based on these findings, is he likely to benefit from Atezolizumab therapy? Access the Compass platform to perform a transcriptomic analysis that targets biomarkers associated with macrophage activation, interferon-gamma signaling, genomic integrity, cell proliferation, and cytotoxic T-lymphocyte function. Evaluate these biomarkers as potential predictors of the patient’s response to immune checkpoint inhibitor therapy. Then, integrate these molecular insights with the patient’s clinical history to compile a comprehensive diagnostic report that includes personalized treatment recommendations.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-c1b27b-ar-c1b27bc.pkl. "
BLCA,,,excluded,R,"A white male patient diagnosed with bladder urothelial carcinoma underwent a bladder biopsy, and analysis of the tumor immune microenvironment transcriptome showed that the tumor mutational burden (TMB) is not available. Based on this information, can we assess whether the patient is likely to respond to atezolizumab therapy?","A white male patient diagnosed with bladder urothelial carcinoma underwent a bladder biopsy, and analysis of the tumor immune microenvironment transcriptome showed that the tumor mutational burden (TMB) is not available. Based on this information, can we assess whether the patient is likely to respond to atezolizumab therapy? Please use the Compass platform to conduct a transcriptomic analysis that focuses on genes related to macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-lymphocyte activity. Assess these biomarkers to determine their potential in predicting the patient’s response to immune checkpoint inhibitor therapy. Afterward, integrate these molecular findings with the patient’s clinical history to develop a detailed diagnostic report that includes personalized treatment recommendations.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-c2a182-ar-c2a1820.pkl. "
BLCA,3.0,0.196078431,desert,NR,"I have a patient diagnosed with bladder urothelial carcinoma. The transcriptomic analysis of the tumor immune microenvironment from a bladder biopsy shows a TMB of 3.0. Based on these findings, how likely is it that the patient will respond to Atezolizumab therapy?","I have a patient diagnosed with bladder urothelial carcinoma. The transcriptomic analysis of the tumor immune microenvironment from a bladder biopsy shows a TMB of 3.0. Based on these findings, how likely is it that the patient will respond to Atezolizumab therapy? Please use the Compass platform to perform a transcriptomic analysis that targets genes involved in macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-lymphocyte function. Evaluate these biomarkers to determine their ability to predict the patient’s response to immune checkpoint inhibitor therapy. Then, combine these molecular insights with the patient's clinical history to create a comprehensive diagnostic report that includes personalized treatment recommendations.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-c57ead-ar-c57eadb.pkl. "
BLCA,10.0,,desert,NR,"For a white male patient diagnosed with bladder urothelial carcinoma, a ureter biopsy revealed a transcriptomic profile of the tumor immune microenvironment with a tumor mutational burden (TMB) of 10. Based on these findings, how likely is he to respond to Atezolizumab therapy?","For a white male patient diagnosed with bladder urothelial carcinoma, a ureter biopsy revealed a transcriptomic profile of the tumor immune microenvironment with a tumor mutational burden (TMB) of 10. Based on these findings, how likely is he to respond to Atezolizumab therapy? Using the Compass platform, conduct a transcriptomic analysis that focuses on genes associated with macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-lymphocyte function. Assess these biomarkers to evaluate their predictive value for the patient's response to immune checkpoint inhibitor therapy. Finally, integrate these molecular findings with the patient's clinical history to generate a comprehensive diagnostic report that includes personalized treatment recommendations.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-c69253-ar-c692536.pkl. "
BLCA,3.0,0.450980392,excluded,NR,"For a white male patient with bladder urothelial carcinoma whose lymph node biopsy transcriptomic analysis shows a tumor mutational burden of 3.0, how likely is it that he will respond to Atezolizumab treatment?","For a white male patient with bladder urothelial carcinoma whose lymph node biopsy transcriptomic analysis shows a tumor mutational burden of 3.0, how likely is it that he will respond to Atezolizumab treatment? Please use the Compass platform to perform a transcriptomic analysis targeting genes involved in macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-lymphocyte function. Evaluate these biomarkers to determine their potential in predicting the patient’s response to immune checkpoint inhibitor therapy. Then, combine the molecular data with the patient’s clinical history to create a detailed diagnostic report that includes personalized treatment recommendations.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-c6eff0-ar-c6eff05.pkl. "
BLCA,3.0,0.607843137,inflamed,R,"For a white male patient with bladder urothelial carcinoma whose biopsy transcriptomic analysis indicates a tumor mutation burden of 3.0, how likely is it that he will respond to Atezolizumab therapy?","For a white male patient with bladder urothelial carcinoma whose biopsy transcriptomic analysis indicates a tumor mutation burden of 3.0, how likely is it that he will respond to Atezolizumab therapy? Please use the Compass platform to conduct a transcriptomic analysis focused on gene expression related to macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-lymphocyte function. Assess these biomarkers to evaluate their ability to predict the patient’s response to immune checkpoint inhibitor therapy. Then, integrate the molecular data with the patient’s clinical history to develop a comprehensive diagnostic report that includes tailored treatment recommendations.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-c919ae-ar-c919aeb.pkl. "
BLCA,11.0,1.352941176,inflamed,NR,"In a Black or African American female patient with bladder urothelial carcinoma, a lung biopsy of the tumor immune microenvironment revealed a tumor mutation burden (TMB) of 11.0. Based on these findings, what are the implications for her response to Atezolizumab therapy?","In a Black or African American female patient with bladder urothelial carcinoma, a lung biopsy of the tumor immune microenvironment revealed a tumor mutation burden (TMB) of 11.0. Based on these findings, what are the implications for her response to Atezolizumab therapy? Please use the Compass platform to perform a transcriptomic analysis targeting gene expression markers associated with macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-lymphocyte function. Evaluate these biomarkers as potential predictors of the patient’s response to immune checkpoint inhibitor therapy. Then, integrate these molecular findings with the patient’s clinical history to generate a comprehensive diagnostic report that includes personalized treatment recommendations.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-cabb6d-ar-cabb6d5.pkl. "
BLCA,,0.843137255,desert,NR,"For a white male patient diagnosed with bladder urothelial carcinoma, a lymph node biopsy was used to assess the transcriptomic profile of the tumor immune microenvironment, which yielded a TMB value of ""nan."" How should this result be interpreted in terms of his likely response to atezolizumab therapy?","For a white male patient diagnosed with bladder urothelial carcinoma, a lymph node biopsy was used to assess the transcriptomic profile of the tumor immune microenvironment, which yielded a TMB value of ""nan."" How should this result be interpreted in terms of his likely response to atezolizumab therapy? Please use the Compass platform to conduct transcriptomic profiling focusing on gene expression markers indicative of macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-lymphocyte function. Assess these markers for their potential to predict the patient's response to immune checkpoint inhibitor therapy. Subsequently, integrate these molecular findings with the patient's clinical history to create a detailed diagnostic report that includes individualized treatment recommendations.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-cb132b-ar-cb132b0.pkl. "
BLCA,,,,NR,"I have a White male patient with bladder urothelial carcinoma (BLCA) whose liver biopsy was evaluated by transcriptomic profiling of the tumor immune microenvironment. The report indicates a tumor mutational burden (TMB) value of ""nan."" Based on this finding, can we determine if the patient is likely to respond to Atezolizumab therapy?","I have a White male patient with bladder urothelial carcinoma (BLCA) whose liver biopsy was evaluated by transcriptomic profiling of the tumor immune microenvironment. The report indicates a tumor mutational burden (TMB) value of ""nan."" Based on this finding, can we determine if the patient is likely to respond to Atezolizumab therapy? Please use the Compass platform to perform transcriptomic profiling, focusing specifically on gene expression markers related to macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-lymphocyte function. Evaluate whether these markers can help predict the patient’s response to immune checkpoint inhibitor therapy. Then, combine these molecular findings with the patient’s clinical history to prepare a comprehensive diagnostic report that includes personalized treatment recommendations.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-cc4675-ar-cc4675f.pkl. "
BLCA,26.0,4.960784314,inflamed,R,"A white female patient with bladder urothelial carcinoma has a tumor immune microenvironment transcriptomic profile from a ureter biopsy indicating a TMB of 26.0. Based on these findings, could you assess her likelihood of responding to atezolizumab therapy?","A white female patient with bladder urothelial carcinoma has a tumor immune microenvironment transcriptomic profile from a ureter biopsy indicating a TMB of 26.0. Based on these findings, could you assess her likelihood of responding to atezolizumab therapy? Please utilize the Compass platform to conduct transcriptomic profiling, concentrating on gene expression markers that indicate macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T lymphocyte function. Assess whether these specific markers can predict the patient’s response to immune checkpoint inhibitor therapy. Then, integrate these molecular findings with the patient's clinical history to generate a comprehensive diagnostic report that includes personalized treatment recommendations.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-cc7a42-ar-cc7a42d.pkl. "
BLCA,14.0,0.843137255,inflamed,NR,"For a white male patient with bladder urothelial carcinoma whose biopsy transcriptomic analysis shows a tumor mutation burden of 14.0, what is the likelihood of a favorable response to Atezolizumab therapy?","For a white male patient with bladder urothelial carcinoma whose biopsy transcriptomic analysis shows a tumor mutation burden of 14.0, what is the likelihood of a favorable response to Atezolizumab therapy? Please use the Compass platform to perform transcriptomic profiling, specifically evaluating gene expression markers for macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T lymphocyte function. Determine if these markers have predictive value for the patient's response to immune checkpoint inhibitor therapy. After obtaining these molecular data, integrate them with the patient’s clinical history to compile a comprehensive diagnostic report that includes personalized treatment recommendations.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-ce39dd-ar-ce39dd7.pkl. "
BLCA,,,excluded,NR,I have a white male patient diagnosed with bladder urothelial carcinoma. A transcriptomic analysis of the tumor immune microenvironment obtained from a lung biopsy revealed a tumor mutational burden value that is not available (nan). Could you advise on whether these findings suggest he might respond to atezolizumab therapy?,"I have a white male patient diagnosed with bladder urothelial carcinoma. A transcriptomic analysis of the tumor immune microenvironment obtained from a lung biopsy revealed a tumor mutational burden value that is not available (nan). Could you advise on whether these findings suggest he might respond to atezolizumab therapy? Please use the Compass platform to conduct transcriptomic profiling on the patient’s sample. Focus on quantifying gene expression levels related to macrophage activation, interferon-gamma signaling, genomic integrity, cell proliferation, and cytotoxic T lymphocyte activity. After analyzing these markers, assess their potential to predict the patient’s response to immune checkpoint inhibitor therapy. Finally, incorporate these molecular findings with the patient’s clinical history to generate a comprehensive diagnostic report that also outlines personalized treatment recommendations.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-cf018f-ar-cf018fe.pkl. "
BLCA,4.0,0.764705882,desert,R,"In a white female patient diagnosed with bladder urothelial carcinoma, transcriptomic profiling of her tumor immune microenvironment from a ureter biopsy revealed a tumor mutational burden of 4.0. Based on this information, how likely is she to respond to atezolizumab therapy?","In a white female patient diagnosed with bladder urothelial carcinoma, transcriptomic profiling of her tumor immune microenvironment from a ureter biopsy revealed a tumor mutational burden of 4.0. Based on this information, how likely is she to respond to atezolizumab therapy? Please perform transcriptomic profiling on the patient's sample using the Compass platform. Specifically, quantify gene expression levels associated with macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell function. Evaluate these markers to determine their predictive value for the patient’s response to immune checkpoint inhibitors. Finally, integrate these molecular findings with the patient’s clinical history to create a comprehensive diagnostic report that includes personalized treatment recommendations.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-d02712-ar-d027124.pkl. "
BLCA,3.0,0.607843137,excluded,NR,"I have a White male patient diagnosed with bladder urothelial carcinoma (BLCA). Transcriptomic profiling from a bladder biopsy of the tumor immune microenvironment indicates a tumor mutational burden (TMB) of 3.0. Based on these findings, what is the anticipated response to Atezolizumab therapy?","I have a White male patient diagnosed with bladder urothelial carcinoma (BLCA). Transcriptomic profiling from a bladder biopsy of the tumor immune microenvironment indicates a tumor mutational burden (TMB) of 3.0. Based on these findings, what is the anticipated response to Atezolizumab therapy? Please carry out transcriptomic profiling on the patient's sample using the Compass platform. As part of this analysis, measure gene expression levels linked to macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell function. Use these measurements to assess the potential predictive value for the patient's response to immune checkpoint inhibitors. Finally, combine these transcriptomic results with the patient’s clinical history to develop a comprehensive diagnostic report that includes personalized treatment recommendations.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-d135d5-ar-d135d58.pkl. "
BLCA,22.0,,,NR,"We have a white male patient diagnosed with bladder urothelial carcinoma (BLCA). The transcriptomic analysis of his tumor immune microenvironment from a bladder biopsy reveals a tumor mutational burden (TMB) of 22.0. Based on these findings, what is the likelihood that he will respond to Atezolizumab therapy?","We have a white male patient diagnosed with bladder urothelial carcinoma (BLCA). The transcriptomic analysis of his tumor immune microenvironment from a bladder biopsy reveals a tumor mutational burden (TMB) of 22.0. Based on these findings, what is the likelihood that he will respond to Atezolizumab therapy? Please perform transcriptomic profiling of the patient's sample using the Compass platform. Analyze gene expression profiles specifically related to macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell function. Evaluate these expression patterns to determine their potential predictive value for the patient's response to immune checkpoint inhibitors. Finally, integrate these findings with the patient's clinical history to produce a comprehensive diagnostic report that also includes personalized treatment recommendations.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-d1bd63-ar-d1bd637.pkl. "
BLCA,,,,NR,"I have a white male patient diagnosed with bladder urothelial carcinoma. A transcriptomic analysis of his tumor immune microenvironment from a bladder biopsy reported a TMB value as ""nan."" Based on this finding, could you advise on the likelihood of his response to atezolizumab therapy?","I have a white male patient diagnosed with bladder urothelial carcinoma. A transcriptomic analysis of his tumor immune microenvironment from a bladder biopsy reported a TMB value as ""nan."" Based on this finding, could you advise on the likelihood of his response to atezolizumab therapy? Please perform transcriptomic profiling of this patient's sample using the Compass platform. Focus the analysis on gene expression related to macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell function. Assess these gene expression patterns to evaluate their potential for predicting response to immune checkpoint inhibitors. Finally, combine these molecular findings with the patient's clinical history to generate a comprehensive diagnostic report that includes personalized treatment recommendations.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-d215b5-ar-d215b50.pkl. "
BLCA,3.0,0.490196078,desert,NR,"For a white female patient with bladder urothelial carcinoma (BLCA), whose lymph node biopsy shows a tumor mutational burden (TMB) of 3.0, how likely is she to respond to Atezolizumab therapy?","For a white female patient with bladder urothelial carcinoma (BLCA), whose lymph node biopsy shows a tumor mutational burden (TMB) of 3.0, how likely is she to respond to Atezolizumab therapy? Please use the Compass platform to conduct a transcriptomic analysis on this patient’s sample. Concentrate on gene expression profiles related to macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell function. Evaluate these gene expression patterns for their potential to predict responsiveness to immune checkpoint inhibitors. Then, integrate these molecular findings with the patient’s clinical history to develop a comprehensive diagnostic report that includes personalized treatment recommendations.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-d2492b-ar-d2492b2.pkl. "
BLCA,62.0,10.01960784,excluded,R,"In a white male patient with bladder urothelial carcinoma, a kidney biopsy-based transcriptomic analysis revealed a tumor mutational burden (TMB) of 62.0. How does this high TMB inform the likelihood of a favorable response to Atezolizumab therapy?","In a white male patient with bladder urothelial carcinoma, a kidney biopsy-based transcriptomic analysis revealed a tumor mutational burden (TMB) of 62.0. How does this high TMB inform the likelihood of a favorable response to Atezolizumab therapy? Please use the Compass platform to perform a transcriptomic analysis on this patient’s sample. Your assessment should focus on gene expression profiles associated with macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell function. Analyze these expression patterns to determine their potential to predict responsiveness to immune checkpoint inhibitors. Finally, integrate these molecular findings with the patient’s clinical history to compile a comprehensive diagnostic report that includes personalized treatment recommendations.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-d35318-ar-d353181.pkl. "
BLCA,14.0,0.784313725,excluded,R,"I have a patient diagnosed with bladder urothelial carcinoma whose tumor immune microenvironment transcriptomic profile shows a tumor mutational burden (TMB) of 14. Based on these findings, do you consider this patient likely to respond to Atezolizumab therapy?","I have a patient diagnosed with bladder urothelial carcinoma whose tumor immune microenvironment transcriptomic profile shows a tumor mutational burden (TMB) of 14. Based on these findings, do you consider this patient likely to respond to Atezolizumab therapy? Please use the Compass platform to analyze the transcriptome of the patient’s sample. Focus your evaluation on gene expression patterns related to macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and the function of cytotoxic T-cells. Assess how these molecular markers might predict the patient’s response to immune checkpoint inhibitors. Finally, integrate these findings with the patient’s clinical history to generate a comprehensive diagnostic report that includes tailored treatment recommendations.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-d36012-ar-d360128.pkl. "
BLCA,7.0,1.568627451,excluded,R,"In a white male patient with bladder urothelial carcinoma, the transcriptomic profile from a lymph node biopsy reveals a tumor mutational burden (TMB) of 7.0. Based on these findings, is there evidence to suggest that he would respond favorably to Atezolizumab therapy?","In a white male patient with bladder urothelial carcinoma, the transcriptomic profile from a lymph node biopsy reveals a tumor mutational burden (TMB) of 7.0. Based on these findings, is there evidence to suggest that he would respond favorably to Atezolizumab therapy? Please utilize the Compass platform to perform a transcriptome analysis on the patient's sample. Concentrate on gene expression profiles associated with macrophage activation, interferon-gamma signaling, genomic integrity, cell proliferation, and cytotoxic T-cell function. Evaluate how these specific molecular markers may correlate with the patient’s potential response to immune checkpoint inhibitors. Finally, integrate your molecular findings with the patient's clinical history to produce a detailed diagnostic report that includes personalized treatment recommendations.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-d3bd67-ar-d3bd679.pkl. "
BLCA,15.0,1.882352941,inflamed,R,"In a male patient with bladder urothelial carcinoma whose bladder biopsy shows a tumor immune microenvironment with a TMB of 15.0, how likely is it that he will respond to atezolizumab therapy?","In a male patient with bladder urothelial carcinoma whose bladder biopsy shows a tumor immune microenvironment with a TMB of 15.0, how likely is it that he will respond to atezolizumab therapy? Please use the Compass platform to conduct a transcriptome analysis on the patient's sample. Focus on obtaining detailed gene expression profiles related to macrophage activation, interferon-gamma signaling, genomic integrity, cell proliferation, and the activity of cytotoxic T-cells. Assess whether these molecular markers are linked to the patient’s likely response to immune checkpoint inhibitors. Then, combine these molecular findings with the patient’s clinical history to create a comprehensive diagnostic report that includes personalized treatment recommendations.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-d43f89-ar-d43f893.pkl. "
BLCA,5.0,0.529411765,excluded,NR,"I have a white male patient with bladder urothelial carcinoma whose kidney biopsy-based transcriptomic analysis of the tumor immune microenvironment shows a tumor mutation burden of 5.0. Based on these findings, how likely is it that he will respond to Atezolizumab therapy?","I have a white male patient with bladder urothelial carcinoma whose kidney biopsy-based transcriptomic analysis of the tumor immune microenvironment shows a tumor mutation burden of 5.0. Based on these findings, how likely is it that he will respond to Atezolizumab therapy? Please utilize the Compass platform to perform a transcriptome analysis on the patient's sample. Your analysis should specifically examine gene expression profiles associated with macrophage activation, interferon-gamma signaling, genomic integrity, cell proliferation, and the function of cytotoxic T-cells. Evaluate whether these molecular markers correlate with the patient’s potential responsiveness to immune checkpoint inhibitors. Finally, integrate these molecular findings with the patient's clinical history to prepare a comprehensive diagnostic report that includes individualized treatment recommendations.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-d4c083-ar-d4c0837.pkl. "
BLCA,,0.196078431,inflamed,NR,"I have a Caucasian male patient diagnosed with bladder urothelial carcinoma. A bladder biopsy was performed for transcriptomic profiling of the tumor immune microenvironment, but the tumor mutational burden (TMB) data are not available. Based on this information, what is the likelihood that he will respond to Atezolizumab therapy?","I have a Caucasian male patient diagnosed with bladder urothelial carcinoma. A bladder biopsy was performed for transcriptomic profiling of the tumor immune microenvironment, but the tumor mutational burden (TMB) data are not available. Based on this information, what is the likelihood that he will respond to Atezolizumab therapy? Please use the Compass platform to conduct a transcriptome analysis on the patient’s sample. In this analysis, focus on gene expression related to macrophage activation, interferon-gamma signaling, genomic integrity, cell proliferation, and cytotoxic T-cell function. Determine if these molecular markers are associated with the patient’s likely response to immune checkpoint inhibitors. Then, integrate these molecular insights with the patient’s clinical history to produce a comprehensive diagnostic report that includes personalized treatment recommendations.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-d636e3-ar-d636e34.pkl. "
BLCA,,,excluded,NR,"I am evaluating a Caucasian female patient diagnosed with bladder urothelial carcinoma. Her tumor’s immune microenvironment was profiled from a ureteral biopsy, and the analysis returned an indeterminate tumor mutational burden. Based on this information, what is the likelihood that she will respond to Atezolizumab therapy?","I am evaluating a Caucasian female patient diagnosed with bladder urothelial carcinoma. Her tumor’s immune microenvironment was profiled from a ureteral biopsy, and the analysis returned an indeterminate tumor mutational burden. Based on this information, what is the likelihood that she will respond to Atezolizumab therapy? Using the Compass platform, please perform a transcriptome analysis on the patient's sample. Focus on evaluating gene expression profiles associated with macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. Assess whether these molecular markers correlate with the patient’s potential response to immune checkpoint inhibitors. Finally, integrate these molecular findings with the patient’s clinical history to develop a comprehensive diagnostic report that includes personalized treatment recommendations.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-d697ba-ar-d697ba7.pkl. "
BLCA,24.0,,inflamed,R,"In a White male patient with bladder urothelial carcinoma, the tumor transcriptomic analysis from a bladder biopsy reveals a tumor mutational burden of 24.0. Based on this information, what is the expected likelihood of a positive response to Atezolizumab therapy?","In a White male patient with bladder urothelial carcinoma, the tumor transcriptomic analysis from a bladder biopsy reveals a tumor mutational burden of 24.0. Based on this information, what is the expected likelihood of a positive response to Atezolizumab therapy? Please use the Compass platform to conduct a transcriptome analysis on the patient's sample. Evaluate the gene expression levels related to macrophage activation, interferon-gamma signaling, genomic integrity, cell proliferation, and cytotoxic T-cell function. Determine if these markers are associated with the patient’s potential responsiveness to immune checkpoint inhibitors. Lastly, synthesize these molecular findings with the patient's clinical background to formulate a detailed diagnostic report that includes individualized treatment recommendations.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-d7d57e-ar-d7d57ee.pkl. "
BLCA,,1.411764706,desert,NR,"In a white male patient diagnosed with bladder urothelial carcinoma (BLCA), transcriptomic analysis of the tumor immune microenvironment from a bladder biopsy reported a tumor mutational burden (TMB) value of ""nan"". Could you help determine whether this patient is likely to respond to Atezolizumab therapy?","In a white male patient diagnosed with bladder urothelial carcinoma (BLCA), transcriptomic analysis of the tumor immune microenvironment from a bladder biopsy reported a tumor mutational burden (TMB) value of ""nan"". Could you help determine whether this patient is likely to respond to Atezolizumab therapy? Using the Compass platform, perform a transcriptome analysis on the patient's sample. Specifically, assess gene expression associated with macrophage activation, interferon-gamma signaling, genomic integrity, cell proliferation, and cytotoxic T-cell function. Evaluate whether these markers indicate potential responsiveness to immune checkpoint inhibitors. Finally, integrate these molecular findings with the patient’s clinical history to compile a comprehensive diagnostic report that includes tailored treatment recommendations.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-d86389-ar-d86389d.pkl. "
BLCA,8.0,0.725490196,desert,NR,"In a white male patient diagnosed with bladder urothelial carcinoma, the transcriptomic analysis of a ureter biopsy revealed a tumor mutation burden (TMB) of 8.0. Based on these findings, what is your assessment of the likelihood that the patient will respond to Atezolizumab therapy?","In a white male patient diagnosed with bladder urothelial carcinoma, the transcriptomic analysis of a ureter biopsy revealed a tumor mutation burden (TMB) of 8.0. Based on these findings, what is your assessment of the likelihood that the patient will respond to Atezolizumab therapy? Please use the Compass platform to analyze the transcriptome of the patient’s sample. In particular, assess gene expression related to macrophage activation, interferon-gamma signaling, genomic integrity, cell proliferation, and cytotoxic T-cell function. Determine if these markers suggest that the patient might respond to immune checkpoint inhibitors. Finally, integrate these molecular findings with the patient's clinical history to create a comprehensive diagnostic report that includes personalized treatment recommendations.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-d98bac-ar-d98bac0.pkl. "
BLCA,4.0,0.274509804,,NR,"A Caucasian male patient with bladder urothelial carcinoma has a transcriptomic profile from a kidney biopsy showing a tumor mutational burden of 4.0. Based on this information, what is the likelihood that he will respond to atezolizumab therapy?","A Caucasian male patient with bladder urothelial carcinoma has a transcriptomic profile from a kidney biopsy showing a tumor mutational burden of 4.0. Based on this information, what is the likelihood that he will respond to atezolizumab therapy? Please use the Compass platform to perform a transcriptome analysis on the patient’s sample. Specifically, evaluate the expression levels of genes involved in macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. Assess whether these molecular markers may indicate a potential response to immune checkpoint inhibitors. Finally, correlate these findings with the patient’s clinical history to compile a detailed diagnostic report that includes personalized treatment recommendations.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-da4d89-ar-da4d892.pkl. "
BLCA,14.0,2.921568627,excluded,NR,"I have a white male patient diagnosed with bladder urothelial carcinoma. A transcriptomic analysis of his tumor immune microenvironment from a bladder biopsy revealed a tumor mutational burden (TMB) of 14. Based on these findings, what is the likelihood that he will respond to atezolizumab therapy?","I have a white male patient diagnosed with bladder urothelial carcinoma. A transcriptomic analysis of his tumor immune microenvironment from a bladder biopsy revealed a tumor mutational burden (TMB) of 14. Based on these findings, what is the likelihood that he will respond to atezolizumab therapy? Use the Compass platform to analyze the transcriptome of the patient's sample. Focus on quantifying the expression of genes linked to macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell function. Determine if these molecular markers suggest that the patient may respond to immune checkpoint inhibitors. Then, integrate these results with the patient’s clinical history to create a comprehensive diagnostic report that includes personalized treatment recommendations.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-dab9ca-ar-dab9ca8.pkl. "
BLCA,5.0,0.666666667,excluded,NR,"We have a Caucasian male patient diagnosed with bladder urothelial carcinoma. The transcriptomic analysis from his bladder biopsy indicates a tumor mutation burden of 5.0 mutations per megabase. Based on these findings, how likely is he to respond to Atezolizumab therapy?","We have a Caucasian male patient diagnosed with bladder urothelial carcinoma. The transcriptomic analysis from his bladder biopsy indicates a tumor mutation burden of 5.0 mutations per megabase. Based on these findings, how likely is he to respond to Atezolizumab therapy? Please use the Compass platform to evaluate the patient's transcriptome. Quantify gene expression related to macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell function. Assess whether these molecular markers indicate a potential response to immune checkpoint inhibitors. Finally, incorporate these findings along with the patient's clinical history to develop a comprehensive diagnostic report that includes personalized treatment recommendations.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-dad5c2-ar-dad5c29.pkl. "
BLCA,10.0,0.509803922,excluded,NR,"For a white male patient with bladder urothelial carcinoma whose bladder biopsy transcriptomic analysis indicates a tumor mutational burden of 10.0, what is the likelihood of a favorable response to Atezolizumab therapy?","For a white male patient with bladder urothelial carcinoma whose bladder biopsy transcriptomic analysis indicates a tumor mutational burden of 10.0, what is the likelihood of a favorable response to Atezolizumab therapy? Please use the Compass platform to analyze the patient’s transcriptome, focusing on quantifying gene expression associated with macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell function. Evaluate whether these biomarkers suggest a potential benefit from immune checkpoint inhibitors. Finally, combine these molecular findings with the patient’s clinical history to create a detailed diagnostic report that includes individualized treatment recommendations.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-db3f50-ar-db3f50c.pkl. "
BLCA,,1.431372549,excluded,NR,"A white male patient diagnosed with bladder urothelial carcinoma underwent a kidney biopsy for transcriptomic analysis of his tumor immune microenvironment, which revealed an indeterminate tumor mutational burden. Based on these findings, can we predict his likelihood of responding to Atezolizumab therapy?","A white male patient diagnosed with bladder urothelial carcinoma underwent a kidney biopsy for transcriptomic analysis of his tumor immune microenvironment, which revealed an indeterminate tumor mutational burden. Based on these findings, can we predict his likelihood of responding to Atezolizumab therapy? Please use the Compass platform to analyze the patient’s transcriptome. Focus on measuring gene expression related to macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell function. Assess whether these biomarkers indicate that the patient may benefit from immune checkpoint inhibitors. Finally, integrate these molecular findings with the patient’s clinical history and prepare a comprehensive diagnostic report that includes personalized treatment recommendations.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-dcae54-ar-dcae54f.pkl. "
BLCA,,,,NR,"I have a white male patient diagnosed with bladder urothelial carcinoma. A transcriptomic analysis of the tumor immune microenvironment obtained from a lymph node biopsy reported a tumor mutational burden value of ""nan."" Can we determine if this result indicates a likelihood of response to Atezolizumab therapy?","I have a white male patient diagnosed with bladder urothelial carcinoma. A transcriptomic analysis of the tumor immune microenvironment obtained from a lymph node biopsy reported a tumor mutational burden value of ""nan."" Can we determine if this result indicates a likelihood of response to Atezolizumab therapy? Please use the Compass platform to analyze the patient’s transcriptome with a focus on gene expression associated with macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell function. Evaluate whether these molecular biomarkers support the potential benefit of immune checkpoint inhibitors for the patient. Then, combine these findings with the patient’s clinical history to create a comprehensive diagnostic report that includes personalized treatment recommendations.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-dee101-ar-dee1011.pkl. "
BLCA,19.0,3.235294118,inflamed,NR,"I have a white male patient diagnosed with bladder urothelial carcinoma. A transcriptomic analysis of his bladder biopsy revealed a tumor mutational burden (TMB) of 19.0. Based on this profile, what is the likelihood that he will respond to Atezolizumab therapy?","I have a white male patient diagnosed with bladder urothelial carcinoma. A transcriptomic analysis of his bladder biopsy revealed a tumor mutational burden (TMB) of 19.0. Based on this profile, what is the likelihood that he will respond to Atezolizumab therapy? Please use the Compass platform to review the patient’s transcriptome, focusing on markers related to macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell function. Assess if these molecular biomarkers suggest that immune checkpoint inhibitors might be beneficial. Finally, integrate these results with the patient’s clinical history to develop a detailed diagnostic report that includes individualized treatment recommendations.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-df3e42-ar-df3e42c.pkl. "
BLCA,5.0,0.549019608,desert,NR,"I have a patient with bladder urothelial carcinoma (BLCA) whose tumor immune microenvironment was characterized via transcriptomic profiling from a ureter biopsy, revealing a tumor mutational burden (TMB) of 5.0. Based on these findings, how likely is the patient to respond to Atezolizumab therapy?","I have a patient with bladder urothelial carcinoma (BLCA) whose tumor immune microenvironment was characterized via transcriptomic profiling from a ureter biopsy, revealing a tumor mutational burden (TMB) of 5.0. Based on these findings, how likely is the patient to respond to Atezolizumab therapy? Use the Compass platform to analyze the patient’s transcriptome with particular attention to markers of macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell function. Evaluate whether the identified biomarkers indicate a potential benefit from immune checkpoint inhibitors. Then, synthesize these molecular findings with the patient’s clinical history to create a comprehensive diagnostic report, including personalized treatment recommendations.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-e07c45-ar-e07c456.pkl. "
BLCA,2.0,,excluded,NR,"For a white female patient diagnosed with bladder urothelial carcinoma, the tumor immune microenvironment transcriptomic analysis from her biopsy reveals a tumor mutational burden (TMB) of 2.0 mutations per megabase. Based on this finding, what is the likelihood that she will respond to Atezolizumab therapy?","For a white female patient diagnosed with bladder urothelial carcinoma, the tumor immune microenvironment transcriptomic analysis from her biopsy reveals a tumor mutational burden (TMB) of 2.0 mutations per megabase. Based on this finding, what is the likelihood that she will respond to Atezolizumab therapy? Please use the Compass platform to analyze the patient’s transcriptomic data, concentrating on markers indicative of macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell function. Assess whether these biomarkers suggest that the patient might benefit from immune checkpoint inhibitors. Then, integrate these molecular findings with the clinical history to develop a comprehensive diagnostic report that includes personalized treatment recommendations.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-e0c49e-ar-e0c49ea.pkl. "
BLCA,14.0,2.274509804,inflamed,R,"A white male patient diagnosed with bladder urothelial carcinoma has a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy showing a tumor mutational burden of 14.0. Based on this information, could you provide an assessment of his potential response to atezolizumab therapy?","A white male patient diagnosed with bladder urothelial carcinoma has a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy showing a tumor mutational burden of 14.0. Based on this information, could you provide an assessment of his potential response to atezolizumab therapy? Please use the Compass platform to examine the patient’s transcriptomic data. Focus specifically on biomarkers related to macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell function. Evaluate whether these markers indicate that the patient could benefit from treatment with immune checkpoint inhibitors. Finally, combine these molecular results with the patient’s clinical history to create a detailed diagnostic report that offers personalized treatment recommendations.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-e1eb5d-ar-e1eb5d9.pkl. "
BLCA,17.0,0.862745098,inflamed,NR,"I have a Caucasian female patient with bladder urothelial carcinoma whose nanobiopsy-derived transcriptomic profiling of the tumor immune microenvironment revealed a tumor mutational burden of 17. Based on these findings, what is the likelihood that she will respond to Atezolizumab therapy?","I have a Caucasian female patient with bladder urothelial carcinoma whose nanobiopsy-derived transcriptomic profiling of the tumor immune microenvironment revealed a tumor mutational burden of 17. Based on these findings, what is the likelihood that she will respond to Atezolizumab therapy? Please access the patient’s transcriptomic data using the Compass platform. Analyze markers associated with macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell function. Determine whether these biomolecular indicators suggest that the patient may respond favorably to immune checkpoint inhibitor therapy. Finally, integrate these molecular findings with the patient’s clinical history to compile a comprehensive diagnostic report that includes personalized treatment recommendations.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-e3210d-ar-e3210d3.pkl. "
BLCA,,,,NR,"I have a white male patient diagnosed with bladder urothelial carcinoma. A transcriptomic analysis of his tumor immune microenvironment from a bladder biopsy reports a tumor mutational burden (TMB) value of ""nan."" Based on this finding, how likely is it that he will respond to Atezolizumab therapy?","I have a white male patient diagnosed with bladder urothelial carcinoma. A transcriptomic analysis of his tumor immune microenvironment from a bladder biopsy reports a tumor mutational burden (TMB) value of ""nan."" Based on this finding, how likely is it that he will respond to Atezolizumab therapy? Please retrieve the patient's transcriptomic data via the Compass platform and focus on evaluating markers associated with macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell function. Assess whether the levels and patterns of these biomarkers indicate a potential positive response to immune checkpoint inhibitor therapy. Finally, integrate these molecular insights with the patient’s clinical history to prepare a detailed diagnostic report that includes personalized treatment recommendations.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-e3d426-ar-e3d4266.pkl. "
BLCA,6.0,0.470588235,excluded,NR,"In a white male patient diagnosed with bladder urothelial carcinoma with a tumor mutation burden (TMB) of 6.0 from a biopsy-derived transcriptomic analysis, how likely is it that treatment with Atezolizumab would be effective?","In a white male patient diagnosed with bladder urothelial carcinoma with a tumor mutation burden (TMB) of 6.0 from a biopsy-derived transcriptomic analysis, how likely is it that treatment with Atezolizumab would be effective? Access the patient's transcriptomic data through the Compass platform. Focus specifically on markers indicative of macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell function. Evaluate whether the patterns and levels of these biomarkers suggest a favorable response to immune checkpoint inhibitor therapy. Finally, combine these molecular insights with the patient's clinical history to compile a comprehensive diagnostic report that includes personalized treatment recommendations.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-e41b1e-ar-e41b1e7.pkl. "
BLCA,9.0,2.176470588,desert,R,"For a white female patient with bladder urothelial carcinoma whose tumor biopsy transcriptomic analysis indicates a tumor mutation burden of 9.0, what is the likelihood that she will respond to Atezolizumab therapy?","For a white female patient with bladder urothelial carcinoma whose tumor biopsy transcriptomic analysis indicates a tumor mutation burden of 9.0, what is the likelihood that she will respond to Atezolizumab therapy? Please log in to the Compass platform to obtain the patient's transcriptomic data. Concentrate on biomarkers associated with macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell function. Analyze the expression patterns and levels of these markers to determine if they support a likely positive response to immune checkpoint inhibitor therapy. Lastly, integrate these molecular findings with the patient's clinical history to produce a comprehensive diagnostic report that includes individualized treatment recommendations.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-e50d15-ar-e50d15f.pkl. "
BLCA,5.0,0.098039216,excluded,NR,"In a white female patient with bladder urothelial carcinoma (BLCA), a transcriptomic analysis of her tumor immune microenvironment from a kidney biopsy shows a tumor mutational burden (TMB) of 5.0 mutations/Mb. Could you assess her likelihood of responding to Atezolizumab therapy?","In a white female patient with bladder urothelial carcinoma (BLCA), a transcriptomic analysis of her tumor immune microenvironment from a kidney biopsy shows a tumor mutational burden (TMB) of 5.0 mutations/Mb. Could you assess her likelihood of responding to Atezolizumab therapy? Please access the Compass platform to retrieve the patient's transcriptomic data. Focus your analysis on biomarkers related to macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell function. Evaluate the expression patterns and levels of these markers to assess whether they indicate a favorable response to immune checkpoint inhibitor therapy. Finally, correlate these molecular findings with the patient’s clinical history to compile a detailed diagnostic report that offers personalized treatment recommendations.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-e56c96-ar-e56c96c.pkl. "
BLCA,5.0,0.274509804,excluded,NR,"I have a white male patient with bladder urothelial carcinoma. A transcriptomic analysis of his tumor immune microenvironment from a liver biopsy indicates a tumor mutation burden of 5.0 mutations per megabase. Based on this information, is he likely to respond favorably to Atezolizumab therapy?","I have a white male patient with bladder urothelial carcinoma. A transcriptomic analysis of his tumor immune microenvironment from a liver biopsy indicates a tumor mutation burden of 5.0 mutations per megabase. Based on this information, is he likely to respond favorably to Atezolizumab therapy? Please log into the Compass platform to obtain the patient's transcriptomic data. You should concentrate on assessing biomarkers linked to macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell function. Analyze the expression levels and patterns of these markers to determine whether they suggest a positive response to immune checkpoint inhibitor therapy. Afterward, integrate these molecular insights with the patient's clinical history to develop a comprehensive diagnostic report that includes personalized treatment recommendations.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-e5bc41-ar-e5bc417.pkl. "
BLCA,,,desert,R,"For a Caucasian male patient diagnosed with bladder urothelial carcinoma, whose tumor immune microenvironment transcriptomic profile from a bladder biopsy shows an undefined tumor mutation burden, how likely is he to benefit from Atezolizumab therapy?","For a Caucasian male patient diagnosed with bladder urothelial carcinoma, whose tumor immune microenvironment transcriptomic profile from a bladder biopsy shows an undefined tumor mutation burden, how likely is he to benefit from Atezolizumab therapy? Please access the Compass platform to retrieve the patient’s transcriptomic data. Focus on reviewing biomarkers associated with macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell function. Evaluate the expression levels and patterns of these markers to assess their potential indication of a favorable response to immune checkpoint inhibitor therapy. Then, combine these molecular findings with the patient’s clinical history to compile a thorough diagnostic report that includes tailored treatment recommendations.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-e71235-ar-e712352.pkl. "
BLCA,,,,NR,"In a white male patient with bladder urothelial carcinoma, a kidney biopsy yielded a transcriptomic profile of the tumor immune microenvironment indicating a tumor mutational burden (TMB) reported as ""nan."" Could you help assess whether this patient is likely to respond to Atezolizumab therapy?","In a white male patient with bladder urothelial carcinoma, a kidney biopsy yielded a transcriptomic profile of the tumor immune microenvironment indicating a tumor mutational burden (TMB) reported as ""nan."" Could you help assess whether this patient is likely to respond to Atezolizumab therapy? Please log into the Compass platform and retrieve the patient's transcriptomic data. Specifically, examine biomarkers related to macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell function. Assess the expression levels and patterns of these markers to determine if they may indicate a beneficial response to immune checkpoint inhibitor therapy. Then, integrate these molecular findings with the patient's clinical history to prepare a detailed diagnostic report that includes individualized treatment recommendations.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-e7bcab-ar-e7bcab0.pkl. "
BLCA,7.0,1.37254902,inflamed,NR,"I have a white male patient with bladder urothelial carcinoma whose tumor immune microenvironment was profiled via a kidney biopsy, revealing a tumor mutational burden of 7. Could you assess the likelihood of a favorable response to atezolizumab therapy?","I have a white male patient with bladder urothelial carcinoma whose tumor immune microenvironment was profiled via a kidney biopsy, revealing a tumor mutational burden of 7. Could you assess the likelihood of a favorable response to atezolizumab therapy? Please access the Compass platform to obtain the patient's transcriptomic data. Focus on biomarkers related to macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell function. Evaluate these markers' expression levels and patterns to determine whether they suggest a favorable response to immune checkpoint inhibitor therapy. Finally, combine these molecular findings with the patient’s clinical history to create a comprehensive diagnostic report that includes tailored treatment recommendations.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-e7bf6c-ar-e7bf6c0.pkl. "
BLCA,1.0,0.196078431,inflamed,NR,"In a white male patient with bladder urothelial carcinoma, the tumor biopsy showed a tumor mutational burden of 1.0 within the immune microenvironment. Based on this information, is he likely to respond to Atezolizumab therapy?","In a white male patient with bladder urothelial carcinoma, the tumor biopsy showed a tumor mutational burden of 1.0 within the immune microenvironment. Based on this information, is he likely to respond to Atezolizumab therapy? Please log into the Compass platform to retrieve the patient’s transcriptomic data. Focus on evaluating biomarkers associated with macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell function. Assess the expression levels and patterns of these markers to ascertain if they support a potentially favorable response to immune checkpoint inhibitor therapy. Finally, integrate these molecular findings with the patient’s clinical history to compile a detailed diagnostic report that includes personalized treatment recommendations.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-e7e4f7-ar-e7e4f7c.pkl. "
BLCA,,,excluded,NR,"I am managing a Caucasian male patient with bladder urothelial carcinoma. The tumor immune microenvironment transcriptomic analysis from his bladder biopsy did not yield a tumor mutational burden (TMB) value. Based on this information, could you help determine whether he would likely respond to Atezolizumab therapy?","I am managing a Caucasian male patient with bladder urothelial carcinoma. The tumor immune microenvironment transcriptomic analysis from his bladder biopsy did not yield a tumor mutational burden (TMB) value. Based on this information, could you help determine whether he would likely respond to Atezolizumab therapy? Access the Compass platform and retrieve the patient's transcriptomic data. Then, examine biomarkers related to macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell function. Assess both the expression levels and patterns of these markers to determine whether they indicate the potential for a favorable response to immune checkpoint inhibitor therapy. Finally, integrate these molecular insights with the patient's clinical history to prepare a comprehensive diagnostic report that includes personalized treatment recommendations.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-e9475f-ar-e9475f7.pkl. "
BLCA,6.0,1.019607843,excluded,NR,"In a white male patient diagnosed with bladder urothelial carcinoma, transcriptomic analysis of a bladder biopsy revealed a tumor mutational burden (TMB) of 6.0. Based on this TMB level, what is the anticipated likelihood of response to Atezolizumab therapy?","In a white male patient diagnosed with bladder urothelial carcinoma, transcriptomic analysis of a bladder biopsy revealed a tumor mutational burden (TMB) of 6.0. Based on this TMB level, what is the anticipated likelihood of response to Atezolizumab therapy? Please log into the Compass platform and obtain the patient’s transcriptomic data. Next, review the biomarkers associated with macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell function. Evaluate both the expression levels and the distribution patterns of these markers to assess whether they suggest a likely positive response to immune checkpoint inhibitor therapy. Finally, combine these molecular findings with the patient’s clinical history and compile a detailed diagnostic report that includes individualized treatment recommendations.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-e94c30-ar-e94c30c.pkl. "
BLCA,3.0,0.705882353,excluded,NR,"For a white female patient diagnosed with bladder urothelial carcinoma (BLCA) whose tumor biopsy transcriptomic profile reveals a tumor mutation burden (TMB) of 3.0, what is the expected likelihood of a favorable response to Atezolizumab therapy?","For a white female patient diagnosed with bladder urothelial carcinoma (BLCA) whose tumor biopsy transcriptomic profile reveals a tumor mutation burden (TMB) of 3.0, what is the expected likelihood of a favorable response to Atezolizumab therapy? Log into the Compass platform to retrieve the patient's transcriptomic data. Identify and review biomarkers related to macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell function. Carefully analyze their expression levels and distribution patterns to determine whether they indicate a likely positive response to immune checkpoint inhibitor therapy. Finally, integrate these molecular findings with the patient's clinical history and prepare a comprehensive diagnostic report that outlines individualized treatment recommendations.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-e97af0-ar-e97af0f.pkl. "
BLCA,7.0,1.333333333,desert,NR,We have a Caucasian patient with bladder urothelial carcinoma whose tumor transcriptomic profile reveals a tumor mutational burden of 7.0. Can this level of TMB be used to predict a favorable response to atezolizumab therapy?,"We have a Caucasian patient with bladder urothelial carcinoma whose tumor transcriptomic profile reveals a tumor mutational burden of 7.0. Can this level of TMB be used to predict a favorable response to atezolizumab therapy? Please access the Compass platform to retrieve the patient’s transcriptomic data. Next, review the biomarkers associated with macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell function. Examine their expression levels and distribution to assess whether they suggest a positive response to immune checkpoint inhibitor therapy. Finally, integrate these molecular results with the patient’s clinical history and compile a detailed diagnostic report that includes personalized treatment recommendations.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-e9ae8b-ar-e9ae8be.pkl. "
BLCA,14.0,2.764705882,inflamed,R,"For a White male patient diagnosed with bladder urothelial carcinoma whose biopsy transcriptomic analysis shows a tumor mutation burden of 14.0, what is the likelihood that he will respond to Atezolizumab therapy?","For a White male patient diagnosed with bladder urothelial carcinoma whose biopsy transcriptomic analysis shows a tumor mutation burden of 14.0, what is the likelihood that he will respond to Atezolizumab therapy? Please log into the Compass platform and retrieve the patient's transcriptomic data. Then, examine the expression profiles of biomarkers related to macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell function. Evaluate these biomarkers to determine if they indicate a favorable response to immune checkpoint inhibitor therapy. Finally, integrate these molecular findings with the patient's clinical history and prepare a comprehensive diagnostic report that includes personalized treatment recommendations.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-eaa477-ar-eaa477a.pkl. "
BLCA,2.0,0.058823529,excluded,NR,"I have a white male patient with bladder urothelial carcinoma whose tumor immune microenvironment was profiled via a kidney biopsy, revealing a TMB of 2.0. Based on these findings, could you advise on the likelihood of a positive response to Atezolizumab therapy?","I have a white male patient with bladder urothelial carcinoma whose tumor immune microenvironment was profiled via a kidney biopsy, revealing a TMB of 2.0. Based on these findings, could you advise on the likelihood of a positive response to Atezolizumab therapy? Please log into the Compass platform to access the patient’s transcriptomic data. Review the expression profiles for biomarkers associated with macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. Assess these profiles to determine whether they suggest a positive response to immune checkpoint inhibitor therapy. Finally, combine these molecular findings with the patient's clinical history to create a detailed diagnostic report that includes personalized treatment recommendations.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-eb2962-ar-eb29625.pkl. "
BLCA,,,,NR,"For a white male patient with bladder urothelial carcinoma, the transcriptomic profile of the tumor immune microenvironment from a bladder biopsy reports a tumor mutational burden (TMB) value of ""nan."" Based on these findings, how can we assess his likelihood of responding to atezolizumab therapy?","For a white male patient with bladder urothelial carcinoma, the transcriptomic profile of the tumor immune microenvironment from a bladder biopsy reports a tumor mutational burden (TMB) value of ""nan."" Based on these findings, how can we assess his likelihood of responding to atezolizumab therapy? Please sign in to the Compass platform to review the patient's transcriptomic data. Specifically, evaluate the expression levels of biomarkers related to macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. Determine if these molecular findings indicate a favorable response to immune checkpoint inhibitor therapy. Then, integrate these results with the patient's clinical history to prepare a comprehensive diagnostic report that includes personalized treatment recommendations.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-eb587a-ar-eb587a6.pkl. "
BLCA,,,,NR,"A white male patient diagnosed with bladder urothelial carcinoma underwent lymph node biopsy for transcriptomic profiling of the tumor immune microenvironment, which reported a TMB value of ""nan"". Based on this information, can we evaluate the likelihood of a beneficial response to Atezolizumab therapy?","A white male patient diagnosed with bladder urothelial carcinoma underwent lymph node biopsy for transcriptomic profiling of the tumor immune microenvironment, which reported a TMB value of ""nan"". Based on this information, can we evaluate the likelihood of a beneficial response to Atezolizumab therapy? Please log into the Compass platform to access the patient's transcriptomic data. Focus on assessing the expression levels of biomarkers associated with macrophage activation, interferon-gamma signaling, genomic integrity, cell proliferation, and cytotoxic T-cell activity. Evaluate whether these molecular profiles suggest a favorable response to immune checkpoint inhibitor therapy. After your review, integrate these findings with the patient's clinical history to create a comprehensive diagnostic report that includes personalized treatment recommendations.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-ee3844-ar-ee3844c.pkl. "
BLCA,1.0,0.039215686,inflamed,NR,"A white male patient with bladder urothelial carcinoma has a lung biopsy–derived transcriptomic profile of the tumor immune microenvironment showing a TMB of 1.0. Based on these findings, how likely is it that the patient will respond to atezolizumab therapy?","A white male patient with bladder urothelial carcinoma has a lung biopsy–derived transcriptomic profile of the tumor immune microenvironment showing a TMB of 1.0. Based on these findings, how likely is it that the patient will respond to atezolizumab therapy? Please sign into the Compass platform to review the patient’s transcriptomic data. Concentrate on the biomarkers related to macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. Determine if these molecular profiles indicate a potential positive response to immune checkpoint inhibitor therapy. Once you have completed your analysis, merge these molecular findings with the patient's clinical history to develop a comprehensive diagnostic report that offers tailored treatment recommendations.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-ef0e3d-ar-ef0e3d2.pkl. "
BLCA,14.0,,desert,NR,"We have a Caucasian male patient with bladder urothelial carcinoma whose tumor immune microenvironment transcriptomic profile, obtained from a ureter biopsy, reveals a TMB of 14.0. Based on these findings, could you evaluate his likelihood of responding to Atezolizumab therapy?","We have a Caucasian male patient with bladder urothelial carcinoma whose tumor immune microenvironment transcriptomic profile, obtained from a ureter biopsy, reveals a TMB of 14.0. Based on these findings, could you evaluate his likelihood of responding to Atezolizumab therapy? Please log into the Compass platform to review this patient’s transcriptomic data. In your evaluation, focus specifically on biomarkers associated with macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. Assess whether these molecular indicators suggest a potential benefit from immune checkpoint inhibitor therapy. After completing your molecular analysis, integrate your findings with the patient’s clinical history to create a detailed diagnostic report that includes personalized treatment recommendations.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-eff2ce-ar-eff2ce3.pkl. "
BLCA,14.0,1.098039216,inflamed,NR,"I have a White male patient with bladder urothelial carcinoma whose transcriptomic analysis from a kidney biopsy indicates a tumor mutational burden (TMB) of 14.0. Based on these findings, how likely is it that he will respond favorably to Atezolizumab therapy?","I have a White male patient with bladder urothelial carcinoma whose transcriptomic analysis from a kidney biopsy indicates a tumor mutational burden (TMB) of 14.0. Based on these findings, how likely is it that he will respond favorably to Atezolizumab therapy? Please access the Compass platform to review this patient's transcriptomic data. Focus your analysis on biomarkers related to macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity to determine if the molecular profile supports a benefit from immune checkpoint inhibitor therapy. Once your molecular evaluation is complete, combine these results with the patient's clinical history and prepare a detailed diagnostic report that includes personalized treatment recommendations.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-f20b82-ar-f20b827.pkl. "
BLCA,9.0,,excluded,R,"In an African American patient diagnosed with bladder urothelial carcinoma, a bladder biopsy revealed a tumor immune microenvironment with a TMB of 9.0. Based on these findings, how likely is the patient to respond to Atezolizumab therapy?","In an African American patient diagnosed with bladder urothelial carcinoma, a bladder biopsy revealed a tumor immune microenvironment with a TMB of 9.0. Based on these findings, how likely is the patient to respond to Atezolizumab therapy? Please log in to the Compass platform and review this patient's transcriptomic data. As you analyze the data, focus particularly on biomarkers related to macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. Your objective is to assess whether the molecular profile provides evidence that the patient may benefit from immune checkpoint inhibitor therapy. After completing the molecular evaluation, integrate your findings with the patient's clinical history and prepare a comprehensive diagnostic report that includes personalized treatment recommendations.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-f275eb-ar-f275eb8.pkl. "
BLCA,8.0,,desert,NR,"I am evaluating a white male patient with bladder urothelial carcinoma. Transcriptomic profiling of his tumor immune microenvironment from a bladder biopsy reveals a tumor mutational burden of 8.0. Based on this information, what is the likelihood that he will respond to atezolizumab therapy?","I am evaluating a white male patient with bladder urothelial carcinoma. Transcriptomic profiling of his tumor immune microenvironment from a bladder biopsy reveals a tumor mutational burden of 8.0. Based on this information, what is the likelihood that he will respond to atezolizumab therapy? Please log into the Compass platform and review this patient's transcriptomic data. Focus specifically on biomarkers associated with macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. Evaluate whether these molecular findings suggest the patient might benefit from immune checkpoint inhibitor therapy. Once you have completed your molecular assessment, please integrate your observations with the patient’s clinical history and compile a detailed diagnostic report that includes personalized treatment recommendations.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-f28c01-ar-f28c015.pkl. "
BLCA,7.0,0.803921569,desert,NR,"For a Caucasian female patient with bladder urothelial carcinoma whose tumor biopsy revealed a tumor mutational burden of 7.0 mutations per megabase, how can we assess her likelihood of responding favorably to Atezolizumab therapy?","For a Caucasian female patient with bladder urothelial carcinoma whose tumor biopsy revealed a tumor mutational burden of 7.0 mutations per megabase, how can we assess her likelihood of responding favorably to Atezolizumab therapy? Please access the Compass platform and review the patient’s transcriptomic data. Concentrate on biomarkers that indicate macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. Determine if these molecular findings support the use of immune checkpoint inhibitor therapy. After completing your molecular evaluation, integrate these results with the patient’s clinical history and prepare a comprehensive diagnostic report that includes personalized treatment recommendations.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-f2aae1-ar-f2aae14.pkl. "
BLCA,4.0,,excluded,NR,"For an Asian female patient with bladder urothelial carcinoma whose biopsy-based transcriptomic profile shows a tumor mutational burden of 4.0, what evidence is available regarding her potential response to atezolizumab therapy?","For an Asian female patient with bladder urothelial carcinoma whose biopsy-based transcriptomic profile shows a tumor mutational burden of 4.0, what evidence is available regarding her potential response to atezolizumab therapy? Access the Compass platform to review the patient's transcriptomic data. Focus on biomarkers indicative of macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. Evaluate whether these molecular findings support the use of immune checkpoint inhibitor therapy. Finally, integrate your molecular assessment with the patient's clinical history and prepare a detailed diagnostic report that includes individualized treatment recommendations.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-f3a9bc-ar-f3a9bce.pkl. "
BLCA,7.0,0.529411765,desert,NR,"In a white male patient with bladder urothelial carcinoma whose tumor immune microenvironment transcriptomic profile from a kidney biopsy indicates a tumor mutational burden of 7.0 mutations per megabase, what is the likelihood that he will benefit from Atezolizumab therapy?","In a white male patient with bladder urothelial carcinoma whose tumor immune microenvironment transcriptomic profile from a kidney biopsy indicates a tumor mutational burden of 7.0 mutations per megabase, what is the likelihood that he will benefit from Atezolizumab therapy? Please log into the Compass platform and review the patient's transcriptomic data, concentrating on biomarkers related to macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. Assess whether these molecular findings support the use of immune checkpoint inhibitor therapy. Then, integrate your molecular results with the patient’s clinical history and compile a detailed diagnostic report that includes personalized treatment recommendations.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-f82bbd-ar-f82bbdc.pkl. "
BLCA,,5.921568627,inflamed,R,"In a white male patient diagnosed with bladder urothelial carcinoma, transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy returned a TMB value of ""nan."" How should we interpret this finding regarding his potential response to Atezolizumab therapy?","In a white male patient diagnosed with bladder urothelial carcinoma, transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy returned a TMB value of ""nan."" How should we interpret this finding regarding his potential response to Atezolizumab therapy? Please sign into the Compass platform and evaluate the patient's transcriptomic data, specifically focusing on biomarkers relevant to macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. Based on these molecular markers, determine if the findings support the use of immune checkpoint inhibitor therapy. Finally, integrate these molecular insights with the patient's clinical history to prepare a detailed diagnostic report that outlines tailored treatment recommendations.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-fb7aec-ar-fb7aec7.pkl. "
BLCA,5.0,,desert,NR,"In a White male patient diagnosed with bladder urothelial carcinoma, transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy indicates a tumor mutational burden of 5.0 mutations per megabase. Based on these findings, how likely is the patient to respond to Atezolizumab therapy?","In a White male patient diagnosed with bladder urothelial carcinoma, transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy indicates a tumor mutational burden of 5.0 mutations per megabase. Based on these findings, how likely is the patient to respond to Atezolizumab therapy? Please log into the Compass platform and review the patient’s transcriptomic data with an emphasis on biomarkers associated with macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. Use these molecular indicators to assess whether immune checkpoint inhibitor therapy is appropriate. Then, combine these findings with the patient’s clinical history to develop a comprehensive diagnostic report that includes tailored treatment recommendations.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-fd9476-ar-fd94761.pkl. "
BLCA,7.0,0.352941176,desert,NR,"I have a Caucasian female patient diagnosed with bladder urothelial carcinoma. A transcriptomic analysis of her tumor immune microenvironment from a bladder biopsy revealed a tumor mutational burden of 7.0. Based on these findings, how likely is it that she will respond to Atezolizumab therapy?","I have a Caucasian female patient diagnosed with bladder urothelial carcinoma. A transcriptomic analysis of her tumor immune microenvironment from a bladder biopsy revealed a tumor mutational burden of 7.0. Based on these findings, how likely is it that she will respond to Atezolizumab therapy? Please access the Compass platform and review the patient’s transcriptomic data, focusing on biomarkers indicative of macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. Based on these molecular markers, assess the potential suitability of immune checkpoint inhibitor therapy. Finally, integrate these molecular findings with the patient’s clinical history to create a comprehensive diagnostic report that includes personalized treatment recommendations.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-fed609-ar-fed6099.pkl. "
BLCA,10.0,,desert,R,"Given a white male patient diagnosed with bladder urothelial carcinoma, and considering that his tumor immune microenvironment transcriptomic analysis from a biopsy indicates a tumor mutational burden (TMB) of 10.0 mutations per megabase, what is the likelihood that he will respond to Atezolizumab therapy?","Given a white male patient diagnosed with bladder urothelial carcinoma, and considering that his tumor immune microenvironment transcriptomic analysis from a biopsy indicates a tumor mutational burden (TMB) of 10.0 mutations per megabase, what is the likelihood that he will respond to Atezolizumab therapy? Log in to the Compass platform and examine the patient's transcriptomic profile. Specifically, focus on biomarkers related to macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. Evaluate these molecular markers to determine the patient's potential eligibility for immune checkpoint inhibitor therapy. Incorporate these findings with the patient's clinical history to develop a detailed diagnostic report that includes personalized treatment recommendations.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-ffa5c7-ar-ffa5c7c.pkl. "
